WO2008024922A2 - 8-hydroxyquinoline compounds and methods thereof - Google Patents

8-hydroxyquinoline compounds and methods thereof Download PDF

Info

Publication number
WO2008024922A2
WO2008024922A2 PCT/US2007/076661 US2007076661W WO2008024922A2 WO 2008024922 A2 WO2008024922 A2 WO 2008024922A2 US 2007076661 W US2007076661 W US 2007076661W WO 2008024922 A2 WO2008024922 A2 WO 2008024922A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
chloro
hydroxyquinolin
phenoxyacetamide
alkyl
Prior art date
Application number
PCT/US2007/076661
Other languages
French (fr)
Other versions
WO2008024922A3 (en
Inventor
Matthew G. Bursavich
Sabrina Lombardi
Adam M. Gilbert
Leif Mark Laakso
Gulnaz Khafizova
David Brian How
Joshua James Sabatini
Phaik-Eng Sum
Jeremy J. Clemens
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Priority to BRPI0715872-6A2A priority Critical patent/BRPI0715872A2/en
Priority to MX2009001929A priority patent/MX2009001929A/en
Priority to CA002659952A priority patent/CA2659952A1/en
Priority to EP07814400A priority patent/EP2056823A2/en
Priority to AU2007286659A priority patent/AU2007286659A1/en
Publication of WO2008024922A2 publication Critical patent/WO2008024922A2/en
Publication of WO2008024922A3 publication Critical patent/WO2008024922A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to 8-Hydroxyquinoline Compounds, as defined below; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder comprising administering to a mammal in need thereof an effective dose of an 8-Hydroxyquinoline Compound.
  • Metalloproteinases including matrix metalloproteinases and aggrecanases, are known to have a role in the breakdown of connective tissue.
  • Matrix metalloproteinases constitute a superfamily of proteolytic enzymes that are genetically related and capable of degrading almost all the constituents of extracellular matrix and basement membrane that restrict cell movement.
  • Aggrecanases are members of the ADAMTS (A disintegrin and metalloproteinase with thrombospondin motifs) family of proteins.
  • Aggrecanase-1 and aggrecanase-2 have been designated ADAMTS-4 and ADAMTS-5, respectively (Tang, Int. J. Biochem. Cell. Biol. 33:33-44 (2001)).
  • the ADAMTS family is involved in cleaving aggrecan, a cartilage component also known as the large aggregating chondroitin sulphate proteoglycan (Abbaszade et ah, J. Biol. Chem. 274:23443-23450 (1999)), procollagen processing (Colige et ah, Proc. Natl. Acad. Sci. USA 94:2374-2379 (1997)), angiogenesis and tumor invasion (Vazquez et ah, J. Biol. Chem. 274:23349-23357 (1999)), inflammation (Kuno et al, J. Biol. Chem. 272:556- 562 (1997)).
  • aggrecan a cartilage component also known as the large aggregating chondroitin sulphate proteoglycan
  • procollagen processing Coldige et ah, Proc. Natl. Acad. Sci. USA 94:2374-2379 (1997)
  • MMPs have been shown to cleave aggrecan as well.
  • the loss of aggrecan has been implicated in the degradation of articular cartilage in arthritic diseases, for example osteoarthritis is a debilitating disease which affects at least 30 million Americans. Degradation of articular cartilage and the resulting chronic pain can severely reduce quality of life.
  • An early and important characteristic of the osteoarthritic process is loss of aggrecan from the extracellular matrix, resulting in deficiencies in the biomechanical characteristics of the cartilage.
  • MMPs and aggrecanases are known to play a role in many disorders in which extracellular protein degradation or destruction occurs, such as malignant neoplasm, asthma, chronic obstructive pulmonary disease ("COPD”), atherosclerosis, age-related macular degeneration, myocardial infarction, corneal ulceration and other ocular surface diseases, hepatitis, aortic aneurysms, tendonitis, central nervous system diseases, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, and periodontal diseases.
  • COPD chronic obstructive pulmonary disease
  • the present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hyl disorder,
  • X is -N- and Y is -COR 4 , or Y is -N- and X is -COR 4 ; p is 0 or 1;
  • Ri and R 13 are each independently hydrogen, halogen, -OR 7 , -CN, -Ci-C 6 -alkyl, -C 2 -C 6 - alkenyl, -C 2 -C 6 -alkynyl, -NO 2 , -NR 5 R 6 , -SO 2 NR 5 R 6 , -COR 7 , -COOR 7 , -C 5 -C 7 -cycloalkyl or - C 5 -C 7 -aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C 3 -alkyl, provided that when
  • R 2 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR 7 , wherein (a) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, ary
  • R 3 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, -C 5 -C 7 -cycloalkyl, -R 8 -C 5 -C 7 -cycloalkyl, -C 5 -Cio-arylalkyl, -C 7 -Ci 2 -bicyclic hydrocarbon or -Ri 2 -C 7 -Ci 2 - bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO 2 NR 5 R 6 , -COR 7 , - COOR7, -CONR5R6, -CORs-B-R 9 , or -R 8 -B-R 9 , wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycl
  • R 4 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -SO 2 NR 5 R 6 , -SO 2 R 7 , -COR 7 , -COOR7 or -CONR 5 R 6 , wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
  • R 5 and R 6 are each independently hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, - COR 7 , -C 5 -C 7 -aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C 3 -alkyl;
  • R 7 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, or -C 5 -Ci O - arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one halogen, a -Ci-C 3 -alkyl, -C 5 -C 7 -aryl, or -NR 5 R 6 , -OR 5 ;
  • Rs is -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, or -C 2 -C 6 -alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl;
  • R 9 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, -C 5 -Cio-arylalkyl or -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with at least one halogen, a -Ci-C 4 -alkyl that is optionally branched, a -Cs-C7-
  • R 12 is -CH 2 - or -CH 2 CH 2 -; B is a bond, -O-, -NR 7 - or -S-.
  • an arthritic disorder (hereinafter being an "8-Hydroxyquinoline Compound”) is useful for treating or preventing an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, a myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, a wound that has healed abnormally, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, a periodontal disease or a metalloproteinase-related disorder (hereinafter, each individually or collectively, being a "Condition").
  • compositions comprising an 8-Hydroxyquinoline
  • compositions are useful for treating or preventing a Condition.
  • the invention further provides methods for treating or preventing a Condition comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.
  • Ci-C 6 -alkyl refers to a linear or branched, saturated hydrocarbon having from 1 to 6 carbon atoms.
  • Representative Ci-C ⁇ -alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec -butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, and neohexyl.
  • the Ci-C ⁇ -alkyl group is substituted with one or more (e.g., one to three) of the following groups: halogen, - N 3 , -NO 2 , -CN, -OR', -SR', -SO 2 R', -SO 2 N(R') 2 , -N(R') 2 , -COR', -CO 2 R', -NR 5 CO 2 R', - NR'COR', -NR'CONR', or -CON(R') 2 , wherein each R' is independently selected to be hydrogen or unsubstituted -Ci-C 6 -alkyl.
  • each R' is independently selected to be hydrogen or unsubstituted -Ci-C 6 -alkyl.
  • C 2 -C6-alkenyl refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon double bond. In one embodiment, the C 2 -C6-alkenyl has one or two double bonds.
  • the C 2 -C O - alkenyl moiety may exist in the E or Z configuration and the compounds of the present invention include both configurations.
  • Representative C 2 -C6-alkenyl groups include, but are not limited to, ethylenyl, propylenyl, 1-butylenyl, 2-butylenyl, isobutylenyl, sec-butylenyl, 1- pentenyl, 2-pentenyl, isopentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, and isohexenyl.
  • the C 2 -C 6 -alkenyl group is substituted with one or more (e.g., one to three) of the following groups: halogen, -N 3 , -NO 2 , -CN, -OR', -SR', -SO 2 R', -SO 2 N(R') 2 , -N(R') 2 , - COR', -CO 2 R', -NR 5 CO 2 R', -NR'COR', -NR'CONR', or -CON(R' ) 2 , wherein each R' is independently hydrogen or unsubstituted Ci-C 6 -alkyl.
  • Cs-Cv-cycloalkyl refers to a linear or branched, saturated hydrocarbon having from 1 to 6 carbon atoms, which also includes one or more heteroatom each independently selected from sulfur, nitrogen and oxygen.
  • Cs-Cv-cycloalkyl refers to a non-aromatic hydrocarbon ring.
  • Representative C5-C7-cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, and cycloheptyl.
  • the Cs-Cv-cycloalkyl group is independently substituted with one or more of the following groups: halogen, -N 3 , -NO 2 , - CN, -OR', -SR',
  • a C 5 -C 7 -cycloalkyl can have one to three ring carbon atoms each independently optionally replaced with a nitrogen, sulfur or oxygen atom (i.e., a "C5-C7 heterocycloalkyl").
  • C 2 -C 6 -alkynyl refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon triple bond.
  • Representative C 2 -C6-alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, isobutynl, sec-butynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, and isohexynyl.
  • the C 2 -C 6 -alkynyl group is substituted with one or more of the following groups: halogen, -N 3 , -NO 2 , -CN, -OR', -SR', - SO 2 R', -SO 2 N(R') 2 , -N(R') 2 , -COR', -CO 2 R', -NR 5 CO 2 R', -NR'COR', -NR'CONR', or - CON(R' ) 2 , wherein each R' is independently hydrogen or unsubstituted Ci-C ⁇ -alkyl.
  • C 5 -Ci 0 -arylalkyl refers to an alkyl, alkenyl, or alkynyl, respectively, substituted with an aryl group, as those terms are defined herein.
  • Illustrative examples include benzyl, phenethyl, styryl, cinnamyl and the like.
  • administer refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to an animal, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the animal, which can form an equivalent amount of active compound within the animal's body.
  • animal as used herein includes, without limitation, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon, or rhesus. In one embodiment, the animal is a mammal. In another embodiment, the animal is a human.
  • aryl refers to an aromatic species containing 1 to 3 aromatic rings, either fused or linked.
  • the aryl group is independently substituted with one or more of the following groups: -V-halogen, -V-N3, -V-NO 2 , -V-CN, - V-OR', -V-SR', -V-SO 2 R', -V-SO 2 N(R') 2 , -V-N(R') 2 , -V-COR', -V-CO 2 R', -V-NR 5 CO 2 R', - V-NR' COR', -V-NR' CONR', or -V-C0N(R') 2 , wherein each R' is independently hydrogen or unsubstituted Ci-C ⁇ -alkyl; and wherein each V is independently a bond or Ci-C 6 -alkyl.
  • aryl as used herein, may therefore be understood to refer to substituted aryl, heteroaryl, or substituted heteroaryl groups.
  • a "C5-C7 aryl,” for example, has from 5 to 7 carbon atoms, wherein one to three carbon atoms of the aryl are each independently optionally replaced with a nitrogen, sulfur or oxygen atom (i.e., a "C 5 -C 7 heteroaryl” group").
  • condition effective to refers to synthetic reaction conditions which will be apparent to those skilled in the art.
  • effective amount refers to an amount of a compound or pharmaceutically acceptable salt of a compound that, when administered to an animal, is effective to prevent, to at least partially ameliorate, or to cure, a condition from which the animal suffers or is suspected to suffer.
  • carrier encompasses carriers, excipients, and diluents.
  • prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula (I).
  • halogen refers to fluorine, chlorine, bromine, and iodine.
  • isolated and purified refers to a component separated from other components of a reaction mixture or a natural source.
  • the isolate contains at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the compound or pharmaceutically acceptable salt of the compound by weight of the isolate.
  • pharmaceutically acceptable salt refers to a salt of an acid and a basic nitrogen atom of a compound of an 8-Hydroxyquinoline Compound.
  • Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, hydrochloride, bromide, hydrobromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, succinate, fumarate, maleate, malonate, mandelate, malate, phthalate, and pamo
  • phenyl refers to a substituted or unsubstituted phenyl group. In one embodiment, the phenyl group is substituted with one or more of the following groups: -V-halogen, -V-N 3 , -V-NO 2 , -V-CN, -V-OR', -V-SR', -V-SO 2 R', -V-
  • each R' is independently hydrogen or unsubstituted Ci-C ⁇ -alkyl; and wherein each V is independently a bond or Ci-C ⁇ -alkyl.
  • substantially free of its corresponding opposite enantiomer means that the compound contains no more than about 10% by weight of its corresponding opposite enantiomer. In other embodiments, the compound that is substantially free of its corresponding opposite enantiomer contains no more than about 5%, no more than about 1%, no more than about 0.5%, or no more than about 0.1% by weight of its corresponding opposite enantiomer.
  • An enantiomer that is substantially free of its corresponding opposite enantiomer includes a compound that has been isolated and purified or has been prepared substantially free of its corresponding opposite enantiomer.
  • tautomer refers to compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See, Jerry
  • treating refers to improving at least one symptom of the animal's disease or disorder. Treating can be curing the disease or condition or improving it.
  • ACN or MeCN is acetonitrile
  • DIEA diisopropyl ethylamine
  • DMF dimethylformamide
  • DMSO dimethylsulfoxide
  • HPLC high-performance liquid chromatograpy
  • LC/MS liquid chromatography/mass spectrometry
  • NMP N-methyl-2- pyrrolidone
  • THF is tetrahydrofuran
  • ⁇ -BuOK is potassium tert-butoxide.
  • the present invention encompasses 8-Hydroxyquinoline
  • X is -N- and Y is -COR 4 , or Y is -N- and X is -COR 4 ; p is 0 or 1;
  • Ri and R 13 are each independently hydrogen, halogen, -OR 7 , -CN, -Ci-C 6 -alkyl, -C 2 -C 6 - alkenyl, -C 2 -C 6 -alkynyl, -NO 2 , -NR 5 R 6 , -SO 2 NR 5 R 6 , -COR 7 , -COOR 7 , -C 5 -C 7 -cycloalkyl or - C 5 -C 7 -aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C 3 -alkyl, provided that when
  • R 2 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, -C 5 -Ci 0 -arylalkyl, -C 5 -Cio-arylalkenyl, -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, Cg-Cis-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR 7 , wherein (a) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl
  • R 3 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, -C 5 -C 7 -cycloalkyl, -R8-C5-C 7 -cycloalkyl, -Cs-Qo-arylalkyl, -C7-Ci 2 -bicyclic hydrocarbon or -R 12 -C 7 -C 12 - bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO 2 NR5R6, -COR7, - COOR 7 , -CONR 5 R 6 , -COR 8 -B-R 9 , or -R 8 -B-R 9 , wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl,
  • R 4 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -SO 2 NR 5 R 6 , -SO 2 R 7 , -COR 7 , -COOR 7 or -CONR 5 R 6 , wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
  • R 5 and R 6 are each independently hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, - COR 7 , -C 5 -C 7 -aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C 3 -alkyl;
  • R 7 is hydrogen, -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -C 5 -C 7 -aryl, or -C 5 -Ci O - arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one halogen, a -Ci-C 3 -alkyl, -C 5 -C 7 -aryl, or -NR 5 R 6 , -OR 5 ;
  • R 8 is -Ci-C 6 -alkyl, -C 2 -C 6 -alkenyl, or -C 2 -C 6 -alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C 3 -alkyl;
  • Rg is hydrogen, -Ci-C ⁇ -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -Cs-C 7 -aryl, -Cs-Cio-arylalkyl or -C7-Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a)
  • Ri 2 is -CH 2 - or -CH 2 CH 2 -;
  • B is a bond, -O-, -NR 7 - or -S-.
  • Ri is a halogen, for example, chlorine, bromine or fluorine.
  • Ri is a -Ci-C 6 -alkyl, for example, -CH 3 .
  • Ri is hydrogen
  • Ri is -NO 2 .
  • Ri is -NR5R6, for example, -NH 2 or -N(CH 3 ) 2 .
  • Ri is a -C5-C7- cycloalkyl, -Cs-Cv-heterocyloalkyl, or -Cs-Cv-heteroaryl, for example,
  • compounds according to Formula (I) include those wherein R 2 is a
  • -C5-C 7 -aryl which is optionally substituted with one to three hydroxyl, halogen, -Ci-C ⁇ -alkyl, -C 2 -C 6 -alkynyl, -Cs-C 7 -aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -Cs-Cio-arylalkynyl, - NO 2 , -Cs-Cr-cycloalkyl, -Ci-C3-alkyl-C 5 -C 7 -cycloalkyl, BR 9 , -COR 7 , -Ci-Cs-alkyl-COR?, - CH 2 NRSRO, or -NR5R6, and wherein one to three carbon atoms of the aryl or the substituent are each independently optionally replaced with a nitrogen, sulfur or oxygen atom, for example, and the substituent is optionally branche
  • R 2 is a -Cs-C7-aryl, wherein one to three of the carbon atoms is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and the aryl group is optionally substituted with one or more -Cs-C 7 -aryl, -Cs-Cio-arylalkyl, -C 5 - Cio-arylalkenyl, -Cs-Cio-arylalkynyl, which optionally (1) has one to three of the carbon atoms each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) is substituted with a halogen, -Ci-C 3 -alkyl that optionally has one to three of the carbon atoms optionally independently replaced with a nitrogen, sulfur or oxygen atom, for example:
  • R 2 is a -C7-Ci 2 -bicyclic or a C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic, one to three carbon atoms are each independently, optionally replaced with a nitrogen, sulfur or oxygen atom, and the hydrocarbon group is optionally substituted with one or more oxygen atoms, halogen atoms, or one to three -Ci-C ⁇ -alkyl groups having one to three carbon atoms optionally replaced with an oxygen, for example:
  • compounds of Formula (I) are those wherein R 2 is a -C 2 -Ce- alkenyl, for example:
  • R 2 is a -Cs-Cio-arylalkyl or -Cs-Cio-arylalkenyl, which is optionally substituted with a -Ci-C ⁇ -alkyl, and wherein one to three carbon atoms of the alkyl is optionally replaced with an oxygen, for example:
  • R 2 is a -C5-C7-aryl, which is optionally substituted with -CH2NR5R6, -NR5R6 or -NR5SO2R6, wherein one to three of the carbon atoms is each independently optionally replaced with a nitrogen or oxygen atom, for example:
  • compounds of Formula (I) include those wherein Ri and R 2 are, in combination, as specified in the above identified embodiments.
  • compounds of Formula (I) are those wherein R 3 is -CORs-B-Rg or -R 8 -B-R 9 , wherein R 8 is a -Ci-C 3 -alkyl, R 9 is a -Cs-C 7 -aryl or C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein the aryl or bicyclic hydrocarbon is optionally substituted with one to three halogen atoms, -Ci-C4-alkyl groups, -C5-C7- cycloalkyl groups, -Cs-C7-aryl groups, -B-C5-C7-aryl groups, -NR5R6 groups, or -COR7 groups and wherein one to three carbon atoms in the substituent
  • R 3 is -COR 8 -B-R 9 , -Rg-Cs-Cy-cycloalkyl, or -R 8 -B-R 9 , wherein R 8 is a -Ci-C 3 -alkyl, R 7 is a -Ci-C 3 -alkyl or hydrogen; R 9 is a -Cs-C 7 -aryl, -R 12 -Cs- C 7 -cycloalkyl, or -Ri 2 -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic and R12 is -CH 2 -, wherein (a) one or more of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom, and (b) the cycloalkyl, aryl or bicyclic hydrocarbon group is optionally substituted with one to three halogen, -C 1 - C 4 -alkyl groups,
  • R 3 is -Rs-Cs ⁇ -cycloalkyl or -R 8 -B-
  • Rg wherein R 8 is a -Ci-C 3 -alkyl, B is -NR 7 -, R7 is a -Ci-C3-alkyl or hydrogen, R 9 is a -C5-C7- aryl or a -Ri 2 -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic and R 12 is -CH 2 -, wherein (a) one or more of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom, and (b) the cycloalkyl, aryl or bicyclic hydrocarbon group is optionally substituted with a -Ci-C3-alkyl or a -Cs-C7-aryl, for example:
  • compounds of Formula (I) include those wherein R 3 is -COR7, wherein R 7 is a -Ci-C ⁇ -alkyl, -Cs-C 7 -aryl or -Cs-Cio-arylalkyl, for example:
  • R 3 is a -Cs-Cio-arylalkyl, and a carbon atom is optionally replaced with an oxygen atom, for example:
  • Particular embodiments of the compounds of Formula (I) include those wherein R 1 , R 2 and R3 are, in combination, as specified in the above identified embodiments.
  • compounds according to Formula (I) include those wherein R 4 is
  • compounds according to Formula (I) include those wherein R 4 is hydrogen.
  • compounds according to Formula (I) also include those wherein
  • R 4 is -SO 2 R 7 .
  • Particular embodiments of the compounds of Formula (I) include those wherein R 1 , R 2 , R3 and R 4 are, in combination, as specified in the above identified embodiments.
  • the 8 -hydroxy quinoline Compounds of the invention may contain one or more asymmetric centers, and can thus give rise to optical isomers and diastereomers. While depicted without respect to stereochemistry in the compounds or pharmaceutically acceptable salts of compounds of the present invention, the present invention includes such optical isomers and diastereomers, as well as racemic and resolved, enantiomerically pure R and S stereoisomers, and also other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Where a stereoisomer is provided, it can in some embodiments be provided substantially free of its corresponding opposite enantiomer.
  • the compounds and pharmaceutically acceptable salts of compounds of the present invention may exist as tautomers.
  • Such tautomers can be transient or isolatable as a stable product. These tautomers are within the scope of the present invention.
  • the first step may be run at a temperature between
  • the second step may be run at a temperature between 0-100 0 C, alternatively between 25-75°C, and preferably between 40-
  • weak bases such as DIEA or K 2 CO3 are used to create the basic conditions during the second step.
  • the polar aprotic solvent may be DMF, DMSO, NMP,
  • R3 is -COR7
  • R7 is as defined above.
  • Hal is halogen
  • Z is chlorine, bromine, or iodine
  • A is -OR 7 , -NR 5 R 6 or -OR 8 -B-R 9 ,
  • R 5 , R 6 , R7 and R9 are each independently -Cs-C7-aryl or -Cs-Cio-arylalkyl, as defined above, and R 1 , R 2 , R 4 and R 8 are as defined above.
  • the first step may be run at a temperature between
  • the temperature may be between -15°C and 20 0 C, preferably between -5°C and 10 0 C.
  • strong bases such as NaH, KH, or ?-BuOK are used to create the basic conditions.
  • AH is and the compound produced is of the formula:
  • Ri 0 is a hydrogen, halogen or -Ci-C 3 -alkyl
  • R 1 , R2, and R 4 are as previously defined.
  • the temperature may be between 10 0 C and 30 0 C, preferably between 15°C and 25°C.
  • weak bases such as DIEA or K2CO3 are used to create the basic conditions.
  • AH is
  • R 10 is a hydrogen, halogen or -Ci-C 3 -alkyl, and R 1 , R 2 , R3, and R 4 are as previously defined.
  • the polar aprotic solvent may be DMF, DMSO, NMP, MeCN, or THF.
  • the third step may be run at a temperature between 0-
  • Scheme 1 is used to make the 8-Hydroxyquinoline
  • Ri and R 7 are as previously defined, and Rn may be a hydrogen, halogen or a C 1 -C 3 alkyl.
  • 8-Hydroxyquinoline target molecules IV may be prepared according to
  • Aryl or heteroaryl aldehydes II can be purchased commercially or prepared synthetically via standard organic chemistry protocols.
  • Acetamides III can be purchased commercially or prepared synthetically via standard organic chemistry protocols.
  • Scheme 2 is used to make the 8-Hydroxyquinoline
  • R 1 , Rs 1 R 4 , Rio and Rn are as previously defined.
  • 8-Hydroxyquinoline target molecules VII may be prepared according to
  • Scheme 2 by reacting 8-Hydroxyquinolines I with aryl or heteroaryl aldehydes II and chloro acetamide V at 150 0 C similar to procedures found in Mohrle, H et. al. Chem. Ber. 1974, 707, 2675, Pirrone, F. Gazz. CMm Ital. 1936, 66, 518, and Pirrone, F. Gazz. CMm Ital. 1937, 67, 529. Displacement of the chloride from resulting compound VI with commercially purchased or readily available phenols with a strong base such as NaH, KH or ?-BuOK in a polar aprotic solvent such as DMF, DMSO, NMP, MeCN or THF affords VII. [0084] In yet another embodiment, Scheme 3 is used to make the 8-Hydroxyquinoline
  • R 1 , Ri 0 and Rn are as previously defined.
  • 8-Hydroxyquinoline target molecules VIII may be prepared according to
  • Ri is hydrogen or halogen provided that Option 1 is used when Ri is halogen;
  • R 2 is -C 5 -C 7 -aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C 7 -Ci 2 -bicyclic hydrocarbon wherein at least one cyclic group is aromatic, or C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic.
  • 8-Hydroxyquinoline target molecules IX and X may be prepared according to Scheme 4 by O-allylating 8-Hydroxyquinolines unsubstituted or substituted at the 5-position using allyl halide and an appropriate base such as potassium carbonate in acetone followed by Claisen rearrangement of the neat material or as a solution in a high-boiling solvent conducted by conventional heating or in a microwave reactor. The products are then O- benzyl protected with benzyl bromide and an appropriate base such as potassium carbonate in acetone followed by dihydroxylation of the double bond using a suitable oxidant such as the osmium tetroxide/4-methylmorpholine N-oxide system in water/acetone.
  • a suitable oxidant such as the osmium tetroxide/4-methylmorpholine N-oxide system in water/acetone.
  • the diols then undergo oxidative cleavage using sodium metaperiodate in water and a polar aprotic solvent miscible with water such as tetrahydrofuran to give the aldehydes that are stable at room temperature.
  • a polar aprotic solvent miscible with water such as tetrahydrofuran
  • Addition of aryl Grignard reagents to the aldehydes at low temperature in dry tetrahydrofuran or ether provides the alcohols.
  • the alcohols are either converted to the azides with diphenyl phosphoryl azide and an appropriate base such as 1,8- diazabicyclo[5.4.0]undec-7-ene at elevated temperatures, hydrogenated under standard conditions using and appropriate metal catalyst such as 10% palladium on carbon and N- acylated with an acid chloride such as phenoxyacetyl chloride and an appropriate base such as triethylamine in tetrahydrofuran (Option 1 to give compounds IX) or subjected to a Ritter reaction with a nitrile such as phenoxyacetonitrile and strong acid such as sulfuric acid followed by deprotection with 3N HCl in a polar protic solvent such as methanol (Option 2 to give compounds X).
  • Ri is halogen
  • R 2 is -C5-C7-aryl that is optionally substituted with at least one -Ci-C ⁇ -alkyl, -C 2 -C6-alkenyl,
  • R 3 is -COR 7 or -COR 8 -B-R 9
  • R 7 is -Ci-C ⁇ -alkyl, -C 2 -C 6 -alkenyl, -C 2 -C 6 -alkynyl, -Cs-C 7 -aryl, or -Cs-Cio-arylalkyl, wherein
  • At least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is optionally replaced with one to three nitrogen, sulfur or oxygen atoms
  • the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one -Ci-C 3 -alkyl or - C 5 -C 7 -aryl or is optionally branched; and Rs, R9, and B are as defined above.
  • the azides are subjected to a Staudinger reduction using triphenylphosphine in aqueous tetrahydrofuran followed by N- acylation with an acid chloride and an appropriate base such as triethylamine in tetrahydrofuran.
  • the final O-benzyl deprotection is conducted with in situ generated iodotrimethylsilane using sodium iodide and chlorotrimethylsilane in acetonitrile at elevated temperature to give the final products XL
  • R 2 contains thiophene
  • the aryl bromide was synthesized from 3-bromophenacylbromide by condensation with acetone in the presence of zinc chloride using the procedure found in Nevar, N. et al. Synthesis, 2000, 1259.
  • the resulting 1,4-diketone is then cyclized in the presence of Lawesson's reagent at high temperature to give the required thiophene.
  • the 8-Hydroxyquinoline Compounds are advantageously useful in veterinary and human medicine. As described above, the 8-Hydroxyquinoline Compounds are useful for treating or preventing a Condition in a mammal in need thereof. [0089] When administered to a mammal, the 8-Hydroxyquinoline Compounds can be administered as a component of a composition that comprises a physiologically acceptable carrier or vehicle. The present compositions, which comprise an 8-Hydroxyquinoline Compound, can be administered orally.
  • the 8-Hydroxyquinoline Compounds can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, or intestinal mucosa), by intratracheal administration, or by inhalation, and can be administered together with another biologically active agent. Administration can be systemic or local.
  • Various known delivery systems including encapsulation in liposomes, microparticles, microcapsules, and capsules, can be used.
  • Methods of administration include, but are not limited to, intradermal, intratracheal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin.
  • administration results in the release of the 8-Hydroxyquinoline Compounds into the bloodstream.
  • the mode of administration can be left to the discretion of the practitioner.
  • the 8-Hydroxyquinoline Compounds are administered orally.
  • the 8-Hydroxyquinoline Compounds are administered intravenously.
  • the 8-Hydroxyquinoline Compounds are administered topically.
  • the 8-Hydroxyquinoline Compounds are administered via inhalation.
  • Hydroxyquinoline Compounds locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by intubation, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • Hydroxyquinoline Compounds into the central nervous system, circulatory system or gastrointestinal tract by any suitable route including intraventricular, intrathecal injection, paraspinal injection, epidural injection, enema, and by injection adjacent to a peripheral nerve.
  • Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler of nebulizer, by intubation, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant.
  • an inhaler of nebulizer e.g., by use of an inhaler of nebulizer, by intubation, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant.
  • Hydroxyquinoline Compounds can be formulated as a suppository, with traditional binders and excipients such as triglycerides. [0098] In another embodiment the 8-Hydroxyquinoline Compounds can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1533 (1990) and Lopez- Berestein et al, Liposomes in the Therapy of Infectious Disease and Cancer, 317-327 and 353-365 (1989)).
  • the 8-Hydroxyquinoline Compounds can be delivered in a controlled-release system or sustained-release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).
  • Other controlled or sustained-release systems discussed in the review by Langer, Science 249: 1527-1533 (1990) can be used.
  • a pump can be used (Langer, Science 249: 1527-1533 (1990); Sefton, CRC Crit. Ref Biomed. Eng. 14:201 (1987); Buchwald et al, Surgery 88:507 (1980); and Saudek et al., N. Engl. J. Med.
  • polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J. Macromol. ScL Rev. Macromol. Chem. 2:61 (1983); Levy et al, Science 228: 190 (1935); During et al, Ann. Neural. 25:351 (1989); and Howard et al, J. Neurosurg. 71: 105 (1989)).
  • a controlled- or sustained-release system can be placed in proximity of a target of the 8-Hydroxyquinoline Compounds, e.g., the spinal column, brain, colon, skin, heart, lung, trachea or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
  • a target of the 8-Hydroxyquinoline Compounds e.g., the spinal column, brain, colon, skin, heart, lung, trachea or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
  • compositions can optionally comprise a suitable amount of a physiologically acceptable excipient.
  • physiologically acceptable excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • the physiologically acceptable excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
  • auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used.
  • the physiologically acceptable excipients are sterile when administered to a mammal. Water can be a particularly useful excipient when the 8-Hydroxyquinoline Compound is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions.
  • suitable physiologically acceptable excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • compositions can take the form of solutions, suspensions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays or any other form suitable for use.
  • the composition is in the form of a capsule.
  • suitable physiologically acceptable excipients are described in Remington 's Pharmaceutical Sciences (21st ed. 2005), incorporated herein by reference.
  • compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example.
  • Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
  • compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
  • Selectively permeable membranes surrounding an osmotically active platform driving an 8-Hydroxyquinoline Compound are also suitable for orally administered compositions.
  • fluid from the environment surrounding the capsule can be imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
  • delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations.
  • a time-delay material such as glycerol monostearate or glycerol stearate can also be used.
  • compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment the excipients are of pharmaceutical grade.
  • the 8-Hydroxyquinoline Compounds can be formulated for intravenous administration.
  • compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent.
  • Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection.
  • compositions' components can be supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water- free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of 8- Hydroxyquinoline Compound.
  • a hermetically sealed container such as an ampule or sachette indicating the quantity of 8- Hydroxyquinoline Compound.
  • the 8-Hydroxyquinoline Compounds are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
  • the 8-Hydroxyquinoline Compounds can be administered by controlled- release or sustained-release means or by delivery devices that are well known to those skilled in the art.
  • dosage forms can be used to provide controlled- or sustained-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
  • a controlled- or sustained-release composition comprises a minimal amount of an 8-Hydroxyquinoline Compound to treat or prevent the Condition in a minimal amount of time.
  • Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the 8- Hydroxyquinoline Compound, and can thus reduce the occurrence of adverse side effects.
  • Controlled- or sustained-release compositions can initially release an amount of an 8-Hydroxyquinoline Compound that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the 8- Hydroxyquinoline Compound to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the 8-Hydroxyquinoline Compound can be released from the dosage form at a rate that will replace the amount of 8-Hydroxyquinoline Compound being metabolized and excreted from the body.
  • Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions.
  • the amount of the 8-Hydroxyquinoline Compound that is effective for treating or preventing a Condition can be determined by standard clinical techniques.
  • in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of a health-care practitioner. Suitable effective dosage amounts, however, range from about 10 micrograms to about 5 grams about every 4 h, although they are typically about 500 mg or less per every 4 hours.
  • Examples of effective dosages include about 0.01 mg, 0.5 mg, about 1 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1 g, about 1.2 g, about 1.4 g, about 1.6 g, about 1.8 g, about 2.0 g, about 2.2 g, about 2.4 g, about 2.6 g, about 2.8 g, about 3.0 g, about 3.2 g, about 3.4 g, about 3.6 g, about 3.8 g, about 4.Og, about 4.2 g, about 4.4 g, about 4.6 g, about 4.8 g, and about 5.0 g, every 4 hours.
  • Equivalent dosages can be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months.
  • the number and frequency of dosages corresponding to a completed course of therapy can be determined according to the judgment of a health-care practitioner.
  • the effective dosage amounts described herein refer to total amounts administered; that is, if more than one 8- Hydroxyquinoline Compound is administered, the effective dosage amounts correspond to the total amount administered.
  • the amount of an 8-Hydroxyquinoline Compound that is effective for treating or preventing a Condition typically ranges from about 0.01 mg/kg to about 100 mg/kg of body weight per day, in one embodiment, from about 0.1 mg/kg to about 50 mg/kg body weight per day, and in another embodiment, from about 1 mg/kg to about 20 mg/kg of body weight per day.
  • the concentration of the 8- Hydroxyquinoline Compound in the solution that is effective for maintaining the viability of the organ is between about 1 nM to about 1 mM.
  • the 8-Hydroxyquinoline Compounds can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans.
  • Animal model systems can be used to demonstrate safety and efficacy.
  • the present methods for treating or preventing a Condition can further comprise administering another therapeutic agent to the mammal being administered an 8- Hydroxyquinoline Compound.
  • the other therapeutic agent is administered in an effective dose.
  • Effective doses of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective dose range. In one embodiment of the invention, where, another therapeutic agent is administered to a mammal, the effective dose of the 8- Hydroxyquinoline Compound is less than its effective dose would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that the 8-Hydroxyquinoline Compounds and the other therapeutic agent act synergistically.
  • the other therapeutic agent is an anti-inflammatory agent.
  • useful anti-inflammatory agents include, but are not limited to, adrenocorticosteroids, such as Cortisol, cortisone, fluorocortisone, prednisone, prednisolone, 6 ⁇ -methylprednisolone, triamcinolone, betamethasone, and dexamethasone; and nonsteroidal anti-inflammatory agents (NSAIDs), such as aspirin, acetaminophen, indomethacin, sulindac, tolmetin, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefenamic acid, meclofenamic acid, piroxicam, meloxicam, nabumetone, rofecoxib, celecoxib, etodolac, and nimesulide.
  • NSAIDs nonsteroidal anti-inflammatory agents
  • the other therapeutic agent is an anti-cardiovascular- disease agent.
  • useful anti-cardiovascular-disease agents include, but are not limited to, carnitine; thiamine; lidocaine; amiodarone; procainamide; mexiletine; bretylium tosylate; propanolol; sotalol; and muscarinic receptor antagonists, such as atropine, scopolamine, homatropine, tropicamide, pirenzipine, ipratropium, tiotropium, and tolterodine.
  • An 8-Hydroxyquinoline Compound and the other therapeutic agent can act additively or, in one embodiment, synergistically.
  • an 8- Hydroxyquinoline Compound is administered concurrently with another therapeutic agent.
  • the present compositions can further comprise another therapeutic agent.
  • a composition comprising an effective dose of an 8- Hydroxyquinoline Compound and an effective dose of another therapeutic agent can be administered.
  • a composition comprising an effective dose of an 8- Hydroxyquinoline Compound and a different composition comprising an effective dose of another therapeutic agent can be concurrently administered.
  • an effective dose of an 8-Hydroxyquinoline Compound is administered prior or subsequent to administration of an effective dose of another therapeutic agent.
  • the 8- Hydroxyquinoline Compound is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the 8- Hydroxyquinoline Compound exerts its preventative or therapeutic effect for treating or preventing a Condition.
  • a composition of the invention can be prepared using a method comprising admixing an 8-Hydroxyquinoline Compound and a physiologically acceptable carrier or excipient. Admixing can be accomplished using methods well known for admixing a compound (or salt) and a physiologically acceptable carrier or excipient.
  • the 8-Hydroxyquinoline Compounds of the present invention and compositions thereof are useful as metalloproteinase modulators.
  • the 8-Hydroxyquinoline Compounds of the present invention and compositions thereof are useful for treating a condition.
  • the invention provides a method for treating a metalloproteinase-related disorder, comprising administering to a mammal in need thereof an effective dose of an 8-Hydroxyquinoline Compound or a composition thereof.
  • the 8-Hydroxyquinoline Compounds and compositions thereof are useful for treating or preventing the following disorders: an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease.
  • the disorder is osteoarthritis.
  • the present invention provides a method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of an 8-Hydroxyquinoline Compound or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease.
  • the disorder is an arthritic disorder, osteoarthriti
  • kits that can simplify the administration of the 8-
  • a typical kit of the invention comprises a unit dosage of an 8-
  • the unit dosage form is in a container, which can be sterile, containing an effective dose of an 8-Hydroxyquinoline Compound and a physiologically acceptable vehicle.
  • the unit dosage form is in a container containing an effective dose of an 8-Hydroxyquinoline Compound as a lyophilate or pharmaceutically acceptable salt.
  • the kit can further comprise another container that contains a solution useful for the reconstitution of the lyophilate or dissolution of the salt.
  • the kit can also comprise a label or printed instructions for use of the 8- Hydroxyquinoline Compounds.
  • the kit comprises a unit dosage form of a composition of the invention.
  • Kits of the invention can further comprise one or more devices that are useful for administering the unit dosage forms of the 8-Hydroxyquinoline Compounds or a composition of the invention.
  • devices include, but are not limited to, a syringe, a drip bag, a patch or an enema, which optionally contain the unit dosage forms.
  • the present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention.
  • Examples 1-121 are prepared by one of the following procedures as set forth below (Procedures A, B and C).
  • the Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 ⁇ m GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci 8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et 3 N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound.
  • the Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 ⁇ m GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci 8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et 3 N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound and then 0 min at 150 0 C, poured onto 100 mL MeOH, and the reaction allowed to cool to room temperature upon which a solid precipitated.
  • the suspension was filtered and the solid recrystallized with MeOH. If purification via preparative HPLC was necessary the following conditions were utilized.
  • the Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 ⁇ m GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA C 18 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et 3 N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound.
  • the hydroxyquinolines were prepared in a single step by means of a three component coupling reaction [an aromatic variant of the Mannich reaction]: A mixture of 5- chloro-8-hydroxyquinoline (1-1.1 equiv.), amide component (1 equiv.) and aldehyde component (2.5-4 equiv.) were heated neat at 145-15O 0 C for 3-6 hours. Typically, the hydroxyquinoline was isolated by multiple trituration with hexanes and isopropyl ether followed by recrystallization from ethanol furnishing product in 14-80% yield.
  • Examples 237-278 were accomplished using commercially available dry solvents. The reactions were performed under an inert atmosphere of nitrogen unless otherwise noted. All reagents were purchased from either Aldrich (Milwaukee, WI), Sigma (St. Louis, MO), Acros (Pittsburgh, PA), or Alfa Aesar (Ward Hill, MA). Microwave reactions were conducted using a Biotage (Personal Chemistry) Emrys Optimizer microwave reactor.
  • Analtech uniplate F254 precoated 250 ⁇ M glass backed plates were used for thin layer chromatography (TLC) analysis.
  • TLC thin layer chromatography
  • ISCO Combi- Flash Companion system was used for column chromatography. Redi-Sep columns containing normal phase silica gel, 35-60 micron average, 230-400 mesh particle size were utilized with monitoring at 254 nM for collection of fractions. For 12Og columns, flow rate was set at 85 mL/min; for 4Og columns, flow rate was set at 40 mL/min.
  • TLC single spot
  • spectroscopic methods including HPLC and mass spectrometry.
  • the filtrate was then concentrated to a yellow foam that was treated with a small amount of ether that initially dissolved the foam and then resulted in a precipitate that was filtered.
  • the filtrate was concentrated to a yellow foam and ether addition resulted in a second crop of precipitate that was filtered and combined with the first crop.
  • the combined yellow solid was used directly in the ensuing step without further purification.
  • RArylMgBr THF -78°C or 0°C ⁇ rt DPPA, DBU, 12 - 51 % DMF, PhCH 3 PPh3, THF, H2 ⁇ > or "BuLi, RArylBr 0°C ⁇ rtor 65°C or 70°C, 88 - 92% THF, -78°C ⁇ rt 80°C, 56% - quant 46%
  • a round bottom flask containing zinc chloride (71.95 mmol, 2.0 eq.) was heated under vacuum until the solid melted ( ⁇ 300°C) and the molten solid was kept under vacuum for 5 min. The molten solid was then allowed to cool to room temperature resulting in solidification. The flask was then filled with nitrogen and benzene (36 mL) was added followed by diethylamine (53.97 mmol, 1.5 eq.) and tert-butanol (53.97 mmol, 1.5 eq.).
  • the reaction mixture was then cooled to room temperature and concentrated by rotary evaporation to remove the vast majority of the solvent.
  • Water (5 mL) was added and the resulting suspension was stirred Ih and concentrated by rotary evaporation to a brown solid.
  • Water (5 mL) was added and the resulting mixture was sonicated for 5 min then filtered with the solid being washed with additional water.
  • the solid was returned to a round bottom flask and toluene (5 mL) was added followed by removal of the solvent by rotary evaporation.
  • the solid was then dissolved in a warm solution of 19: 1 chloroform/methanol (10 mL) and this solution was washed with a 10% aqueous solution of sodium thiosulfate.
  • N- ⁇ 2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl ⁇ -2-phenoxy-acetamide was prepared from 2-[8-(benzyloxy)-5-chloroquinolin- 7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.404 mmol) and phenoxyacetyl chloride (0.445 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations).
  • N- ⁇ 2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl ⁇ -2-(4-chloro-phenoxy)-2-methyl-propionamide was prepared from 2-[8- (benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.409 mmol) and 2-(4-chlorophenoxy)-2-methylpropanoyl chloride (0.450 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations).
  • N- ⁇ 2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl ⁇ -2-(4-tert-butyl-phenoxy)-acetamide was prepared from 2-[8-(benzyloxy)-5- chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.414 mmol) and 4-tert- butyl-phenoxyacetyl chloride (0.455 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations).
  • a continuous assay was used in which the substrate was a synthetic peptide containing a fluorescent group (o-aminobenzyl, Abz), which was quenched by energy transfer to a 2,4-dinitrophenyl group (Dnp).
  • the buffer used in this assay was 50 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM CaCl2, 0.1 % CHAPS, 5% glycerol.
  • the final concentration of Agg2-Phe6 2 8 was 0.5 ⁇ g/ml.
  • the concentration of this substrate stock was spectrophotometrically determined using the extinction coefficient at 354nm of 18,172 M 1 Cm "1 .
  • the F max and K m for this enzyme/substrate reaction were determined to be insensitive to DMSO up to at least 10% (v/v).
  • the final concentration of substrate in the assay was 25 ⁇ M.
  • Test compounds (in duplicate) were serially diluted from 2 mM to 0.01 ⁇ M in
  • the total reaction volume was 100 ⁇ l.
  • the buffer and enzyme were added first followed by addition of 1OX inhibitor from the dilution plate. Enzyme and buffer alone samples were included in order to obtain the maximal rate of substrate cleavage.
  • the reaction was allowed to stand at 30 0 C for 15 min. Then substrate was added, mixed and the reaction monitored for 40 min at 30 0 C in kinetic mode using ⁇ ex : 340 nm and ⁇ em : 420
  • Compound A a hydroxamic acid with an Agg2 IC50 of 36 +/- 4 nM, is of formula:
  • Compound A was run on each plate (in duplicate) as a positive control for the assay at the following concentrations: 200 nM, 20 nM and 10 nM which correspond to 100, 60 and 40 % inhibition of Agg2-Phe628 activity respectively.
  • the fluorescence polarization assay is used to determine the dissociation constant of the enzyme nhibitor complex (Ki) and the binding interaction mode (competitive, non-competitive or uncompetitive) of reversible inhibitors.
  • the fluorescence polarization assay monitors the rotational motion of the fluorescent ligand. In the free state the fluorescent ligand has high rotational motion corresponding to a low polarization value and when fully bound to the protein, the fluorescent ligand has a lower rotational motion, corresponding to a higher polarization value.
  • the rotational motion of the fluorescent ligand bound to the enzyme is compared to the rotational motion of the fluorescent ligand in the presence of increasing concentrations of inhibitors in order to assess the potency of small molecules.
  • the source of enzyme was purified recombinant human Aggrecanase-2, Agg2-
  • Phe6 2 8 (41737 Da). This is a truncated form of full-length human aggrecanase-2 that is purified. Aliquots of this enzyme are stored at -80 0 C in 5OmM HEPES-NaOH (pH 7.4), 10OmM NaCl, 5mM CaCl 2 , 20% glycerol. [0222] A fluorescent ligand was constructed from Compound B:
  • the fluorescent ligand, Compound C has a mass of 815.8, is >95% pure based upon HPLC analysis and has the structure:
  • the fluorescent polarization assay buffer contains 5OmM HEPES-NaOH (pH
  • Each well of black polystyrene 384-well plate contains a 70 ⁇ l reaction consisting of assay buffer, Aggrecanase-2 (final concentration 165 nM; 2.75 times Kd), fluorescent ligand Compound C (final concentration 2 nM), and varied concentrations of inhibitor (prepared by serial dilution in DMSO in 96-well round- bottom polypropylene plates). For each compound a 12-point titration of sample and control (minus enzyme) is performed in duplicate. The reaction is mixed by pipetting up and down and allowed to reach equilibrium over 30 minutes, at room temperature. Final DMSO concentration is 10% - 7.14% from the addition of the compound and 2.86% from the addition of Compound C.
  • Bovine carpal joints were obtained from young (1-2-week-old) animals, disinfected with 10% Wescodyne (Steris Corporation, St. Louis, MO) followed by 70% ethanol. Full-depth articular cartilage plugs were harvested using a cork borer and then sliced to generate individual articular cartilage discs about 6 mm wide and 1 mm thick. These cartilage discs (explants) were used for the explant assay.
  • Cartilage explants were cultured at 37°C for 5 days in a humidified atmosphere of 5% CO 2 in air in cartilage explant culture medium. Explants were washed with media and 1 weighed explant per well were placed in a 96-well culture dish with 0.2 ml of medium and 6-8 replicates per treatment and cultured for 3 days in the presence or absence of recombinant human IL-I (rhIL-1, 5 ng/ml, Sigma, St. Louis, MO) and presence or absence of test compounds. Media were replaced every day. The aggrecan content in the medium was measured each day by Dimethylmethelene Blue (DMMB) assay using chondroitin sulphate C as a standard. Measured aggrecan was expressed per weight of cartilage.
  • DMMB Dimethylmethelene Blue

Abstract

The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.

Description

8-HYDROXYOUINOLINE COMPOUNDS AND METHODS THEREOF
1. FIELD OF THE INVENTION
[0001] This application claims the benefit under 35 U.S. C. 119(e) of U.S. Provisional
Application No. 60/839,568, filed August 23, 2006. The entire disclosure of that application is relied upon and incorporated herein by reference.
[0002] The present invention relates to 8-Hydroxyquinoline Compounds, as defined below; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder comprising administering to a mammal in need thereof an effective dose of an 8-Hydroxyquinoline Compound.
2. BACKGROUND OF THE INVENTION
[0003] Metalloproteinases, including matrix metalloproteinases and aggrecanases, are known to have a role in the breakdown of connective tissue. Matrix metalloproteinases ("MMPs") constitute a superfamily of proteolytic enzymes that are genetically related and capable of degrading almost all the constituents of extracellular matrix and basement membrane that restrict cell movement. Aggrecanases are members of the ADAMTS (A disintegrin and metalloproteinase with thrombospondin motifs) family of proteins. Aggrecanase-1 and aggrecanase-2 have been designated ADAMTS-4 and ADAMTS-5, respectively (Tang, Int. J. Biochem. Cell. Biol. 33:33-44 (2001)).
[0004] The ADAMTS family is involved in cleaving aggrecan, a cartilage component also known as the large aggregating chondroitin sulphate proteoglycan (Abbaszade et ah, J. Biol. Chem. 274:23443-23450 (1999)), procollagen processing (Colige et ah, Proc. Natl. Acad. Sci. USA 94:2374-2379 (1997)), angiogenesis and tumor invasion (Vazquez et ah, J. Biol. Chem. 274:23349-23357 (1999)), inflammation (Kuno et al, J. Biol. Chem. 272:556- 562 (1997)). MMPs have been shown to cleave aggrecan as well. [0005] The loss of aggrecan has been implicated in the degradation of articular cartilage in arthritic diseases, for example osteoarthritis is a debilitating disease which affects at least 30 million Americans. Degradation of articular cartilage and the resulting chronic pain can severely reduce quality of life. An early and important characteristic of the osteoarthritic process is loss of aggrecan from the extracellular matrix, resulting in deficiencies in the biomechanical characteristics of the cartilage. Likewise, MMPs and aggrecanases are known to play a role in many disorders in which extracellular protein degradation or destruction occurs, such as malignant neoplasm, asthma, chronic obstructive pulmonary disease ("COPD"), atherosclerosis, age-related macular degeneration, myocardial infarction, corneal ulceration and other ocular surface diseases, hepatitis, aortic aneurysms, tendonitis, central nervous system diseases, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, and periodontal diseases.
[0006] Accordingly, there is a need for metalloproteinase inhibitors, such as inhibitors of MMPs and aggrecanases. The present invention addresses this need. [0007] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.
3. SUMMARY OF THE INVENTION
[0008] The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof. [0009] The invention provides compounds of the Formula (I):
Figure imgf000003_0001
(I) and pharmaceutically acceptable salts or hydrates thereof, wherein
X is -N- and Y is -COR4, or Y is -N- and X is -COR4; p is 0 or 1;
Ri and R13 are each independently hydrogen, halogen, -OR7, -CN, -Ci-C6-alkyl, -C2-C6- alkenyl, -C2-C6-alkynyl, -NO2, -NR5R6, -SO2NR5R6, -COR7, -COOR7, -C5-C7-cycloalkyl or - C5-C7-aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C3-alkyl, provided that when X is -N- then R13 is hydrogen and when Y is-N- then Ri is hydrogen;
R2 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR7, wherein (a) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is optionally substituted with at least one hydroxyl, halogen, oxygen, -Ci-C6-alkyl, -C2- C6-alkenyl, -C2-C6-alkynyl, -C5-C7-cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, -C5-C7-aryl, - Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C5-Cio-arylalkynyl, -NO2, -CH2NR5R6, -NR5R6, - NR5SO2R6, -SO2NR5R6, -SO2R7, -COR7, -Ci-C3-alkyl-COR7, -COOR7 or -CONR5R6, wherein (1) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a - C5-C7-aryl;
R3 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-C7-cycloalkyl, -R8-C5-C7-cycloalkyl, -C5-Cio-arylalkyl, -C7-Ci2-bicyclic hydrocarbon or -Ri2-C7-Ci2- bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO2NR5R6, -COR7, - COOR7, -CONR5R6, -CORs-B-R9, or -R8-B-R9, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with at least one, (e.g., one to three) halogen or a -Ci-C4-alkyl that is optionally branched, -C2-C3-alkynyl, -C5-C7-aryl, -NR5R6, -C≡N, or -COR7;
R4 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -SO2NR5R6, -SO2R7, -COR7, -COOR7 or -CONR5R6, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
R5 and R6 are each independently hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, - COR7, -C5-C7-aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C3-alkyl;
R7 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, or -C5-CiO- arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one halogen, a -Ci-C3-alkyl, -C5-C7-aryl, or -NR5R6, -OR5;
Rs is -Ci-C6-alkyl, -C2-C6-alkenyl, or -C2-C6-alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl;
R9 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Cio-arylalkyl or -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with at least one halogen, a -Ci-C4-alkyl that is optionally branched, a -Cs-C7-aryl, B-Cs-C7-aryl, -NR5R6, or -COR7, and wherein one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom;
R12 is -CH2- or -CH2CH2-; B is a bond, -O-, -NR7- or -S-.
[0010] A compound of Formula (I) or a pharmaceutically acceptable salt thereof,
(hereinafter being an "8-Hydroxyquinoline Compound") is useful for treating or preventing an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, a myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, a wound that has healed abnormally, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, a periodontal disease or a metalloproteinase-related disorder (hereinafter, each individually or collectively, being a "Condition").
[0011] The invention also provides compositions comprising an 8-Hydroxyquinoline
Compound and a physiologically acceptable carrier or vehicle. The compositions are useful for treating or preventing a Condition.
[0012] The invention further provides methods for treating or preventing a Condition comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.
[0013] The details of the invention are set forth in the accompanying description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. All patents, patent applications and publications cited in this specification are incorporated herein by reference for all purposes.
4. DETAILED DESCRIPTION OF THE INVENTION 4.1 DEFINITIONS AND ABBREVIATIONS
[0014] The term "Ci-C6-alkyl" as used herein refers to a linear or branched, saturated hydrocarbon having from 1 to 6 carbon atoms. Representative Ci-Cβ-alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec -butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, and neohexyl. In one embodiment, the Ci-Cβ-alkyl group is substituted with one or more (e.g., one to three) of the following groups: halogen, - N3, -NO2, -CN, -OR', -SR', -SO2R', -SO2N(R')2, -N(R')2, -COR', -CO2R', -NR5CO2R', - NR'COR', -NR'CONR', or -CON(R')2, wherein each R' is independently selected to be hydrogen or unsubstituted -Ci-C6-alkyl.
[0015] The term "C2-C6-alkenyl" as used herein refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon double bond. In one embodiment, the C2-C6-alkenyl has one or two double bonds. The C2-CO- alkenyl moiety may exist in the E or Z configuration and the compounds of the present invention include both configurations. Representative C2-C6-alkenyl groups include, but are not limited to, ethylenyl, propylenyl, 1-butylenyl, 2-butylenyl, isobutylenyl, sec-butylenyl, 1- pentenyl, 2-pentenyl, isopentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, and isohexenyl. In one embodiment, the C2-C6-alkenyl group is substituted with one or more (e.g., one to three) of the following groups: halogen, -N3, -NO2, -CN, -OR', -SR', -SO2R', -SO2N(R')2, -N(R')2, - COR', -CO2R', -NR5CO2R', -NR'COR', -NR'CONR', or -CON(R' )2, wherein each R' is independently hydrogen or unsubstituted Ci-C6-alkyl.
[0016] The term "Ci-C6-heteroalkyl" refers to a linear or branched, saturated hydrocarbon having from 1 to 6 carbon atoms, which also includes one or more heteroatom each independently selected from sulfur, nitrogen and oxygen. [0017] The term "Cs-Cv-cycloalkyl" as used herein refers to a non-aromatic hydrocarbon ring. Representative C5-C7-cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, and cycloheptyl. In one embodiment, the Cs-Cv-cycloalkyl group is independently substituted with one or more of the following groups: halogen, -N3, -NO2, - CN, -OR', -SR',
-SO2R', -SO2N(R')2, -N(R')2, -COR', -CO2R', -NR5CO2R', -NR'COR', -NR'CONR', or -C0N(R')2, wherein each R' is independently hydrogen or unsubstituted Ci-Cβ-alkyl. When so specified, a C5-C7-cycloalkyl can have one to three ring carbon atoms each independently optionally replaced with a nitrogen, sulfur or oxygen atom (i.e., a "C5-C7 heterocycloalkyl"). [0018] The term "C2-C6-alkynyl" as used herein refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon triple bond. Representative C2-C6-alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, isobutynl, sec-butynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, and isohexynyl. In one embodiment, the C2-C6-alkynyl group is substituted with one or more of the following groups: halogen, -N3, -NO2, -CN, -OR', -SR', - SO2R', -SO2N(R')2, -N(R')2, -COR', -CO2R', -NR5CO2R', -NR'COR', -NR'CONR', or - CON(R' )2, wherein each R' is independently hydrogen or unsubstituted Ci-Cβ-alkyl. [0019] The terms "C5-Ci0-arylalkyl," "C5-Ci0-arylalkenyl," or "C5-Ci0-arylalkynyl" as used herein refer to an alkyl, alkenyl, or alkynyl, respectively, substituted with an aryl group, as those terms are defined herein. Illustrative examples include benzyl, phenethyl, styryl, cinnamyl and the like.
[0020] The term "administer", "administering", or "administration", as used herein refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to an animal, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the animal, which can form an equivalent amount of active compound within the animal's body. [0021] The term "animal" as used herein includes, without limitation, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon, or rhesus. In one embodiment, the animal is a mammal. In another embodiment, the animal is a human. [0022] The term "aryl" as used herein refers to an aromatic species containing 1 to 3 aromatic rings, either fused or linked. In one embodiment, the aryl group is independently substituted with one or more of the following groups: -V-halogen, -V-N3, -V-NO2, -V-CN, - V-OR', -V-SR', -V-SO2R', -V-SO2N(R')2, -V-N(R')2, -V-COR', -V-CO2R', -V-NR5CO2R', - V-NR' COR', -V-NR' CONR', or -V-C0N(R')2, wherein each R' is independently hydrogen or unsubstituted Ci-Cβ-alkyl; and wherein each V is independently a bond or Ci-C6-alkyl. The term "aryl" as used herein, may therefore be understood to refer to substituted aryl, heteroaryl, or substituted heteroaryl groups. A "C5-C7 aryl," for example, has from 5 to 7 carbon atoms, wherein one to three carbon atoms of the aryl are each independently optionally replaced with a nitrogen, sulfur or oxygen atom (i.e., a "C5-C7 heteroaryl" group").
[0023] The term "conditions effective to" as used herein refers to synthetic reaction conditions which will be apparent to those skilled in the art. [0024] The term "effective amount" as used herein refers to an amount of a compound or pharmaceutically acceptable salt of a compound that, when administered to an animal, is effective to prevent, to at least partially ameliorate, or to cure, a condition from which the animal suffers or is suspected to suffer.
[0025] The term "carrier", as used herein, encompasses carriers, excipients, and diluents. [0026] The term "prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula (I). [0027] The term "halogen" as used herein refers to fluorine, chlorine, bromine, and iodine.
[0028] The term "isolated and purified" as used herein refers to a component separated from other components of a reaction mixture or a natural source. In certain embodiments, the isolate contains at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the compound or pharmaceutically acceptable salt of the compound by weight of the isolate. [0029] The term "pharmaceutically acceptable salt" as used herein refers to a salt of an acid and a basic nitrogen atom of a compound of an 8-Hydroxyquinoline Compound. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, hydrochloride, bromide, hydrobromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, succinate, fumarate, maleate, malonate, mandelate, malate, phthalate, and pamoate. The term "pharmaceutically acceptable salt" as used herein also refers to a salt of a compound of the present invention having an acidic functional group, such as a carboxylic acid functional group, and a base. Exemplary bases include, but are not limited to, hydroxide of alkali metals including sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, organic amines such as unsubstituted or hydroxyl-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(Ci-C6)-alkylamine), such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2- hydroxyethyl)amine; N-methyl-D-glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, and the like. The term "pharmaceutically acceptable salt" also includes a hydrate of an 8-Hydroxyquinoline Compound and a hydrate of a pharmaceutically acceptable salt of an 8-Hydroxyquinoline Compound. [0030] The term "phenyl" as used herein refers to a substituted or unsubstituted phenyl group. In one embodiment, the phenyl group is substituted with one or more of the following groups: -V-halogen, -V-N3, -V-NO2, -V-CN, -V-OR', -V-SR', -V-SO2R', -V-
SO2N(R')2,
-V-N(R' )2, -V-COR', -V-CO2R', -V-NR5CO2R', -V-NR' COR', -V-NR' CONR', or
-V-C0N(R')2, wherein each R' is independently hydrogen or unsubstituted Ci-Cβ-alkyl; and wherein each V is independently a bond or Ci-Cβ-alkyl.
[0031] The term "substantially free of its corresponding opposite enantiomer" as used herein means that the compound contains no more than about 10% by weight of its corresponding opposite enantiomer. In other embodiments, the compound that is substantially free of its corresponding opposite enantiomer contains no more than about 5%, no more than about 1%, no more than about 0.5%, or no more than about 0.1% by weight of its corresponding opposite enantiomer. An enantiomer that is substantially free of its corresponding opposite enantiomer includes a compound that has been isolated and purified or has been prepared substantially free of its corresponding opposite enantiomer.
[0032] The term "tautomer" as used herein refers to compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See, Jerry
March, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, Fourth
Edition, John Wiley & Sons, pages 69-74 (1992).
[0033] The term "treating", with regard to an animal, refers to improving at least one symptom of the animal's disease or disorder. Treating can be curing the disease or condition or improving it.
[0034] The following abbreviations are used herein and have the indicated definitions: ACN or MeCN is acetonitrile; DIEA is diisopropyl ethylamine; DMF is dimethylformamide; DMSO is dimethylsulfoxide; HPLC is high-performance liquid chromatograpy; LC/MS is liquid chromatography/mass spectrometry; NMP is N-methyl-2- pyrrolidone; THF is tetrahydrofuran; and ^-BuOK is potassium tert-butoxide.
4.2 8-HYDROXYOUINOLINE COMPOUNDS
[0035] As stated above, the present invention encompasses 8-Hydroxyquinoline
Compounds of Formula (I):
Figure imgf000011_0001
and pharmaceutically acceptable salts or hydrates thereof, wherein
X is -N- and Y is -COR4, or Y is -N- and X is -COR4; p is 0 or 1;
Ri and R13 are each independently hydrogen, halogen, -OR7, -CN, -Ci-C6-alkyl, -C2-C6- alkenyl, -C2-C6-alkynyl, -NO2, -NR5R6, -SO2NR5R6, -COR7, -COOR7, -C5-C7-cycloalkyl or - C5-C7-aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C3-alkyl, provided that when X is -N- then Ri3 is hydrogen and when Y is-N- then Ri is hydrogen;
R2 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Ci0-arylalkyl, -C5-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, Cg-Cis-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR7, wherein (a) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is optionally substituted with at least one hydroxyl, halogen, oxygen, -Ci-C6-alkyl, -C2- C6-alkenyl, -C2-C6-alkynyl, -C5-C7-cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, -C5-C7-aryl, - Cs-Cio-arylalkyl, -Cj-Cio-arylalkenyl, -C5-Ci0-arylalkynyl, -NO2, -CH2NR5R6, -NR5R6, - NR5SO2R6, -SO2NR5R6, -SO2R7, -COR7, -Ci-C3-alkyl-COR7, -COOR7 or -CONR5R6, wherein (1) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a - C5-C7-MyI;
R3 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-C7-cycloalkyl, -R8-C5-C7-cycloalkyl, -Cs-Qo-arylalkyl, -C7-Ci2-bicyclic hydrocarbon or -R12-C7-C12- bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO2NR5R6, -COR7, - COOR7, -CONR5R6, -COR8-B-R9, or -R8-B-R9, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with at least one, (e.g., one to three) halogen or a -C1-C4-alkyl that is optionally branched, -C2-C3-alkynyl, -C5-C7-aryl, -NR5R6, -C≡N, or -COR7;
R4 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -SO2NR5R6, -SO2R7, -COR7, -COOR7 or -CONR5R6, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
R5 and R6 are each independently hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, - COR7, -C5-C7-aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C3-alkyl;
R7 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, or -C5-CiO- arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one halogen, a -Ci-C3-alkyl, -C5-C7-aryl, or -NR5R6, -OR5;
R8 is -Ci-C6-alkyl, -C2-C6-alkenyl, or -C2-C6-alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl; Rg is hydrogen, -Ci-Cβ-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -Cs-C7-aryl, -Cs-Cio-arylalkyl or -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with at least one halogen, a -Ci-C4-alkyl that is optionally branched, a -Cs-C7-aryl, B-Cs-C7-aryl, -NR5R6, or -COR7, and wherein one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom;
Ri2 is -CH2- or -CH2CH2-; B is a bond, -O-, -NR7- or -S-.
[0036] In some embodiments of the compound of Formula (I), Ri is a halogen, for example, chlorine, bromine or fluorine.
[0037] In other embodiments of the compound of Formula (I), Ri is a -Ci-C6-alkyl, for example, -CH3.
[0038] In still other embodiments of the compound of Formula (I), Ri is hydrogen.
[0039] In other embodiments of the compound of Formula (I), Ri is -NO2.
[0040] In other embodiments of the compound of Formula (I), Ri is -NR5R6, for example, -NH2 or -N(CH3)2.
[0041] In other embodiments, in the compound of Formula (I), Ri is a -C5-C7- cycloalkyl, -Cs-Cv-heterocyloalkyl, or -Cs-Cv-heteroaryl, for example,
Figure imgf000013_0001
[0042] In addition, compounds according to Formula (I) include those wherein R2 is a
-C5-C7-aryl, which is optionally substituted with one to three hydroxyl, halogen, -Ci-Cβ-alkyl, -C2-C6-alkynyl, -Cs-C7-aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -Cs-Cio-arylalkynyl, - NO2, -Cs-Cr-cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, BR9, -COR7, -Ci-Cs-alkyl-COR?, - CH2NRSRO, or -NR5R6, and wherein one to three carbon atoms of the aryl or the substituent are each independently optionally replaced with a nitrogen, sulfur or oxygen atom, for example, and the substituent is optionally branched and optionally substituted with one to three halogen atoms or -Ci-C3-alkyl groups. Examples of such R2 include:
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000016_0001
Figure imgf000017_0001
[0043] In other embodiments, R2 is a -Cs-C7-aryl, wherein one to three of the carbon atoms is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and the aryl group is optionally substituted with one or more -Cs-C7-aryl, -Cs-Cio-arylalkyl, -C5- Cio-arylalkenyl, -Cs-Cio-arylalkynyl, which optionally (1) has one to three of the carbon atoms each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) is substituted with a halogen, -Ci-C3-alkyl that optionally has one to three of the carbon atoms optionally independently replaced with a nitrogen, sulfur or oxygen atom, for example:
Figure imgf000017_0002
Figure imgf000018_0001
Figure imgf000019_0001
[0044] Also included are compounds of Formula (I), wherein R2 is a -C7-Ci2-bicyclic or a C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic, one to three carbon atoms are each independently, optionally replaced with a nitrogen, sulfur or oxygen atom, and the hydrocarbon group is optionally substituted with one or more oxygen atoms, halogen atoms, or one to three -Ci-Cβ-alkyl groups having one to three carbon atoms optionally replaced with an oxygen, for example:
Figure imgf000019_0002
Figure imgf000020_0001
[0045] In addition, compounds of Formula (I) are those wherein R2 is a -C2-Ce- alkenyl, for example:
Figure imgf000021_0001
[0046] In other embodiments, R2 is a -Cs-Cio-arylalkyl or -Cs-Cio-arylalkenyl, which is optionally substituted with a -Ci-Cβ-alkyl, and wherein one to three carbon atoms of the alkyl is optionally replaced with an oxygen, for example:
Figure imgf000021_0002
[0047] Further compounds of Formula (I) include those wherein R2 is a -C5-C7-aryl, which is optionally substituted with -CH2NR5R6, -NR5R6 or -NR5SO2R6, wherein one to three of the carbon atoms is each independently optionally replaced with a nitrogen or oxygen atom, for example:
Figure imgf000021_0003
Figure imgf000022_0001
[0048] Particular embodiments of the compounds of Formula (I) include those wherein Ri and R2 are, in combination, as specified in the above identified embodiments. [0049] Additionally, compounds of Formula (I) are those wherein R3 is -CORs-B-Rg or -R8-B-R9, wherein R8 is a -Ci-C3-alkyl, R9 is a -Cs-C7-aryl or C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein the aryl or bicyclic hydrocarbon is optionally substituted with one to three halogen atoms, -Ci-C4-alkyl groups, -C5-C7- cycloalkyl groups, -Cs-C7-aryl groups, -B-C5-C7-aryl groups, -NR5R6 groups, or -COR7 groups and wherein one to three carbon atoms in the substituents are each independently optionally replaced with an oxygen or nitrogen atom, and B is a bond or -O-, for example:
Figure imgf000022_0002
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
[0050] In other embodiments, R3 is -COR8-B-R9, -Rg-Cs-Cy-cycloalkyl, or -R8-B-R9, wherein R8 is a -Ci-C3-alkyl, R7 is a -Ci-C3-alkyl or hydrogen; R9 is a -Cs-C7-aryl, -R12-Cs- C7-cycloalkyl, or -Ri2-C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic and R12 is -CH2-, wherein (a) one or more of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom, and (b) the cycloalkyl, aryl or bicyclic hydrocarbon group is optionally substituted with one to three halogen, -C1- C4-alkyl groups, -C2-C3-alkynyl groups, -Cs-C7-aryl groups, -NR5R6, -C≡N or -COR7, or any combination thereof; and B is -NR7-, for example:
Figure imgf000025_0002
Figure imgf000026_0001
[0051] Other compounds include those wherein R3 is -Rs-Cs^-cycloalkyl or -R8-B-
Rg, wherein R8 is a -Ci-C3-alkyl, B is -NR7-, R7 is a -Ci-C3-alkyl or hydrogen, R9 is a -C5-C7- aryl or a -Ri2-C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic and R12 is -CH2-, wherein (a) one or more of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom, and (b) the cycloalkyl, aryl or bicyclic hydrocarbon group is optionally substituted with a -Ci-C3-alkyl or a -Cs-C7-aryl, for example:
Figure imgf000026_0002
Figure imgf000027_0001
[0052] Alternatively, compounds of Formula (I) include those wherein R3 is -COR7, wherein R7 is a -Ci-Cβ-alkyl, -Cs-C7-aryl or -Cs-Cio-arylalkyl, for example:
Figure imgf000027_0002
[0053] Also included are compounds of Formula (I) wherein R3 is a -Cs-Cio-arylalkyl, and a carbon atom is optionally replaced with an oxygen atom, for example:
Figure imgf000027_0003
[0054] Compounds according to Formula (I) also include those wherein R3 is a
-Ci-Cβ-alkyl optionally substituted with a halogen, for example:
XN, [0055] Particular embodiments of the compounds of Formula (I) include those wherein R1, R2 and R3 are, in combination, as specified in the above identified embodiments.
[0056] Additionally, compounds according to Formula (I) include those wherein R4 is
-Ci -alkyl.
[0057] Additionally, compounds according to Formula (I) include those wherein R4 is hydrogen.
[0058] Alternatively, compounds according to Formula (I) also include those wherein
R4 is -SO2R7.
[0059] Particular embodiments of the compounds of Formula (I) include those wherein R1, R2, R3 and R4 are, in combination, as specified in the above identified embodiments.
[0060] The 8 -hydroxy quinoline Compounds of the invention may contain one or more asymmetric centers, and can thus give rise to optical isomers and diastereomers. While depicted without respect to stereochemistry in the compounds or pharmaceutically acceptable salts of compounds of the present invention, the present invention includes such optical isomers and diastereomers, as well as racemic and resolved, enantiomerically pure R and S stereoisomers, and also other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Where a stereoisomer is provided, it can in some embodiments be provided substantially free of its corresponding opposite enantiomer.
[0061] In addition, the compounds and pharmaceutically acceptable salts of compounds of the present invention may exist as tautomers. Such tautomers can be transient or isolatable as a stable product. These tautomers are within the scope of the present invention.
[0062] The following are examples of compounds of Formula (I):
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(pyridin-3- yloxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-[3- (dimethylamino)phenoxy]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methoxypheny l)methy 1] acetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-[3- (dimethylamino)phenoxy]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxy acetamide
N- [(5 -chloro-8-hydroxyquinolin-7-yl)(3 -nitrophenyl)methyl] -2-(pyridin-3 - yloxy)acetamide
2-(4-acetylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitrophenyl)methyl] acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
N- [(5 -chloro-8-hydroxyquinolin-7-yl)(3 -nitrophenyl)methyl] -2-(3 ,5 - dichlorophenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-2-(pyridin-3- yloxy)acetamide
N- [(5 -chloro-8-hydroxyquinolin-7-yl)(3 -fluorophenyl)methyl] -2- [3 - (dimethylamino)phenoxy]acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-(4-tert-butylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(3,5- dichlorophenyl)glycinamide Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-(4- cyanophenyl)glycinamide
N2-(4-acetylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-[3- (dimethylamino)phenyl]glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-(4-tert-butylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-pyridin-3- ylglycinamide
N2-(4-acetylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitropheny l)methy 1] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-[4-(acetylamino)phenyl]-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitropheny l)methy 1] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-fluorophenyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-cyanophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,4-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,5-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(2-chloro-4-hydroxyphenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide N-[(2-chloro-6-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(2-chloro-4-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N- { (5 -chloro- 8-hydroxyquinolin-7 -y 1) [2-(trifluoromethy l)pheny 1] methyl } -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,4-dichlorophenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chloro-5-nitrophenyl)methyl]-2- phenoxyacetamide
N-[(2-chlorophenyl)(8-hydroxy-5-methylquinolin-7-yl)methyl]-2 -phenoxyacetamide N-[(8-hydroxy-5-methylquinolin-7-yl)(3-nitrophenyl)methyl]-2 -phenoxyacetamide N-[(8-hydroxy-5-methylquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide N-[(5-bromo-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2 -phenoxyacetamide N-[(5-bromo-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2 -phenoxyacetamide N-[(5-bromo-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methyl]glycinamide
2-(benzyloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-methyl-N2- phenylglycinamide N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
2-(benzyloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]glycinamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]benzamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]benzamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(pyridin-3-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-thienyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,5-dimethoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,4-dichlorophenyl)methyl]-2- phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-methoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-phenoxyphenoxy)acetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- methoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-phenoxyacetamide
N-[(2-chlorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(4-chlorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(3-fluorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[[4-(dimethylamino)phenyl](8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-hydroxy-3-methoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-chlorophenoxy)acetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-2-phenoxyacetamide
N-[(3-chloro-4-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,6-dichlorophenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(pyridin-3-yloxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(3- methoxyphenoxy)acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methoxypheny l)methy 1] acetamide
N-[(2-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-nitroquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl]-2-phenoxy acetamide
N-[(5-fluoro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-methoxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-methoxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenoxy acetamide
N-[(S)-(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2- phenoxyacetamide
N-[(R)-(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2- phenoxyacetamide
N-[(R)-(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxy acetamide N-[(S)-(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-morpholin-4-ylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-hydroxyphenyl)methyl]-2-phenoxyacetamide 2-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}benzoic acid N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-methoxyphenyl)methyl]-2- phenoxyacetamide ethyl(3-{(5-chloro-8-hydroxyquinolin-7- yl)[(phenoxyacetyl)amino]methyl}phenyl)acetate
N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-methoxyphenoxy)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-chlorophenoxy)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-methylphenoxy)phenyl]methyl}-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-phenoxyphenyl)methyl]-2- phenoxyacetamide
N- [ [3 -(benzy loxy)pheny 1] (5 -chloro- 8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-fluorophenyl)methyl]-2-phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(dimethylamino)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(diethylamino)phenyl]methyl}-2- phenoxyacetamide
N- { (5 -chloro- 8-hy droxy quinolin-7 -y 1) [4-(dibuty lamino)pheny 1] methyl } -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-isopropylphenyl)methyl]-2- phenoxyacetamide
N- [ [4-(ally loxy)pheny 1] (5 -chloro- 8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(4-butoxyphenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-hex- 1 -yn- 1 -ylphenyl)methyl]-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(phenylethynyl)phenyl]methyl}-2- phenoxyacetamide
N- [ [4-(benzy loxy)pheny 1] (5 -chloro- 8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[biphenyl-4-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-pyridin-4-ylphenyl)methyl]-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(lH-pyrazol-l-yl)phenyl]methyl}-2- phenoxyacetamide
N-[[4-(4-tert-butyl-l,3-thiazol-2-yl)phenyl](5-chloro-8-hydroxyquinolin-7- yl)methyl]-2-phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(l,2,3-thiadiazol-4-yl)phenyl]methyl}-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,4-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,4-dimethoxyphenyl)methyl]-2- phenoxyacetamide
N-[[3-(benzyloxy)-4-methoxyphenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(5-methyl-2-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(5-phenyl-2-furyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-methyl-2-thienyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(lH-indol-7-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(lH-indol-4-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(l-methyl-lH-indol-3-yl)methyl]-2- phenoxyacetamide
N-[l,3-benzodioxol-4-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-8-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-4-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-5-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxy-l-naphthyl)methyl]-2- phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(9-phenanthryl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(6-methoxy-2-naphthyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,3-dihydro-l,4-benzodioxin-6-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-3-yl)methyl]-2-phenoxyacetamide N-[l-benzofuran-2-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(l-methyl-lH-indol-2-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,3-dihydro-l-benzofuran-5-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,2-dimethyl-3,4-dihydro-2H-chromen-6- yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-oxo-4H-chromen-3-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(6-methyl-4-oxo-4H-chromen-3-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4H-pyrazolo[l,5-c][l,3]thiazol-2-yl)methyl]-2- phenoxyacetamide
N-[l,3-benzodioxol-5-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(6-chloro-l,3-benzodioxol-5-yl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(l-methyl-lH-l,2,3-benzotriazol-5-yl)methyl]- 2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(5,6-dihydro-8H-imidazo[2,l-c][l,4]oxazin-2- yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-2- yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-3-phenylpropanamide benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(pyridin-2-yl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(2-furyl)methyl]carbamate benzyl [l,3-benzodioxol-5-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]carbamate
N- [ 1 -(5 -chloro-8-hydroxyquinolin-7-yl)prop-2-en- 1 -yl] -2-phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)but-2-en-l-yl]-2-phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)hex-2-en-l-yl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(cyclohex-l-en-l-yl)methyl]-2- phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylprop-2-en-l-yl]-2- phenoxyacetamide
N-[(2Z)-l-(5-chloro-8-hydroxyquinolin-7-yl)-2-methoxy-3-phenylprop-2-en-l-yl]-2- phenoxyacetamide benzyl [ 1 -(5-chloro-8-hydroxyquinolin-7-yl)-2-phenylethyl]carbamate
N-[l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylpropyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-fluorophenyl)methyl]-2-phenylacetamide
N-[[3-(benzyloxy)-4-methoxyphenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenylacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylprop-2-en-l-yl]-2- phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-methyl-2-thienyl)methyl]-2-phenylacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-chloroacetamide
N-[(4-chloro-l-hydroxy-2-naphthyl)(phenyl)methyl]-2-phenoxyacetamide
N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
5-chloro-7-{ {3-
[(methylsulfonyl)amino]phenyl} [(phenoxyacetyl)amino]methyl}quinolin-8-yl methanesulfonate N-[[3-(acetylamino)phenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
2 -chloro-N-(3 - { (5 -chloro- 8 -hydroxy quinolin-7 - yl)[(phenoxyacetyl)amino]methyl}phenyl)acetamide
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)- N2,N2-dimethylglycinamide
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)-N2- methylglycinamide
(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)acetic acid
2-(4-bromophenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(3,4,5- trimethoxyphenoxy)acetamide
2-(biphenyl-4-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(3,5- dimethoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- pentylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- propylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- isopropylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- cyclopentylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(3- ethylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(3,5- dimethoxyphenoxy)acetamide
2-(biphenyl-4-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-(4-bromophenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-(l,3-benzodioxol-5-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N2-benzyl-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-phenylpiperidin-l- yl)acetamide
N2-(l,3-benzodioxol-5-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7- yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-2- ylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-3- ylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-4- ylmethyl)glycinamide
N2-(biphenyl-4-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7- yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N2-(l,3-benzodioxol-5-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[[5-(dimethylamino)-8-hydroxyquinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide
N-[[8-hydroxy-5-(lH-pyrrol-l-yl)quinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-pyrrolidin-l-ylquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[2-(8-Hydroxyquinolin-7-yl)-l-phenylethyl]-2-phenoxyacetamide
N-[l-(l,3-Benzodioxol-5-yl)-2-(5-chloro-8-hydroxyquinolin-7-yl)ethyl]-2- phenoxyacetamide
2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- y lmethy l)pheny 1] ethanamine
2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(pyrrolidin-l- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[4-(morpholin-4- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l-ylmethyl)phenyl]ethyl}- 2-phenoxyacetamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l-ylmethyl)phenyl]ethyl}- 2-(4-chlorophenoxy)-2-methylpropanamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2-thienyl)phenyl]ethyl}-2- phenoxyacetamide
2-(Benzyloxy)-N-{2-(5-chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl] ethyl} acetamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2-thienyl)phenyl]ethyl}-2- (4-chlorophenoxy)-2-methylpropanamide
2-(4-tert-Butylphenoxy)-N-{2-(5-chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl] ethyl} acetamide
2 - [ 8 -(Benzy loxy)-5 -chloroquinolin-7 -y 1] - 1 - { 5 - [(dimethy lamino)methy 1] -2- furyl} ethanamine
N-(2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]- 1 - {5-[(dimethylamino)methyl]-2- furyl} ethyl)-2-phenoxyacetamide
N-[2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-{5-[(dimethylamino)methyl]-2- furyl} ethyl]-2-phenoxyacetamide
N-[2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-(5-dimethylaminomethyl-furan-2-yl)- ethyl] -isobutyramide
N-[2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-{5-[(dimethylamino)methyl]-2- furyl}ethyl]-2-methylpropanamide
2- { [(phenoxyacetyl)amino](phenyl)methyl}quinolin-8-yl phenoxyacetate N-[(8-hydroxyquinolin-2-yl)(phenyl)methyl]-2-phenoxyacetamide 2-[amino(phenyl)methyl]quinolin-8-ol and pharmaceutically acceptable salts thereof.
4.3 METHODS OF MAKING 8-HYDROXYOUINOLINE COMPOUNDS
[0063] The following methods may yield a mixture of stereoisomers or isolated stereoisomers. Any stereoisomers produced as mixtures can obviously be isolated if so desired. Both mixtures of any stereoisomers and any isolated stereoisomers are thus encompassed within the scope of this invention.
First General Synthetic Scheme for Preparation of 8-Hydroxyquinoline Compounds
[0064] Compounds of Formula (I) in which X is -N-, Y is -COR4, R43 is hydrogen, and p=0 may be prepared by the following synthetic scheme:
Figure imgf000042_0001
R4Z Basic conditions, polar aprotic solvent
Figure imgf000042_0002
wherein Z is chlorine, bromine, or iodine and R1, R2, R3, and R4 are as defined above. [0065] In certain embodiments, the first step may be run at a temperature between
100-2000C, alternatively between 120-1800C, and preferably between 140-1600C.
[0066] Additionally, in certain embodiments, the second step may be run at a temperature between 0-1000C, alternatively between 25-75°C, and preferably between 40-
600C.
[0067] In certain embodiments, weak bases such as DIEA or K2CO3 are used to create the basic conditions during the second step.
[0068] In some embodiments, the polar aprotic solvent may be DMF, DMSO, NMP,
MeCN, or THF.
[0069] In one embodiment in the First General Synthetic Scheme, R3 is -COR7, and
R7 is as defined above.
Second General Synthetic Scheme for the Preparation of 8-Hydroxyquinoline Compounds
[0070] Alternatively, compounds of Formula (I) in which X is -N-, Y is -COR4, R13 is hydrogen, and p=0 may be prepared by this second synthetic scheme:
Figure imgf000044_0001
wherein Hal is halogen,
Z is chlorine, bromine, or iodine,
A is -OR7, -NR5R6 or -OR8-B-R9,
R5, R6, R7 and R9 are each independently -Cs-C7-aryl or -Cs-Cio-arylalkyl, as defined above, and R1, R2, R4 and R8 are as defined above.
[0071] In certain embodiments, the first step may be run at a temperature between
100-2000C, alternatively between 120-1800C, and preferably between 140-1600C.
[0072] When the second step is run with a strong base in a polar aprotic solvent, the temperature may be between -15°C and 200C, preferably between -5°C and 100C.
[0073] In some embodiments, strong bases such as NaH, KH, or ?-BuOK are used to create the basic conditions.
[0074] In some embodiments, AH is
Figure imgf000045_0001
and the compound produced is of the formula:
Figure imgf000045_0002
wherein Ri0 is a hydrogen, halogen or -Ci-C3-alkyl, and R1, R2, and R4 are as previously defined.
[0075] When the second step is run with a weak base in a polar aprotic solvent, the temperature may be between 100C and 300C, preferably between 15°C and 25°C.
[0076] In some embodiments, weak bases such as DIEA or K2CO3 are used to create the basic conditions.
[0077] In some embodiments, AH is
Figure imgf000045_0003
and the compound produced is of the formula:
Figure imgf000046_0001
wherein R10 is a hydrogen, halogen or -Ci-C3-alkyl, and R1, R2, R3, and R4 are as previously defined.
[0078] In some embodiments using the Second General Synthetic Scheme, the polar aprotic solvent may be DMF, DMSO, NMP, MeCN, or THF.
[0079] In certain embodiments, the third step may be run at a temperature between 0-
1000C, alternatively between 25-75°C, and preferably between 40-600C.
[0080] In one embodiment, Scheme 1 is used to make the 8-Hydroxyquinoline
Compounds.
Scheme 1
1
Figure imgf000046_0002
wherein Ri and R7 are as previously defined, and Rn may be a hydrogen, halogen or a C1-C3 alkyl.
[0081] 8-Hydroxyquinoline target molecules IV may be prepared according to
Scheme 1 by reacting 8-Hydroxyquinolines I with aryl or heteroaryl aldehydes II and acetamides III at 1500C similar to procedures found in Mohrle, H et. al. Chem. Ber. 1974, 707, 2675, Pirrone, F. Gazz. CMm Ital. 1936, 66, 518, and Pirrone, F. Gazz. CMm Ital. 1937, 67, 529 (all three references are fully incorporated herein by reference). 8- Hydroxyquinolines I can be purchased commercially or prepared synthetically via standard organic chemistry protocols. (Two examples include Shen, Liang et. al. Tetrahedron Letters 2004, 45, 3961, and Bradshaw, Jerald S. et. al. Supramolecular Chemistry 2001, 13, 499. Both are fully incorporated herein by reference.) Aryl or heteroaryl aldehydes II can be purchased commercially or prepared synthetically via standard organic chemistry protocols. Acetamides III can be purchased commercially or prepared synthetically via standard organic chemistry protocols.
[0082] In another embodiment, Scheme 2 is used to make the 8-Hydroxyquinoline
Compounds.
Scheme 2
Figure imgf000047_0001
wherein R1, Rs1 R4, Rio and Rn are as previously defined.
[0083] 8-Hydroxyquinoline target molecules VII may be prepared according to
Scheme 2 by reacting 8-Hydroxyquinolines I with aryl or heteroaryl aldehydes II and chloro acetamide V at 1500C similar to procedures found in Mohrle, H et. al. Chem. Ber. 1974, 707, 2675, Pirrone, F. Gazz. CMm Ital. 1936, 66, 518, and Pirrone, F. Gazz. CMm Ital. 1937, 67, 529. Displacement of the chloride from resulting compound VI with commercially purchased or readily available phenols with a strong base such as NaH, KH or ?-BuOK in a polar aprotic solvent such as DMF, DMSO, NMP, MeCN or THF affords VII. [0084] In yet another embodiment, Scheme 3 is used to make the 8-Hydroxyquinoline
Compounds. Scheme 3
Figure imgf000048_0001
wherein R1, Ri0 and Rn are as previously defined.
[0085] 8-Hydroxyquinoline target molecules VIII may be prepared according to
Scheme 3 by reacting 8-hydroxyquinolines I with aryl or heteroaryl aldehydes II and chloro acetamide V at 1500C similar to procedures found in Mohrle, H et. al. Chem. Ber. 1974, 707, 2675, Pirrone, F. Gazz. CMm Ital. 1936, 66, 518, and Pirrone, F. Gazz. Chim ltd. 1937, 67, 529. Displacement of the chloride from resulting compound VI with commercially purchased or readily available anilines, heteroaryl derivatives of anilines, aryl amines, heteroaryl amines, or benzyl amines with a weak base such as DIEA or K2CO3 in a polar aprotic solvent such as DMF, DMSO, NMP, MeCN or THF affords VIII.
Scheme 4
Figure imgf000048_0002
Option 1
Figure imgf000048_0003
Figure imgf000048_0005
Figure imgf000048_0004
wherein
Ri is hydrogen or halogen provided that Option 1 is used when Ri is halogen; R2 is -C5-C7-aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, or C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic.
[0086] 8-Hydroxyquinoline target molecules IX and X may be prepared according to Scheme 4 by O-allylating 8-Hydroxyquinolines unsubstituted or substituted at the 5-position using allyl halide and an appropriate base such as potassium carbonate in acetone followed by Claisen rearrangement of the neat material or as a solution in a high-boiling solvent conducted by conventional heating or in a microwave reactor. The products are then O- benzyl protected with benzyl bromide and an appropriate base such as potassium carbonate in acetone followed by dihydroxylation of the double bond using a suitable oxidant such as the osmium tetroxide/4-methylmorpholine N-oxide system in water/acetone. The diols then undergo oxidative cleavage using sodium metaperiodate in water and a polar aprotic solvent miscible with water such as tetrahydrofuran to give the aldehydes that are stable at room temperature. Addition of aryl Grignard reagents to the aldehydes at low temperature in dry tetrahydrofuran or ether provides the alcohols. The alcohols are either converted to the azides with diphenyl phosphoryl azide and an appropriate base such as 1,8- diazabicyclo[5.4.0]undec-7-ene at elevated temperatures, hydrogenated under standard conditions using and appropriate metal catalyst such as 10% palladium on carbon and N- acylated with an acid chloride such as phenoxyacetyl chloride and an appropriate base such as triethylamine in tetrahydrofuran (Option 1 to give compounds IX) or subjected to a Ritter reaction with a nitrile such as phenoxyacetonitrile and strong acid such as sulfuric acid followed by deprotection with 3N HCl in a polar protic solvent such as methanol (Option 2 to give compounds X).
Scheme 5
PPh3, THF, H2O 65-75°C,
Figure imgf000050_0001
CH3CN^ - 25h
Figure imgf000050_0002
Figure imgf000050_0003
Lawesson's ZnCI2, PhH, HNEt2 Reagent 1BuOH, acetone, rt PhCH3, reflux
Figure imgf000050_0005
Figure imgf000050_0004
3-bromophenacylbromide
When R2 contains thiophene
Figure imgf000050_0006
wherein
Ri is halogen;
R2 is -C5-C7-aryl that is optionally substituted with at least one -Ci-Cβ-alkyl, -C2-C6-alkenyl,
-C2-C6-alkynyl, -Cj-Cv-cycloalkyl, -Q-Cs-alkyl-Cs-Cy-cycloalkyl, -C5-C7-aryl, -C5-C10- arylalkyl, -Cs-Cio-arylalkenyl, -Cs-Cici-arylalkynyl, wherein (1) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is optionally replaced with one to three nitrogen, sulfur or oxygen atoms, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a -Cs-Cv-aryl, or is optionally branched;
R3 is -COR7 or -COR8-B-R9
R7 is -Ci-Cβ-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -Cs-C7-aryl, or -Cs-Cio-arylalkyl, wherein
(a) at least one of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is optionally replaced with one to three nitrogen, sulfur or oxygen atoms, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with at least one -Ci-C3-alkyl or - C5-C7-aryl or is optionally branched; and Rs, R9, and B are as defined above.
[0087] In Scheme 5, the benzyl protected aldehydes whose synthesis is described in Scheme 4 are treated with either aryl Grignard reagents at low temperature in dry tetrahydrofuran or ether or aryl halides that have undergone lithium-halogen exchange at low temperature in dry tetrahydrofuran or ether to provide the alcohols which are then converted to azides using diphenyl phosphoryl azide and an appropriate base such as 1,8- diazabicyclo[5.4.0]undec-7-ene at elevated temperatures. The azides are subjected to a Staudinger reduction using triphenylphosphine in aqueous tetrahydrofuran followed by N- acylation with an acid chloride and an appropriate base such as triethylamine in tetrahydrofuran. The final O-benzyl deprotection is conducted with in situ generated iodotrimethylsilane using sodium iodide and chlorotrimethylsilane in acetonitrile at elevated temperature to give the final products XL When R2 contains thiophene, the aryl bromide was synthesized from 3-bromophenacylbromide by condensation with acetone in the presence of zinc chloride using the procedure found in Nevar, N. et al. Synthesis, 2000, 1259. The resulting 1,4-diketone is then cyclized in the presence of Lawesson's reagent at high temperature to give the required thiophene.
4.4 THERAPEUTIC/PROPHYLACTIC ADMINISTRATION
[0088] Due to their activity, the 8-Hydroxyquinoline Compounds are advantageously useful in veterinary and human medicine. As described above, the 8-Hydroxyquinoline Compounds are useful for treating or preventing a Condition in a mammal in need thereof. [0089] When administered to a mammal, the 8-Hydroxyquinoline Compounds can be administered as a component of a composition that comprises a physiologically acceptable carrier or vehicle. The present compositions, which comprise an 8-Hydroxyquinoline Compound, can be administered orally. The 8-Hydroxyquinoline Compounds can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, or intestinal mucosa), by intratracheal administration, or by inhalation, and can be administered together with another biologically active agent. Administration can be systemic or local. Various known delivery systems, including encapsulation in liposomes, microparticles, microcapsules, and capsules, can be used. [0090] Methods of administration include, but are not limited to, intradermal, intratracheal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin. In some instances, administration results in the release of the 8-Hydroxyquinoline Compounds into the bloodstream. The mode of administration can be left to the discretion of the practitioner.
[0091] In one embodiment, the 8-Hydroxyquinoline Compounds are administered orally.
[0092] In another embodiment, the 8-Hydroxyquinoline Compounds are administered intravenously.
[0093] In another embodiment, the 8-Hydroxyquinoline Compounds are administered topically.
[0094] In still another embodiment, the 8-Hydroxyquinoline Compounds are administered via inhalation.
[0095] In other embodiments, it can be desirable to administer the 8-
Hydroxyquinoline Compounds locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by intubation, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
[0096] In certain embodiments, it can be desirable to introduce the 8-
Hydroxyquinoline Compounds into the central nervous system, circulatory system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal injection, paraspinal injection, epidural injection, enema, and by injection adjacent to a peripheral nerve. Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
[0097] Pulmonary administration can also be employed, e.g., by use of an inhaler of nebulizer, by intubation, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the 8-
Hydroxyquinoline Compounds can be formulated as a suppository, with traditional binders and excipients such as triglycerides. [0098] In another embodiment the 8-Hydroxyquinoline Compounds can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1533 (1990) and Lopez- Berestein et al, Liposomes in the Therapy of Infectious Disease and Cancer, 317-327 and 353-365 (1989)).
[0099] In yet another embodiment the 8-Hydroxyquinoline Compounds can be delivered in a controlled-release system or sustained-release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled or sustained-release systems discussed in the review by Langer, Science 249: 1527-1533 (1990) can be used. In one embodiment, a pump can be used (Langer, Science 249: 1527-1533 (1990); Sefton, CRC Crit. Ref Biomed. Eng. 14:201 (1987); Buchwald et al, Surgery 88:507 (1980); and Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J. Macromol. ScL Rev. Macromol. Chem. 2:61 (1983); Levy et al, Science 228: 190 (1935); During et al, Ann. Neural. 25:351 (1989); and Howard et al, J. Neurosurg. 71: 105 (1989)). [0100] In yet another embodiment a controlled- or sustained-release system can be placed in proximity of a target of the 8-Hydroxyquinoline Compounds, e.g., the spinal column, brain, colon, skin, heart, lung, trachea or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
[0101] The present compositions can optionally comprise a suitable amount of a physiologically acceptable excipient.
[0102] Such physiologically acceptable excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The physiologically acceptable excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment the physiologically acceptable excipients are sterile when administered to a mammal. Water can be a particularly useful excipient when the 8-Hydroxyquinoline Compound is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions. Suitable physiologically acceptable excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0103] The present compositions can take the form of solutions, suspensions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays or any other form suitable for use. In one embodiment the composition is in the form of a capsule. Other examples of suitable physiologically acceptable excipients are described in Remington 's Pharmaceutical Sciences (21st ed. 2005), incorporated herein by reference.
[0104] In one embodiment the 8-Hydroxyquinoline Compounds are formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example. Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active platform driving an 8-Hydroxyquinoline Compound are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule can be imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment the excipients are of pharmaceutical grade. [0105] In another embodiment the 8-Hydroxyquinoline Compounds can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection. The compositions' components can be supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water- free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of 8- Hydroxyquinoline Compound. Where the 8-Hydroxyquinoline Compounds are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the 8-Hydroxyquinoline Compounds are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration. [0106] The 8-Hydroxyquinoline Compounds can be administered by controlled- release or sustained-release means or by delivery devices that are well known to those skilled in the art. Such dosage forms can be used to provide controlled- or sustained-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
[0107] In one embodiment a controlled- or sustained-release composition comprises a minimal amount of an 8-Hydroxyquinoline Compound to treat or prevent the Condition in a minimal amount of time. Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the 8- Hydroxyquinoline Compound, and can thus reduce the occurrence of adverse side effects. [0108] Controlled- or sustained-release compositions can initially release an amount of an 8-Hydroxyquinoline Compound that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the 8- Hydroxyquinoline Compound to maintain this level of therapeutic or prophylactic effect over an extended period of time. To maintain a constant level of the 8-Hydroxyquinoline Compound in the body, the 8-Hydroxyquinoline Compound can be released from the dosage form at a rate that will replace the amount of 8-Hydroxyquinoline Compound being metabolized and excreted from the body. Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions.
[0109] The amount of the 8-Hydroxyquinoline Compound that is effective for treating or preventing a Condition can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of a health-care practitioner. Suitable effective dosage amounts, however, range from about 10 micrograms to about 5 grams about every 4 h, although they are typically about 500 mg or less per every 4 hours. Examples of effective dosages include about 0.01 mg, 0.5 mg, about 1 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1 g, about 1.2 g, about 1.4 g, about 1.6 g, about 1.8 g, about 2.0 g, about 2.2 g, about 2.4 g, about 2.6 g, about 2.8 g, about 3.0 g, about 3.2 g, about 3.4 g, about 3.6 g, about 3.8 g, about 4.Og, about 4.2 g, about 4.4 g, about 4.6 g, about 4.8 g, and about 5.0 g, every 4 hours. Equivalent dosages can be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months. The number and frequency of dosages corresponding to a completed course of therapy can be determined according to the judgment of a health-care practitioner. The effective dosage amounts described herein refer to total amounts administered; that is, if more than one 8- Hydroxyquinoline Compound is administered, the effective dosage amounts correspond to the total amount administered.
[0110] The amount of an 8-Hydroxyquinoline Compound that is effective for treating or preventing a Condition typically ranges from about 0.01 mg/kg to about 100 mg/kg of body weight per day, in one embodiment, from about 0.1 mg/kg to about 50 mg/kg body weight per day, and in another embodiment, from about 1 mg/kg to about 20 mg/kg of body weight per day.
[0111] When an 8-Hydroxyquinoline Compound is a component of a solution that is useful for maintaining the viability of an organ ex vivo, the concentration of the 8- Hydroxyquinoline Compound in the solution that is effective for maintaining the viability of the organ is between about 1 nM to about 1 mM.
[0112] The 8-Hydroxyquinoline Compounds can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.
[0113] The present methods for treating or preventing a Condition can further comprise administering another therapeutic agent to the mammal being administered an 8- Hydroxyquinoline Compound. In one embodiment the other therapeutic agent is administered in an effective dose.
[0114] Effective doses of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective dose range. In one embodiment of the invention, where, another therapeutic agent is administered to a mammal, the effective dose of the 8- Hydroxyquinoline Compound is less than its effective dose would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that the 8-Hydroxyquinoline Compounds and the other therapeutic agent act synergistically.
[0115] In one embodiment the other therapeutic agent is an anti-inflammatory agent.
Examples of useful anti-inflammatory agents include, but are not limited to, adrenocorticosteroids, such as Cortisol, cortisone, fluorocortisone, prednisone, prednisolone, 6α-methylprednisolone, triamcinolone, betamethasone, and dexamethasone; and nonsteroidal anti-inflammatory agents (NSAIDs), such as aspirin, acetaminophen, indomethacin, sulindac, tolmetin, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefenamic acid, meclofenamic acid, piroxicam, meloxicam, nabumetone, rofecoxib, celecoxib, etodolac, and nimesulide.
[0116] In a further embodiment the other therapeutic agent is an anti-cardiovascular- disease agent. Examples of useful anti-cardiovascular-disease agents include, but are not limited to, carnitine; thiamine; lidocaine; amiodarone; procainamide; mexiletine; bretylium tosylate; propanolol; sotalol; and muscarinic receptor antagonists, such as atropine, scopolamine, homatropine, tropicamide, pirenzipine, ipratropium, tiotropium, and tolterodine. [0117] An 8-Hydroxyquinoline Compound and the other therapeutic agent can act additively or, in one embodiment, synergistically. In one embodiment, an 8- Hydroxyquinoline Compound is administered concurrently with another therapeutic agent. In another embodiment, the present compositions can further comprise another therapeutic agent. In a further embodiment, a composition comprising an effective dose of an 8- Hydroxyquinoline Compound and an effective dose of another therapeutic agent can be administered. Alternatively, a composition comprising an effective dose of an 8- Hydroxyquinoline Compound and a different composition comprising an effective dose of another therapeutic agent can be concurrently administered. In another embodiment, an effective dose of an 8-Hydroxyquinoline Compound is administered prior or subsequent to administration of an effective dose of another therapeutic agent. In this embodiment, the 8- Hydroxyquinoline Compound is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the 8- Hydroxyquinoline Compound exerts its preventative or therapeutic effect for treating or preventing a Condition.
[0118] A composition of the invention can be prepared using a method comprising admixing an 8-Hydroxyquinoline Compound and a physiologically acceptable carrier or excipient. Admixing can be accomplished using methods well known for admixing a compound (or salt) and a physiologically acceptable carrier or excipient.
4.5 THERAPEUTIC OR PROPHYLACTIC USES OF THE 8- HYDROXYOUINOLINE COMPOUNDS
[0119] In one embodiment, the 8-Hydroxyquinoline Compounds of the present invention and compositions thereof are useful as metalloproteinase modulators.
[0120] In another embodiment, the 8-Hydroxyquinoline Compounds of the present invention and compositions thereof are useful for treating a condition.
[0121] In one embodiment, the invention provides a method for treating a metalloproteinase-related disorder, comprising administering to a mammal in need thereof an effective dose of an 8-Hydroxyquinoline Compound or a composition thereof.
[0122] The 8-Hydroxyquinoline Compounds and compositions thereof are useful for treating or preventing the following disorders: an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease. [0123] In one embodiment, the disorder is osteoarthritis.
[0124] In one embodiment, the present invention provides a method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of an 8-Hydroxyquinoline Compound or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease.
4.6 KITS
[0125] The invention encompasses kits that can simplify the administration of the 8-
Hydroxyquinoline Compounds or compositions of the invention to a mammal. [0126] A typical kit of the invention comprises a unit dosage of an 8-
Hydroxyquinoline Compound. In one embodiment, the unit dosage form is in a container, which can be sterile, containing an effective dose of an 8-Hydroxyquinoline Compound and a physiologically acceptable vehicle. In another embodiment, the unit dosage form is in a container containing an effective dose of an 8-Hydroxyquinoline Compound as a lyophilate or pharmaceutically acceptable salt. In this instance, the kit can further comprise another container that contains a solution useful for the reconstitution of the lyophilate or dissolution of the salt. The kit can also comprise a label or printed instructions for use of the 8- Hydroxyquinoline Compounds.
[0127] In a further embodiment, the kit comprises a unit dosage form of a composition of the invention.
[0128] Kits of the invention can further comprise one or more devices that are useful for administering the unit dosage forms of the 8-Hydroxyquinoline Compounds or a composition of the invention. Examples of such devices include, but are not limited to, a syringe, a drip bag, a patch or an enema, which optionally contain the unit dosage forms. [0129] The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention.
5. EXAMPLES Examples 1-121
[0130] Examples 1-121 are prepared by one of the following procedures as set forth below (Procedures A, B and C).
GENERAL EXPERIMENTAL FOR THE PREPARATION OF 8-HYDROXY- OUINOLIN-7-YL (PROCEDURE A)
[0131] To the desired acetamide (0.45 mmol, 0.9 eq) and desired 8-hydroxyquinoline
(0.5 mmol, 1 eq) was added the desired aromatic/heteroaromatic aldehyde (1.0 mmol, 2 equiv.) The resulting suspension was stirred for 180 min at 180 0C, 5 mL MeOH was added, and the reaction allowed to cool to room temperature upon which a solid often precipitated. The suspension was filtered and the solid recrystallized on purified via preparative HPLC. If no solid was formed the crude mixture was evaporated in a Speed-Vac. [0132] If purification via preparative HPLC was necessary the following conditions were utilized. The Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 μm GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et3N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound.
GENERAL EXPERIMENTAL FOR THE PREPARATION OF 8-HYDROXY- OUINOLIN-7-YL (PROCEDURE B)
[0133] To the desired chloro acetamide (15.6 mmol, 0.9 eq) and desired 8- hydroxyquinoline (17.3 mmol, 1 eq) was added the desired aromatic/heteroaromatic aldehyde (87 mmol, 5 equiv.) The resulting suspension was stirred for 120 min at 150 0C, poured onto 100 mL MeOH, and the reaction allowed to cool to room temperature upon which a solid precipitated. The suspension was filtered and the solid recrystallized with MeOH. In some cases product remained in the filtrate and was subject to recrystallization. The resulting chloro compound was then utilized in the following step.
[0134] To the desired phenol (0.14 mmol, 1 eq) in DMF (1 mL) cooled to 0 0C was added NaH (60% suspension, 0.28 mmol, 2 eq.). The resulting suspension was then stirred at 0 0C for 15 min upon which the desired chloro compound (0.14 mmol, 1 eq) in DMF (1 mL) was added. The suspension was allowed to stir for 12 hrs. The crude mixture was evaporated in a Speed-Vac and purified via preparative HPLC under the following conditions.
[0135] The Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 μm GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et3N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound and then 0 min at 150 0C, poured onto 100 mL MeOH, and the reaction allowed to cool to room temperature upon which a solid precipitated. The suspension was filtered and the solid recrystallized with MeOH. If purification via preparative HPLC was necessary the following conditions were utilized. The Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 μm GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA C18 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et3N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound.
GENERAL EXPERIMENTAL FOR THE PREPARATION OF 8-HYDROXY- OUINOLIN-7-YL (PROCEDURE C)
[0136] To the desired chloro acetamide (15.6 mmol, 0.9 eq) and desired 8- hydroxyquinoline (17.3 mmol, 1 eq) was added the desired aromatic/heteroaromatic aldehyde (87 mmol, 5 equiv.) The resulting suspension was stirred for 120 min at 150 0C, poured onto 100 mL MeOH, and the reaction allowed to cool to room temperature upon which a solid precipitated. The suspension was filtered and the solid recrystallized with MeOH. In some cases product remained in the filtrate and was subject to recrystallization. The resulting chloro compound was then utilized in the following step. [0137] To the desired aniline (0.18 mmol, 1.3 eq) and chloro compound (0.14 mmol,
1 eq) in DMF (1 mL) was added DIEA (0.18 mmol, 1.3 eq). The reaction mixture was headed to 90 0C and allowed to stir for 12 hrs. The crude mixture was evaporated in a Speed- Vac and purified via preparative HPLC under the following conditions. [0138] The Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 μm GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et3N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound and then 0 min at 150 0C, poured onto 100 mL MeOH, and the reaction allowed to cool to room temperature upon which a solid precipitated. The suspension was filtered and the solid recrystallized with MeOH. If purification via preparative HPLC was necessary the following conditions were utilized. The Gilson crude material was dissolved in 1.5 ml DMSO: 0.5 ml MeCN, filtered through a 0.45 μm GMF, and purified on a Gilson HPLC, using a Phenomenex LUNA Ci8 column: 60 mm x 21.20 mm LD. , 5 um particle size: with ACN/water (containing 0.2% TFA or Et3N) gradient elution. The appropriate fractions were analyzed by LC/MS as described below. Combining pure fractions and evaporating the solvent in a Speed-Vac isolated the title compound. [0139] The following compounds were prepared according to the above procedures and analyzed under the following conditions:
ΗPLC Conditions: Instrument - Agilent 1100 Column: Thermo Aquasil C18, 50 x 2.1mm, 5um Mobile Phase A: 0.1% Formic Acid in water
B: 0.1% Formic Acid in ACN Flow Rate: 0.800mL/min Column Temperature: 400C Injection Volume: 5 mL UV: monitor 215, 230, 254, 280, and 300nm Purity is reported at 254nm unless otherwise noted Gradient Table:
Time (min) %B
0 5
2.5 95
4.0 95
4.1 5 5.5 5 MS Conditions: Instrument: Agilent MSD; Ionization Mode: API-ES; Gas Temperature: 3500C; Drying Gas: 11.0 L/min.; Nebulizer Pressure: 55psig; Polarity: 50% positive, 50% negative; VCap: 3000V (positive), 2500V (negative); Fragmentor: 80 (positive), 120 (negative); Mass Range: 100 - 1000m/z; Threshold: 150; Step size: 0.15; Gain: 1; Peak width: 0.15min.
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Examples 122-201
GENERAL EXPERIMENTAL FOR THE PREPARATION OF HYDROXYOUINOLINE COMPOUNDS
[0140] The hydroxyquinolines were prepared in a single step by means of a three component coupling reaction [an aromatic variant of the Mannich reaction]: A mixture of 5- chloro-8-hydroxyquinoline (1-1.1 equiv.), amide component (1 equiv.) and aldehyde component (2.5-4 equiv.) were heated neat at 145-15O0C for 3-6 hours. Typically, the hydroxyquinoline was isolated by multiple trituration with hexanes and isopropyl ether followed by recrystallization from ethanol furnishing product in 14-80% yield.
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Example 202
[0142] A mixture of N-[(3-nitrophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide (2 g, 4.31 mmol) and 10% Pd/C (250mg, Lancaster) in THF was hydrogenated for 20 h at 40 psi. The catalyst was filtered off, and solvent was removed under vacuum. The residue was triturated with ether, filtered and the cake was washed with ether to give 1.1 g ofN-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide as an off-white solid.
N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide MS (ESI) m/z 434.1; MS (ESI) m/z 238.1.
Example 203
[0143] A mixture of N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-
2-phenoxyacetamide (120 mg, .28 mmol), methanesulfonylchloride (39.90 mg, .28 mmol in pyridine ( 7.5 ml) were stirred at room temperature for 18 h. To the reaction mixture was added water and solids were filtered and dried. The brown solid (100 mg) was purified by column chromatography (eluent: ethylacetate/DCM 1 :3) to give 42 mg (29%) of 5-chloro-7- { {3-[(methylsulfonyl)amino]phenyl}[(phenoxyacetyl)amino]methyl}quinolin-8-yl methanesulfonate as a white solid. 5-chloro-7-{ {3-
[(methylsulfonyl)amino]phenyl} [(phenoxyacetyl)amino]methyl}quinolin-8-yl methanesulfonate
MS (ESI) m/z 588.2;
MS (ESI) m/z 1177.4.
Example 204
[0144] To the suspension of N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7- yl)methyl]-2-phenoxyacetamide (150 mg, .35 mmol) in methylenechloride (4 ml) cooled to OC was added DIEA (50 mg, .38 mmol) followed by acetylchloride (32.4 mg, .42 mmol). Purification by flush chromatography (eluent 30% acetone/DCM) afforded 96 mg (57%) of N-[[3-(acetylamino)phenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide as a white solid.
N-[[3-(acetylamino)phenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
MS (ESI) m/z 476.2; MS (ESI) m/z 951.4.
Example 205
[0145] To a suspension of N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7- yl)methyl]-2-phenoxyacetamide (800mg, 1.84 mmol) in methylenechloride (30 ml) cooled to OC was added DIEA (300mg, 2.32mmol) followed by chloroacetyl chloride (300 mg, 2.65mmol). Purification by flush chromatography (eluent 30% acetone/DCM) afforded 500 mg (53%) of 2-chloro-N- (3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino] methyl}phenyl)acetamide an off-white solid.
2 -chloro-N-(3 - { (5 -chloro- 8 -hydroxy quinolin-7 - yl)[(phenoxyacetyl)amino]methyl}phenyl)acetamide MS (ESI) m/z 509.8. Example 206
[0146] A solution of 2-chloro-N-(3- {(5-chloro-8-hydroxyquinolin-7-yl)
[(phenoxyacetyl)amino]methyl}phenyl)acetamide (100 mg, .20 mmol) and dimethylamine (2M/THF,10 eq.) was heated at 45C for 18 h. The solvent was removed in vacuo, the residue was dissolved in methylene chloride and washed with water and brine. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford 48 mg (46%) of N-(3-{(5- chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)-N2,N2- dimethylglycinamide as a beige solid.
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)- N2 ,N2 -dimethy lglycinamide
MS (ESI) m/z 519.3;
MS (ESI) m/z 260.1;
HRMS: calcd for C28H27C1N4O4 + H+, 519.17936; found (ESI-FTMS, [M+H] l+), 519.1812.
Example 207
[0147] A solution of 2-chloro-N-(3- {(5-chloro-8-hydroxyquinolin-7-yl)
[(phenoxyacetyl)amino]methyl}phenyl)acetamide (100 mg, .20 mmol) and methylamine (33% in ethanol,10 eq.) in THF was stirred at room temperature for 4 h. The solvent was removed in vacuo, the residue was dissolved in methylene chloride and washed with water and brine. The organic layer was dried over sodium sulfate and concentrated in vacuo to afford 47 mg (47%) of N-(3-{(5-chloro-8-hydroxyquinolin-7- yl)[(phenoxyacetyl)amino]methyl}phenyl)-N2-methylglycinamide a beige solid.
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)-N2- methylglycinamide
MS (ESI) m/z 505.3;
HRMS: calcd for C27H25C1N4O4 + H+, 505.16371; found (ESI-FTMS, [M+H] l+), 505.16483.
Examples 208-212
[0148] The solution of 100 mg of ethyl(3- {(5-chloro-8-hydroxyquinolin-7-yl)
[(phenoxyacetyl) amino]methyl}phenyl)acetate in THF and Sodium hydroxide (aqueous, 5 eq.) were stirred at room temperature for 48h. The reaction mixture was acidified to pH 3 with 2N aq. HCl, then concentrated. The residue was diluted with methylene chloride, washed with water, dried over sodium sulfate and concentrated. Solids were triturated with ether and filtered to give 40 mg (43 %) of (3-{(5-chloro-8-hydroxyquinolin-7- yl)[(phenoxyacetyl)amino]methyl}phenyl)acetic acid as a white solid.
(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)acetic acid
MS (ESI) m/z 477.1;
[0149] 2-chloro-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide was reacted with a series of aromatic phenols in an acetonitrile/DMPU solution.
[0150] The subsequent four examples follow the above procedure:
Figure imgf000077_0001
Examples 213-215
[0151] 2-chloro-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]acetamide (0.632mmol), was dissolved in acetone (4mL) in a screw-cap 2OmL vial. The phenol (0.948mmol) was added, followed by CsCO3 (1.03g, 3.16mmol). The vial was sealed, heated to 500C, and stirred for 3h. The reaction was then filtered and the white solid was washed with acetone. The filtrate had the solvent removed leaving a brown solid. The solid was dissolved in DMSO, and purified with a Gilson HPLC. Yielding coupled product (15-33%). [0152] The subsequent three examples follow the above procedure:
Figure imgf000077_0002
Examples 216-221
[0153] 2-chloro-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
(0.632mmol), was dissolved in acetone (4mL) in a screw-cap 2OmL vial. The phenol (0.948mmol) was added, followed by CSCO3 (1.03g, 3.16mmol). The vial was sealed, heated to 500C, and stirred for 3h. The reaction was then filtered and the white solid removed was rinsed with acetone. The filtrate had the solvent removed leaving a brown solid. The solid was dissolved in DMSO, and purified on a Gilson HPLC. Yielding coupled product (15-
33%).
[0154] The subsequent six examples follow the above procedure:
Figure imgf000078_0001
Example 222
[0155] To N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-chloroacetamide
(0.632mmol), was added CH3CN (ImL) followed by DMPU(ImL). 1- naphthalenemethylamine (1.55mmol) was added and the reaction stirred at room temp, for 4h. Acetonitrile was removed at reduced pressure, and the remaining material was dissolved in DMSO and purified with a Gilson HPLC. Yielding N-[(5-bromo-8-hydroxyquinolin-7- yl)(phenyl)methyl]-N2-( 1 -naphthylmethyl)glycinamide (62%).
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
HRMS: calcd for C29H24BrN3O2 + H+, 526.11246; found (ESI-FTMS, [M+H]l+), 526.11283.
Examples 223-230
[0156] To 2-chloro-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
(0.632mmol), was added CH3CN (ImL) followed by DMPU(ImL). The amine (1.55mmol) was added and the reaction stirred at room temp, for 4h. Acetonitrile was removed at reduced pressure, and the remaining material was dissolved in DMSO and purified with a Gilson
HPLC. Yielding coupled product (40-60%).
[0157] The subsequent eight examples follow the above procedure:
Figure imgf000079_0001
Examples 231 & 232
[0158] To 2-chloro-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl] acetamide (0.632mmol), was added CH3CN (ImL) followed by DMPU(ImL). The amine (1.55mmol) was added and the reaction stirred at room temp, for 4h. Acetonitrile was removed at reduced pressure, and the remaining material was dissolved in DMSO and purified with a Gilson HPLC. Yielding coupled product (40-60%). [0159] The subsequent two examples follow the above procedure:
Figure imgf000079_0002
Example 233
[0160] N-[(8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
(4.Og, 9.31 mmol) , 10% Pd/C (420 mg) in 70 ml THF were hydrogenated at 42 psi for 2Oh. The reaction mixture was filtered through Celite 545, dried over sodium sulfate and concentrated to afford 2.3 g of N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2- phenoxyacetamide as a brown foam.
N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide MS (ESI) m/z 400.3.
Example 234
[0161] N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
(150 mg, .37 mmol), sodium cyanoborohydrate 1M/THF(.9 ml, 2.5 eq.) and 37% aq. Formaldehyde (.2 ml) in 1.5 ml methanol were stirred at room temperature for 2h. The reaction mixture was concentrated , the residue was diluted with water and pH brought to 3 with IM aq. HCl. After stirring for 20 min the reaction mixture was neutralized with aq. Sodium bicarbonate and filtered. The solids were dissolved in ether, washed with water, dried over sodium sulfate, filtered and concentrated in vacuo to afford N-[[5- (dimethylamino)-8-hydroxyquinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide as a yellow solid.
N-[[5-(dimethylamino)-8-hydroxyquinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide MS (ESI) m/z 428.3; MS (ESI) m/z 486.4.
Example 235
[0162] N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
(150 mg, .37 mmol), 2,5-dimethoxydihydrofuran ( 50 mg, .37 mmol) in acetic acid (1 ml) were heated at 65C for 40 min. The reaction mixture was concentrated, dissolved in ethylacetate, washed with aq. Sodium bicarbonate and dried over sodium sulfate. The solvent was removed in vacuo to afford N-[[8-hydroxy-5-(lH-pyrrol-l-yl)quinolin-7- yl](phenyl)methyl]-2-phenoxyacetamide as a tan solid.
N-[[8-hydroxy-5-(lH-pyrrol-l-yl)quinolin-7-yl](phenyl)methyl]-2- phenoxyacetamide.
Example 236
[0163] N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
(200 mg, .5 mmol), dibromobutane (.1 ml), TEA (.2 ml) in isopropanol were heated at reflux for 16 h. The reaction mixture was concentrated in vacuo, the residue dissolved in methylene chloride, washed with brine. The organic layer was dried over sodium sulfate and filtered. To the filtrate was added IM HCl/ether, the solids filtered, washed with ether to give N-[(8- hydroxy-5-pyrrolidin-l-ylquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide as a purple solid.
N-[(8-hydroxy-5-pyrrolidin-l-ylquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide MS (ESI) m/z 454.4; MS (ESI) m/z 538.4;
Examples 237-278
[0164] Examples 237-278 were accomplished using commercially available dry solvents. The reactions were performed under an inert atmosphere of nitrogen unless otherwise noted. All reagents were purchased from either Aldrich (Milwaukee, WI), Sigma (St. Louis, MO), Acros (Pittsburgh, PA), or Alfa Aesar (Ward Hill, MA). Microwave reactions were conducted using a Biotage (Personal Chemistry) Emrys Optimizer microwave reactor. Preparative scale HPLC separations were conducted on the crude material dissolved in DMSO and filtered through a 0.45 μM GMF filter on a Gilson HPLC using a Phenomenex Gemini Cl 8 column: 100 x 30mm, 5 micron particle size with solvent A = 0.02% TFA in H2O and Solvent B = 0.02% TFA in CH3CN gradient elution. Method I was utilized for the majority of products while Method II was utilized for the less polar products containing the biphenyl functionality. HPLC Methods:
Figure imgf000082_0001
Purity of fractions in separations was determined by analytical HPLC using the following conditions:
ΗPLC Conditions A: Used for all compounds excluding N- {2-(5-Chloro-8- hydroxyquinolin-7-yl)-l-[3-(5-methyl-2-thienyl)phenyl]ethyl}biphenyl-4-carboxamide
Instrument - Agilent 1100
Column: Prodigy ODS3, 0.46 x 15cm, 3 μM particle size
Mobile Phase A: 0.02% TFA in H2O
B: 0.02% TFA in CH3CN Flow Rate: 1.0 mL/min Column Temp.: 4O0C Injection Volume: 3.5 μL UV: PDA, purity reported at 215 nM Gradient Table:
Time (min) %B
0 10
20 95
25 95 30 10 bHPLC Conditions B: Used for N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl]ethyl}biphenyl-4-carboxamide
Instrument: Agilent 1946B
Column: Prodigy ODS3, 0.46 x 15cm, 3 μM particle size Mobile Phase A: 0.1% formic acid in H2O B: 0.1% NH4TFA in ethanol Flow Rate: 1.0 mL/min Column Temp.: 4O0C Injection Volume: 1.0 μL UV: PDA, purity reported at 215nM Gradient Table:
Time (min) %B
0 75
20 95
[0165] Analtech uniplate F254 precoated 250 μM glass backed plates were used for thin layer chromatography (TLC) analysis. For column chromatography, an ISCO Combi- Flash Companion system was used. Redi-Sep columns containing normal phase silica gel, 35-60 micron average, 230-400 mesh particle size were utilized with monitoring at 254 nM for collection of fractions. For 12Og columns, flow rate was set at 85 mL/min; for 4Og columns, flow rate was set at 40 mL/min. Each product was analyzed by TLC (single spot) and spectroscopic methods including HPLC and mass spectrometry.
Scheme A; Synthesis of N-[2-(8-Hvdroxyquinolin-7-yl)-l-phenylethyll-2- phenoxyacetamide
BnBr, K2CO3 „ OsOd. NMO
Figure imgf000083_0001
acetone, Λ, 72%
Figure imgf000083_0002
acetone/H2θ, 84% 8-hydroxyquinoline 8-(Allyloxy)quιnolιne 7-Allylquinolin-8-ol 7-Allyl-8-(benzyloxy)quιnolιne
1 ) phenoxyacetonitπle
1 ) Nalθ4, THF/H2O H2SO4, -15°C → rt, H2O
Figure imgf000083_0004
Ii J PhMgBr, THF, Il ) 3N HCI, MeOH -78°C → rt
Figure imgf000083_0005
55°C, 2h, 12% (2 steps) 34% (2 steps)
Figure imgf000083_0003
3-[8-(Benzyloxy)quinolin- 2-[8-(Benzyloxy)quinolin N-[2-(8-Hyd røxyqu inolin-7-yl)-1 -
7-y[]prapane-1,2-diol 7-yQ-i-phenylethanol phenylethyr]-2-phenoxyacetamide
Scheme B; Synthesis of N-[l-(l,3-Benzodioxol-5-yl)-2-(5-chloro-8-hvdroxyquinolin-7- yl)ethyll-2-phenoxyacetamide
Figure imgf000084_0001
5-chloro-8- 8-(AIIyIoXy)- 7-Allyl-5- hydroxyquinoline 5-chloroquinoline chloroquinolin-8-ol
Figure imgf000084_0002
7-Allyl-8-(benzybxy)- 3-[8-(Benzyloxy)-5- [8-(Benzyloxy)-5- 5-chloroquinoline chloroquinolin-7-yr] propane-1,2-diol chloroquinolin-7-yl]acetaldehyde
Figure imgf000084_0003
1-(1,3-Benzodk>xol-5-yl)- N -[1 -(1 ,3-Benzod ioxo I-5 -yl)-2 -(5-chlo ro-8- 2-[8-(benzyloxy)-5-chloroquinolin-7-y[]ethanol hydroxyquinolin-7-yl)ethyl]-2-phenoxyacetamide
General Procedure for Allylation of Hydroxyquinolines:
[0166] To a stirring solution of the appropriate hydroxyquinoline (55.68 mmol, 1 eq.) in acetone (300 mL) in a round bottom flask equipped with a reflux condenser was added potassium carbonate (904.42 mmol, 16.25 eq.) followed by allyl bromide (83.52 mmol, 1.5 eq.) and the resulting solution was stirred and heated to reflux for 2Oh. The reaction mixture was then cooled to room temperature and diluted with 300 mL of diethyl ether. The resulting suspension was filtered and the filtrate concentrated to an orange oil that solidified under vacuum and was purified by either column chromatography or recrystallization.
Example 237; 8-(Allyloxy)quinoline
[0167] Prepared from 8-hydroxyquinoline (68.90 mmol) according to the general procedure described above. Purified by column chromatography using 5% acetone/dichloromethane to give the product as an orange oil (43.79 mmol, 64%). MS (ESI) m/z 186.1; HRMS: calcd for C12H11N0 + H+, 186.09134; found (ESI-FTMS, [M+H] l+), 186.09107. Example 238; 8-(Allyloxy)-5-chloroquinoline
[0168] Prepared from 5-chloro-8-hydroxyquinoline (278.40 mmol) according to the general procedure described above. Purified by recrystallization from hexanes to give the product as a light beige solid (235.81 mmol, 85%). MS (ESI) m/z 220.1; HRMS: calcd for C12H10C1NO + H+, 220.05237; found (ESI-FTMS, [M+H] l+), 220.05229.
General Procedure for Microwave Induced Claisen Rearrangement:
[0169] The appropriate allylated hydroxyquinoline (40.77 mmol, 1 eq.) was added neat to a microwave vial prior to the vial being sealed. In the cases where the substrate was a solid, the vial was heated with a heat gun until the solid melted and gave a homogenous liquid. The vial was then placed in the microwave and irradiated at 2000C for 60 min. After cooling to room temperature, the vial was uncapped and the pure product was scraped out.
Example 239: 7-Allylquinolin-8-ol
[0170] Prepared from 8-(allyloxy)quinoline (40.77 mmol) using the general procedure described above. Crude product was obtained as a brown solid (40.77 mmol, quant.) and required no further purification. MS (ESI) m/z 184.1; HRMS: calcd for C12H11NO + H+, 186.09134; found (ESI-FTMS, [M+H] l+), 186.09112.
Example 240: 7-Allyl-5-chloroquinolin-8-ol
[0171] Prepared from 8-(allyloxy)-5-chloroquinoline (17.16 mmol) using the general procedure described above. Crude product was obtained as a light brown solid (17.16 mmol, quant.) and required no further purification. MS (ESI) m/z 220.1; HRMS: calcd for C12H10C1NO + H+, 220.05237; found (ESI, [M+H]+ Obs'd), 220.0523.
Example 241: 7-AUyl-8-(benzyloxy)quinoline
[0172] To a stirring solution of 7-allylquinolin-8-ol (14.56 mmol, 1 eq.) in acetone
(50 mL) in a round bottom flask equipped with a reflux condenser was added potassium carbonate (151.94 mmol, 10.44 eq.) followed by benzyl bromide (Il Al mmol, 1.2 eq.) and the resulting solution was stirred and heated to reflux for 2Oh. Additional potassium carbonate (151.94 mmol, 10.44 eq.) was added followed by additional benzyl bromide (29.12 mmol, 2 eq.) and the resulting mixture was heated at reflux and stirred 2h. The reaction mixture was then cooled to room temperature and diluted with 50 mL of diethyl ether. The resulting suspension was filtered and the filtrate concentrated to a yellow oil that was purified by column chromatography using 10% acetone/dichloromethane to give the product as a pale yellow oil (10.48 mmol, 72%). MS (ESI) m/z 276.2; HRMS: calcd for C19H17NO + H+, 276.13829; found (ESI-FTMS, [M+FTJ 1+), 276.13828.
Example 242; 7-Alryl-8-(benzyloxy)-5-chloroquinoline
[0173] To a stirring solution of 7-allyl-5-chloroquinolin-8-ol (17.16 mmol, 1 eq.) in acetone (60 mL) in a round bottom flask equipped with a reflux condenser was added potassium carbonate (179.08 mmol, 10.44 eq.) followed by benzyl bromide (18.02 mmol, 1.05 eq.) and the resulting solution was stirred and heated to reflux for 4h. The reaction mixture was then cooled to room temperature and diluted with 60 mL of diethyl ether. The resulting suspension was filtered and the filtrate concentrated to a yellow oil that was purified by column chromatography using 30% ethyl acetate/hexanes to give the product as a light amber oil (16.08 mmol, 94%). MS (ESI) m/z 310.2; HRMS: calcd for C19H16C1NO + H+, 310.09932; found (ESI, [M+H]+ Obs'd), 310.0993.
General Procedure for Dihydroxylation of Allylated O-Benzyl-hydroxyquinolines:
[0174] To a stirring solution of the appropriate allylated O-benzyl-hydroxyquinoline
(10.13 mmol, 1 eq.) in acetone (100 mL) and water (10 mL) in a round bottom flask was added 4-methylmorpholine-N-oxide (15.20 mmol, 1.5 eq.) followed by a 2.5 wt. % solution of osmium tetroxide in tert-butanol (0.10 mmol, 0.01 eq.) and the resulting solution was stirred for 2Oh. A saturated aqueous solution of sodium metabisulfite (1.5 mL) was added and the solution was stirred 5 min and the acetone was removed by rotary evaporation. Purification was completed by either aqueous workup followed by column chromatography or by recrystallization.
Example 243; 3-[8-(Benzyloxy)quinolin-7-yllpropane-l,2-diol
[0175] Prepared from 7-allyl-8-(benzyloxy)quinoline (10.13 mmol) according to the general procedure described above. To the residue obtained after acetone removal was added water (20 mL) and the resulting solution was extracted with dichloromethane (3 X 15 mL). The organic fractions were dried (MgSO4), filtered and concentrated to the crude product that was purified by column chromatography using 5% methanol/dichloromethane to give the product as thick yellow syrup (8.42 mmol, 84%). MS (ESI) m/z 310.3; HRMS: calcd for C19H19NO3 + H+, 310.14377; found (ESI-FTMS, [M+H]l+), 310.14426.
Example 244 ; 3- [8-(Benzyloxy)-5-chloroq uinolin-7-yll propane-l,2-diol
[0176] Prepared from 7-allyl-8-(benzyloxy)-5-chloroquinoline (72.53 mmol) according to the general procedure described above. To the residue obtained after acetone removal was added a 90/10 mixture of hexanes/ether (50 mL) resulting in precipitation of a solid and all solvent was then removed by rotary evaporation. The solid obtained was recrystallized from dichloromethane/hexanes containing trace ether and methanol (for initial dissolution of the solid crude product) to give the product as a white solid (62.59 mmol, 86%). MS (ESI) m/z 344.2; HRMS: calcd for C19H18C1NO3 + H+, 344.10480; found (ESI, [M+H]+ Obs'd), 344.1048.
Example 245; [8-(Benzyloxy)-5-chloroquinolin-7-yllacetaldehyde
[0177] To a stirring solution of 3-[8-(benzyloxy)-5-chloroquinolin-7-yl]propane-l,2- diol (2.95 mmol) in tetrahydrofuran (21 mL) and water (7 mL) in a round bottom flask was added sodium (meta)periodate (14.73 mmol, 5.0 eq.) all at once and the resulting solution was stirred for 5 min. The tetrahydrofuran was then removed by rotary evaporation at room temperature (elevated temperatures will result in decomposition of the product) and the resulting heterogeneous mixture was diluted with water (30 mL) and washed with diethyl ether (2 X 30 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated (at room temperature) to give the product as a light brown solid (2.95 mmol, quant.) that was analytically pure and used directly in the ensuing step. (Caution: Compound decomposes rapidly at temperatures greater than 250C, in the presence of silica gel, and potentially if brought to dryness in presence of periodate salts present in crude reaction mixture.) MS (ESI) m/z 312.1. Example 246; 2-[8-(Benzyloxy)quinolin-7-yll-l-phenylethanol
[0178] To a stirring solution of 3-[8-(benzyloxy)quinolin-7-yl]propane-l,2-diol (8.08 mmol) in tetrahydrofuran (60 mL) and water (20 mL) in a round bottom flask was added sodium (meta)periodate (8.08 mmol, 1.0 eq.) all at once and the resulting solution was stirred for 30 min. The tetrahydrofuran was then removed by rotary evaporation at room temperature (elevated temperatures will result in decomposition of the product) and the resulting heterogeneous mixture was diluted with water (40 mL) and washed with diethyl ether (2 X 50 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated (at room temperature) to give the product as a pale yellow oil that was analytically pure and used directly in the ensuing step. (Caution: Compound decomposes rapidly at temperatures greater than 250C, in the presence of silica gel, and potentially if brought to dryness in presence of periodate salts present in crude reaction mixture.) To a stirring solution of the (8-benzyloxy-quinolin-7-yl)-acetaldehyde (8.08 mmol, 1.0 eq.) from the initial step in tetrahydrofuran (10 mL) at -780C was dropwise added a IM solution of phenylmagnesium bromide in THF (8.08 mmol, 1.0 eq.). On completion of addition, the reaction mixture was allowed to stir at -780C for Ih and was then warmed to room temperature and stirred 30 min. The reaction was then quenched by addition of saturated aqueous sodium bicarbonate solution (5 mL) and allowed to stir for 5 min. The resulting solution was diluted with water (50 mL) and extracted with ethyl acetate (3 X 50 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated to give a thick yellow syrup that was purified by column chromatography using 20% ethyl acetate/hexanes to give the final product as a pale yellow solid (2.72, 34% for 2 steps). MS (ESI) m/z 356.3; HRMS: calcd for C24H21NO2 + H+, 356.16451; found (ESI-FTMS, [M+H] l+), 356.16552.
Example 247; N-[2-(8-Hvdroxyquinolin-7-yl)-l-phenylethyll-2-phenoxyacetamide
[0179] To a stirring solution of the 2-[8-(benzyloxy)quinolin-7-yl]-l-phenylethanol
(0.302 mmol) in phenoxyacetonitrile (9.05 mmol, 30 eq.) at -1O0C was dropwise added cone, sulfuric acid (1.51 mmol, 5.0 eq.). On completion of addition, the reaction mixture was allowed to warm to room temperature and was stirred 16h. The reaction was then diluted with ice that was allowed to melt and was then stirred 2h. The mixture was next brought to pH=7 by the addition of saturated aqueous sodium bicarbonate solution and then diluted with water (5 mL) and extracted with ethyl acetate (2 X 5 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated to give sulfuric acid mono-{7-[2-(2- phenoxy-acetylamino)-2-phenyl-ethyl]-quinolin-8-yl} ester as a yellow oil that was purified by column chromatography using 20% methanol/dichloromethane. To a stirring suspension of the sulfuric acid mono-{7-[2-(2-phenoxy-acetylamino)-2-phenyl-ethyl]-quinolin-8-yl} ester (0.089 mmol, 1.0 eq.) from the initial step in methanol (9 mL) was added 3N HCl (18 mL) and the resulting suspension was heated to 550C and stirred 2h. The reaction mixture was then cooled to room temperature and organic solvents were removed by rotary evaporation resulting in a precipitate that was filtered yielding the pure product as a yellow solid (0.059 mmol, 12% for 2 steps). HRMS: calcd for C25H22N2O3 + H+, 399.17032; found (ESI-FTMS, [M+H]l+), 399.17059.
Example 248; l-(l,3-Benzodioxol-5-yl)-2-[8-(benzyloxy)-5-chloroquinolin-7-yllethanol
[0180] To a stirring solution of [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde
(0.380 mmol) in tetrahydrofuran (4 mL) at -780C was dropwise added a IM solution of 3,4- (methylenedioxy)phenylmagnesium bromide in 1 : 1 toluene/tetrahydrofuran (0.380 mmol, 1.0 eq.) and stirring at -780C was continued for 10 min. The reaction mixture was then allowed to warm to room temperature and was stirred Ih then quenched with saturated aqueous sodium bicarbonate solution (2 mL). After stirring 15 min the reaction mixture was extracted with ethyl acetate (3 X 5 mL) and the combined organic layers were dried (MgSO4), filtered and concentrated to give a brown oil that was purified by column chromatography using 30% ethyl acetate/hexanes to give the final product as a white foam (0.126 mmol, 33%). MS (ESI) m/z 434.2; HRMS: calcd for C25H20C1NO4 + H+, 434.11536; found (ESI, [M+H]+ Obs'd), 434.1150.
Example 249; N-H-d^-Benzodioxol-S-vD-l-rS-chloro-S-hydroxyquinolin-T-vDethyll-l- phenoxyacetamide
[0181] To a stirring solution of l-(l,3-benzodioxol-5-yl)-2-[8-(benzyloxy)-5- chloroquinolin-7-yl]ethanol (0.893 mmol) in toluene (4.5 mL) and dimethylformamide (0.9 mL) at O0C was added diphenyl phosphoryl azide (1.34 mmol, 1.5 eq.) followed by dropwise addition of l,8-diazabicyclo[5.4.0]undec-7-ene (1.34 mmol, 1.5 eq.). The reaction mixture was then warmed to 650C and stirred 4h then cooled to room temperature. The mixture was next diluted with saturated aqueous lithium bromide solution (5 mL) and extracted with ethyl acetate (3 X 5 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a light brown oil that was purified by column chromatography using 20% ethyl acetate/hexanes to give 7-(2-azido-2-benzo[l,3]dioxol-5-yl-ethyl)-8-benzyloxy-5- chloro-quinoline that was used directly in the next step. To a round bottom flask containing 7-(2-azido-2-benzo[l,3]dioxol-5-yl-ethyl)-8-benzyloxy-5-chloro-quinoline (0.530 mmol, 1.0 eq.) from the initial step was added 10% palladium on carbon (0.053 mmol, 0.1 eq.) followed by methanol (5 mL) and ethyl acetate (0.3 mL). The reaction vessel was flushed with hydrogen then capped with a hydrogen filled balloon and the mixture was stirred 2Oh. The reaction mixture was then filtered through a pad of celite eluting with methanol then a small amount of dimethylformamide. The filtrate was then concentrated to a yellow foam that was treated with a small amount of ether that initially dissolved the foam and then resulted in a precipitate that was filtered. The filtrate was concentrated to a yellow foam and ether addition resulted in a second crop of precipitate that was filtered and combined with the first crop. The combined yellow solid was used directly in the ensuing step without further purification. To a round bottom flask containing the 7-(2-amino-2-benzo[l,3]dioxol-5-yl- ethyl)-5-chloro-quinolin-8-ol (0.297 mmol, 1.0 eq.) from the preceding step at -780C was added a solution of phenoxyacetyl chloride (0.609 mmol, 2.05 eq.) and triethylamine (0.609 mmol, 2.05 eq.) in tetrahydrofuran (3 mL) that was pre-mixed and stirred 5 min prior to addition. After warming to room temperature, the resulting solution was stirred Ih and diluted with water (10 mL) and extracted with ethyl acetate (2 X 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a yellow foam that was purified by preparative scale HPLC to give the final product as a very light yellow solid (0.048 mmol, 5% for 3 steps). MS (ESI) m/z 477.3; HRMS: calcd for C26H21C1N2O5 + H+, 477.12118; found (ESI, [M+H]+ Obs'd), 477.1215.
Scheme C; Synthesis of N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[4-(morpholin-4- ylmethyl)phenyllethylIbiphenyl-4-carboxamide,
N-ll-fS-Chloro-S-hvdroxyquinolin-T-vD-l-fS-rpyrrolidin-l-ylmethvDphenyllethyll-l- phenoxyacetamide,
N-ll-fS-Chloro-S-hvdroxyquinolin-T-vD-l-fS-rpyrrolidin-l-ylmethvDphenyllethyll-l-^- chlorophenoxy)-2-methylpropanamide,
N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[3-(pyrrolidin-l- ylmethyl)phenyllethylIbiphenyl-4-carboxamide, N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-1-[3-(5-methyl-2-thienvl)phenyllethyl}-2- phenoxyacetamide,
2-(Benzyloxy)-N-{2-(5-chloro-8-hvdroxyquinolin-7-yl)-1-[3-(5-methyl-2-thienvl)phenyl]ethyl}acetamide,
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-1-[3-(5-methyl-2-thienvl)phenyllethyl}-2-(4- chlorophenoxy)-2-methylpropanamide,
2-(4-tert-Butylphenoxy)- N-{2-(5-Chloro-8--hvdroxyquinolin-7-yl)-1-[3-(5-methyl-2- thienvl)phenyl]ethyl}acetamide and
N-(2-(5-Chloro-8-hvdroxyquinolin-7-yl-l-[3-(5-methyl-2- thienyl)phenyllethyl}biphenyl-4-carboxamide
RArylMgBr, THF -78°C or 0°C → rt DPPA, DBU, 12 - 51 % DMF, PhCH3 PPh3, THF, H2θ> or "BuLi, RArylBr 0°C → rtor 65°C or 70°C, 88 - 92%
Figure imgf000092_0003
THF, -78°C → rt
Figure imgf000092_0001
80°C, 56% - quant
Figure imgf000092_0002
46%
[8-(Benzyloxy)-5- chloroquinolin- inoline
7-yl]ace1aldehyde
Figure imgf000092_0004
quinoline
Figure imgf000092_0005
Figure imgf000092_0006
Figure imgf000092_0007
2-[8-(Benzy Io xy) -5-ch Io ro qui no Ii n- N-{2-[8-(Benzyloxy)-5-ch Io roqui no Nn- N-{2-(5-Ch b ro -8 -hydroxy qu inol in-7-yl)-1-
7-yl]-1-[4-(morpholin-4-ylmethyl) 7-yl]-1-[4-(morpholin-4-ylmethyl)phenyl] [4-(morpholin-4-ylmethyl)pheny!]ethyl} pheny
Figure imgf000092_0009
2-[8-(Benzyloxy)-5-chloroquinolin- N -{2-(5-Chloro-8-hydroxyqu inolin-7-yl)-1 - 7-yQ-1 -[3-(5-methyl-2-thienyl)
Figure imgf000092_0010
[3-(pyrrolidin-1-ylmethyl)pheny[]ethyl}- phenyl]ethanamine
N -{2-[8-(Benzyloxy)-5-ch loroq ui nol in -
Figure imgf000092_0013
7-yl]-1-[3-(pyrrolidin-1-ylmethyl)phenyl] ethyl}biphenyl-4-carboxamide
Figure imgf000092_0011
N -{2-(5-Chloro-8-hydroxyqu ino Ii n-7-yl)-1 - [3-(pyrrolidin-1-ylmethyl)pheny[]ethyl}-2- (4-chlorophenoxy)-2-methylpropanamide
Figure imgf000092_0015
Figure imgf000092_0012
Figure imgf000092_0008
Figure imgf000092_0014
N-{2-(5-Chloro-8-hydrøxyquinolin-7-yl)-1- 2-(4-tert-Butylphenoxy)-N-{2-(5-chloro-
[3-(5-methyl-2-thienyl)phenyl]ethyl} 8-hydroxyquinolin-7-yl)-1-[3-(5-methyl-2- biphenyl-4-carboxamide thienyl)phenyl]ethyl}acetamide
Figure imgf000092_0016
Example 250; 2-[8-(Benzyloxy)-5-chloroquinolin-7-yll-l-[4-(morpholin-4- ylmethvDphenyll ethanol
[0182] To a stirring solution of [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde
(12.50 mmol) in tetrahydrofuran (100 mL) at O0C was dropwise added a 0.25M solution of [4-(4-morpholinylmethyl)phenyl]magnesium bromide in tetrahydrofuran (12.50 mmol, 1.0 eq.) and stirring at O0C was continued for 30 min. The reaction mixture was then allowed to warm to room temperature and was stirred 20 min then quenched with saturated aqueous sodium bicarbonate solution (100 mL). After stirring 5 min the reaction mixture was extracted with ethyl acetate (3 X 75 mL) and the combined organic layers were dried (MgSO4), filtered and concentrated to give a thick brown syrup that was purified by column chromatography using 30% acetone/dichloromethane to give the final product as a white solid (1.50 mmol, 12%). MS (ESI) m/z 489.3; HRMS: calcd for C29H29C1N2O3 + H+, 489.19395; found (ESI, [M+H]+ Obs'd), 489.1941.
Example 251; l-(3-Bromo-phenyl)-pentane-l,4-dione
[0183] A round bottom flask containing zinc chloride (71.95 mmol, 2.0 eq.) was heated under vacuum until the solid melted (~300°C) and the molten solid was kept under vacuum for 5 min. The molten solid was then allowed to cool to room temperature resulting in solidification. The flask was then filled with nitrogen and benzene (36 mL) was added followed by diethylamine (53.97 mmol, 1.5 eq.) and tert-butanol (53.97 mmol, 1.5 eq.). This mixture was stirred until the solid zinc chloride dissolved and then 3-bromophenacylbromide (35.98 mmol, 1.0 eq.) was added followed by acetone (53.97 mmol, 1.5 eq.). The resulting solution was stirred 4d and quenched by the addition of 0.1N HCl (100 mL) and diluted with brine solution (25 mL) and extracted with ethyl acetate (3 X 75 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give an orange oil that was purified by column chromatography using 5% acetone/dichloromethane to give the final product as an orange solid (18.93 mmol, 53%). HRMS: calcd for Cl IHl lBrO2 + H+, 255.00152; found (ESI, [M+H]+ Obs'd), 255.0020.
Example 252; 2-(3-Bromo-phenyl)-5-methyl-thiophene
[0184] To a stirring solution of l-(3-bromo-phenyl)-pentane-l,4-dione (18.32 mmol) in toluene (90 mL) was added Lawesson's Reagent (19.24 mmol, 1.05 eq.) and the mixture was heated to reflux for 20min. The reaction mixture was then cooled to room temperature and diluted with 1 : 1 hexanes/ether (90 mL) resulting in a precipitate. The mixture was filtered through a small pad of celite and the filtrate was concentrated to a light yellow solid that was purified by recrystallization from hexanes to give the final product as a white solid (12.17 mmol, 66%). MS (ESI) m/z 254.3.
Example 253 ; 2- [8-(Benzyloxy)-5-chloroq uinolin-7-yll -1- [3-(5-methyl-2- thienvl)phenyll ethanol
[0185] To a stirring solution of 2-(3-bromo-phenyl)-5-methyl-thiophene (0.395 mmol) in tetrahydrofuran (4 mL) at -780C was slowly added a 2M solution of n-butyllithium in cyclohexane (0.435 mmol, 1.1 eq.). The resulting solution was stirred 30 min at -780C and solid [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde (0.395 mmol) was added. Stirring at -780C was continued for 10 min and the reaction was allowed to warm to room temperature and was stirred Ih. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (10 mL) and extracted with ethyl acetate (3 X 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give a yellow oil that was purified by column chromatography using 20% ethyl acetate/hexanes to give the final product as a light yellow solid (0.18 mmol, 46%). MS (ESI) m/z 486.4.
General Procedure for Conversion of Alcohols to Azides:
[0186] To a stirring solution of the appropriate alcohol (0.347 mmol, 1.0 eq.) in toluene (1.8 mL) and dimethylformamide (0.35 mL) at O0C was added diphenyl phosphoryl azide (0.866 mmol, 2.5 eq.) followed by dropwise addition of l,8-diazabicyclo[5.4.0]undec- 7-ene (0.866 mmol, 2.5 eq.). The reaction mixture was then warmed to room temperature and stirred 16h. The mixture was next diluted with saturated aqueous lithium bromide solution (5 mL) and extracted with ethyl acetate (3 X 5 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to the crude product that was either taken on crude or purified by column chromatography. Example 254; 7-{2-Azido-2-[4-(morpholin-4-ylmethyl)phenyllethylI-8-(benzyloxy)-5- chloroquinoline
[0187] Prepared from 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- ylmethyl)phenyl]ethanol (0.347 mmol) according to the general procedure described above. Crude product obtained was an amber syrup that was purified by column chromatography using 20% acetone/dichloromethane to give the final product as a clear oil (0.347 mmol, quant). MS (ESI) m/z 514.3; HRMS: calcd for C29H28C1N5O2 + H+, 514.20043; found (ESI, [M+H]+ Obs'd), 514.2006.
Example 255; 7-{2-Azido-2-[3-(5-methyl-2-thienyl)phenyllethylI-8-(benzyloxy)-5- chloroquinoline
[0188] Prepared from 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(5-methyl-2- thienyl)phenyl]ethanol (4.151 mmol) according to the general procedure described above. After stirring the reaction 16h at room temperature, dimethylformamide (10 mL) was added and the resulting solution was heated to 8O0C for 1.5h after which time the reaction was cooled to room temperature and worked up as described above. Crude product obtained was an amber syrup that was purified by column chromatography using 20% ethyl acetate/hexanes to give the final product as a clear syrup (3.16 mmol, 76%). MS (ESI) m/z 511.4.
General Procedure for Staudinger Reduction of Azides:
[0189] To a stirring solution of the appropriate azide (0.970 mmol, 1.0 eq.) in tetrahydrofuran (3.13 mL) and water (1 mL) in a round bottom flask equipped with a reflux condenser was added triphenylphosphine (1.067 mmol, 1.1 eq.) (CAUTION: vigorous gas evolution, do not seal reaction vessel) and the resulting mixture was then warmed to 7O0C and stirred 3h. The reaction mixture was then allowed to cool to room temperature, diluted with ethyl acetate (50 mL) and was washed with IN HCl (3 X 25 mL). The aqueous layers were combined, backextracted with ethyl acetate (25 mL) and then adjusted to pH=12 by addition of 5N NaOH resulting in a precipitate. The aqueous solution was extracted with ethyl acetate (3 X 50 mL) and the organic layers were combined, dried (MgSO4), filtered and concentrated to the product that was either pure or taken on crude. Example 256; 2-[8-(Benzyloxy)-5-chloroquinolin-7-yll-l-[4-(morpholin-4- ylmethvDphenyll ethanamine
[0190] Prepared from 7-{2-azido-2-[4-(morpholin-4-ylmethyl)phenyl]ethyl}-8-
(benzyloxy)-5-chloroquinoline (0.970 mmol) according to the general procedure described above. Pure product as a white solid was obtained from the acid/base extraction (0.890 mmol, 92%). MS (ESI) m/z 488.4; HRMS: calcd for C29H30C1N3O2 + H+, 488.20993; found (ESI, [M+H]+ Obs'd), 488.2106.
Example 257; 2-[8-(Benzyloxy)-5-chloroquinolin-7-yll-l-[3-(5-methyl-2- thienvl)phenyll ethanamine
[0191] Prepared from 7-{2-azido-2-[3-(5-methyl-2-thienyl)phenyl]ethyl}-8-
(benzyloxy)-5-chloroquinoline (3.001 mmol) according to the general procedure described above. Extraction of the product into the aqueous layer was performed using 2N HCl in place of IN HCl. Pure product as a light tan solid was obtained from the acid/base extraction (2.65 mmol, 88%). MS (ESI) m/z 485.3; HRMS: calcd for C29H25C1N2OS + H+, 485.14489; found (ESI, [M+H]+ Obs'd), 485.1455.
General Procedure for N-acylations:
[0192] To a round bottom flask containing the appropriate amine (0.45 mmol, 1.0 eq.) at -780C was added a solution of 4-biphenylcarbonyl chloride (0.50 mmol, 1.1 eq.) and triethylamine (0.50 mmol, 1.1 eq.) in tetrahydrofuran (5 mL) that was pre-mixed and stirred 5 min prior to addition. After warming to room temperature, the resulting solution was stirred 15 min and quenched with saturated aqueous sodium bicarbonate solution (5 mL). The tetrahydrofuran was removed by rotary evaporation and the resulting aqueous solution was extracted with dichloromethane (2 X 5 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to the crude product that was purified by column chromatography or recrystallization. Example 258; N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yll-l-[4-(morpholin-4- ylmethyl)phenyllethyllbiphenyl-4-carboxamide
[0193] Prepared from 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- ylmethyl)phenyl]ethanamine (0.45 mmol) according to the general procedure described above. Crude product obtained was a white solid which was purified by column chromatography using 10% methanol/dichloromethane followed by recrystallization from dichloromethane/hexanes to give the product as a white solid (0.344 mmol, 77%). MS (ESI) m/z 668.4; HRMS: calcd for C42H38C1N3O3 + H+, 668.26745; found (ESI, [M+H]+ Obs'd), 668.2675.
Example 259; N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yll-l-[3-(pyrrolidin-l- ylmethyl)phenyllethyllbiphenyl-4-carboxamide
[0194] To a stirring solution of [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde
(10.54 mmol) in tetrahydrofuran (75 mL) at -780C was slowly added a 0.25M solution of [3- (l-pyrrolidinylmethyl)phenyl]magnesium bromide in tetrahydrofuran (12.50 mmol, 1.2 eq.) and stirring at -780C was continued for 20 min. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (10 mL) and allowed to warm to room temperature. The mixture was then diluted with saturated aqueous ammonium chloride solution (65 mL) and extracted with ethyl acetate (2 X 75 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give 2-(8-benzyloxy-5-chloro-quinolin-7- yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethanol as a yellow oil that was purified by column chromatography using 70/29/1 dichloromethane/acetone/diisopropylethylamine. The 2-(8- benzyloxy-5-chloro-quinolin-7-yl)- 1 -(3 -pyrrolidin- 1 -ylmethyl-phenyl)-ethanol was subjected to the general conditions described above for conversion of alcohols to azides to give 7-[2- Azido-2-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-8-benzyloxy-5-chloro-quinoline. 7-[2- Azido-2-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-8-benzyloxy-5-chloro-quinoline (5.34 mmol) was subjected to the general conditions described above for Staudinger reduction of azides to give 2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)- ethylamine an amber oil and was used directly in the ensuing step. 2-(8-Benzyloxy-5-chloro- quinolin-7-yl)- 1 -(3 -pyrrolidin- l-ylmethyl-phenyl)-ethylamine (0.675 mmol) was subjected to the general conditions described above for N-acylation with 4-biphenylcarbonyl chloride to give an off-white solid which was purified by twice recrystallizing from dichloromethane/hexanes to give the title compound as a white solid (0.311 mmol, 18% for 4 steps). MS (ESI) m/z 652.5; HRMS: calcd for C42H38C1N3O2 + H+, 652.27253; found (ESI, [M+H]+ Obs'd), 652.2730.
Example 260; N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[4-(morpholin-4- ylmethyl)phenyllethylIbiphenyl-4-carboxamide
[0195] To a stirring suspension of N-{2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[4-
(morpholin-4-ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide (0.315 mmol) in acetonitrile (5 mL) was added sodium iodide (1.57 mmol, 5.0 eq.) followed by chlorotrimethylsilane (1.57 mmol, 5.0 eq.) and the resulting solution was heated to 5O0C, capped and stirred Ih. Additional acetonitrile (5 mL) was added and the reaction was stirred at 5O0C for an additional 4h. The reaction mixture was then cooled to room temperature and concentrated by rotary evaporation to a brown solid which was purified by preparative scale HPLC to give the trifluoroacetate salt of the final product as a light brown solid (0.175 mmol, 56%). MS (ESI) m/z 578.4; HRMS: calcd for C35H32C1N3O3 + H+, 578.22050; found (ESI, [M+H]+ Obs'd), 578.2210.
Example 261; N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[3-(pyrrolidin-l- ylmethyl)phenyllethyllbiphenyl-4-carboxamide
[0196] To a stirring suspension of N-{2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[3-
(pyrrolidin-l-ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide (0.303 mmol) in acetonitrile (7.5 mL) was added sodium iodide (1.513 mmol, 5.0 eq.) followed by chlorotrimethylsilane (1.513 mmol, 5.0 eq.) and the resulting solution was heated to 5O0C, capped and stirred 5h. The reaction mixture was then cooled to room temperature and additional sodium iodide (1.513 mmol, 5.0 eq.) and chlorotrimethylsilane (1.513 mmol, 5.0 eq.) were added followed by reheating to 5O0C for 16h. The reaction mixture was then cooled to room temperature and concentrated by rotary evaporation to a brown solid to which was added pH=7.4 phosphate buffer (10 mL). This mixture was extracted with a solution of 19: 1 chloroform/methanol and the combined organic layers were dried (MgSO4), filtered and concentrated to a brown solid which was purified by preparative scale HPLC followed by concentration to a solid which was washed with water (2 X 3 mL) followed by hexanes (4 X 3mL) to give the trifluoroacetate salt of the final product as a light tan solid (0.101 mmol, 33%). MS (ESI) m/z 562.5; HRMS: calcd for C35H32C1N3O2 + H+, 562.22558; found (ESI, [M+H]+ Obs'd), 562.2259.
Alternate General Procedure for N-acylations:
[0197] To a round bottom flask containing the appropriate amine (0.701 mmol, 1.0 eq.) at O0C was added a solution of the acid chloride (0.771 mmol, 1.1 eq.) and triethylamine (0.771 mmol, 1.1 eq.) in tetrahydrofuran (7 mL) that was pre-mixed and stirred 5 min prior to addition. After warming to room temperature, the resulting solution was stirred 15 min and quenched with saturated aqueous sodium bicarbonate solution (7 mL). The tetrahydrofuran was removed by rotary evaporation and the resulting aqueous solution was extracted with dichloromethane (2 X 7 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to the crude product that was either recrystallized or used crude in the ensuing reaction.
Example 262; N-(2-(5-Chloro-8-hvdroxyQuinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyllethyllbiphenyl-4-carboxamide
[0198] 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(5-methyl-2- thienyl)phenyl]ethanamine (0.412 mmol) and 4-biphenylcarbonyl chloride (0.453 mmol, 1.1 eq.) were subjected to the conditions described above (Alternate General Procedure for N- Acylations). Crude N-{2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2- yl)-phenyl]-ethyl}-2-(biphenyl-4-yloxy)-acetamide obtained was a tan solid that was used directly in the ensuing reaction. To a stirring suspension of N-{2-(8-benzyloxy-5-chloro- quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)-phenyl]-ethyl}-2-(biphenyl-4-yloxy)-acetamide (0.226 mmol) in acetonitrile (3.5 mL) and 1,2-dichloroethane (7 mL) was added sodium iodide (2.258 mmol, 10.0 eq.) followed by chlorotrimethylsilane (2.258 mmol, 10.0 eq.) and the resulting solution was heated to 7O0C, capped and stirred 2h. The reaction mixture was then cooled to room temperature and concentrated by rotary evaporation to remove the vast majority of the solvent. Water (5 mL) was added and the resulting suspension was stirred Ih and concentrated by rotary evaporation to a brown solid. Water (5 mL) was added and the resulting mixture was sonicated for 5 min then filtered with the solid being washed with additional water. The solid was returned to a round bottom flask and toluene (5 mL) was added followed by removal of the solvent by rotary evaporation. The solid was then dissolved in a warm solution of 19: 1 chloroform/methanol (10 mL) and this solution was washed with a 10% aqueous solution of sodium thiosulfate. The organic layer was dried (MgSO4), filtered and concentrated to a light green solid that was recrystallized from dichloromethane to give the title compound as an off-white solid (0.191 mmol, 37% for 2 steps). HRMS: calcd for C35H27C1N2O2S + H+, 575.15545; found (ESI, [M+H]+ Obs'd), 575.1555.
General Procedure for TMSI-mediated O-Benzyl Deprotection:
[0199] To a round bottom flask containing the appropriate O-benzyl protected hydroxyquinoline (0.285 mmol, 1.0 eq.) was added sodium iodide (1.423 mmol, 5.0 eq.) followed by acetonitrile (4.5 mL) and finally chlorotrimethylsilane (1.423 mmol, 5.0 eq.). After warming to 7O0C, the solution was capped and stirred 16h then cooled to room temperature and quenched by the addition of pH=7.4 phosphate buffer (0.5 mL) and stirred 5 min. The acetonitrile was then removed by rotary evaporation and the resulting solution was diluted with pH=7.4 phosphate buffer (10 mL) and brine (2 mL) and extracted with a solution of 19: 1 chloroform/methanol (3 X 8 mL). The organic layer was dried (MgSO4), filtered and concentrated to a dark brown solid. To this solid was added toluene (10 mL) and methanol (~5 drops) and the organic solvents were removed by rotary evaporation repeating this process 3 times affording the crude product that was purified by either preparative scale HPLC or column chromatography.
Example 263; N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[3-(pyrrolidin-l- ylmethyl)phenyllethyll-2-phenoxyacetamide
[0200] To a stirring solution of [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde
(10.54 mmol) in tetrahydrofuran (75 mL) at -780C was slowly added a 0.25M solution of [3- (l-pyrrolidinylmethyl)phenyl]magnesium bromide in tetrahydrofuran (12.50 mmol, 1.2 eq.) and stirring at -780C was continued for 20 min. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (10 mL) and allowed to warm to room temperature. The mixture was then diluted with saturated aqueous ammonium chloride solution (65 mL) and extracted with ethyl acetate (2 X 75 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give a yellow oil that was purified by column chromatography using 70/29/1 dichloromethane/acetone/diisopropylethylamine to give 2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethanol as a white solid which was used directly in the next step. 2-(8-benzyloxy-5-chloro-quinolin-7-yl)- l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethanol (5.34 mmol) was subjected to the general conditions described above for conversion of alcohols to azides to give 7-[2-azido-2-(3- pyrrolidin-l-ylmethyl-phenyl)-ethyl]-8-benzyloxy-5-chloro-quinoline as an amber oil that was used directly in the ensuing step. 7-[2-azido-2-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]- 8-benzyloxy-5-chloro-quinoline (5.34 mmol) was subjected to the general conditions described above for Staudinger reduction of azides to give 2-(8-benzyloxy-5-chloro-quinolin- 7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethylamine as an amber oil that was used directly in the ensuing step. 2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl- phenyl)-ethylamine (0.701 mmol) and phenoxyacetyl chloride (0.771 mmol, 1.1 eq.) were subjected to the general procedure described above (Alternate General Procedure for N- Acylations) to give the crude product obtained as an off-white solid that was purified by recrystallization from dichloromethane/ether to give N-[2-(8-benzyloxy-5-chloro-quinolin-7- yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-2-phenoxy-acetamide as a light tan solid. N- [2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-2- phenoxy-acetamide was subjected to the general procedure described above for TMSI- mediated O-benzyl deprotection. After stirring 16h at 7O0C, 1,2-dichloroethane (2 mL) was added and the reaction was stirred 5h at 7O0C after which time the reaction was quenched and worked up as described above. Crude product obtained was a brown oil that was purified by preparative scale HPLC to give the trifluoroacetate salt of the title compound as a yellow solid (0.109 mmol, 9% for 5 steps). MS (ESI) m/z 516.2052; HRMS: calcd for C30H30C1N3O3 + H+, 516.20485; found (ESI, [M+H]+ Obs'd), 516.2052.
Example 264; N-(2-(5-Chloro-8-hvdroxyauinolin-7-ylM-[3-(pyrrolidin-l- ylmethyl)phenyllethyll-2-(4-chlorophenoxy)-2-methylpropanamide
[0201] To a stirring solution of [8-(benzyloxy)-5-chloroquinolin-7-yl]acetaldehyde
(10.54 mmol) in tetrahydrofuran (75 mL) at -780C was slowly added a 0.25M solution of [3- (l-pyrrolidinylmethyl)phenyl]magnesium bromide in tetrahydrofuran (12.50 mmol, 1.2 eq.) and stirring at -780C was continued for 20 min. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (10 mL) and allowed to warm to room temperature. The mixture was then diluted with saturated aqueous ammonium chloride solution (65 mL) and extracted with ethyl acetate (2 X 75 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give a yellow oil that was purified by column chromatography using 70/29/1 dichloromethane/acetone/diisopropylethylamine to give 2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethanol as a white solid which was used directly in the ensuing step. 2-(8-benzyloxy-5-chloro-quinolin-7- yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethanol (5.34 mmol) was subjected to the general conditions described above for conversion of alcohols to azides to give 7-[2-azido-2-(3- pyrrolidin-l-ylmethyl-phenyl)-ethyl]-8-benzyloxy-5-chloro-quinoline as an amber oil that was used directly in the ensuing step. 7-[2-azido-2-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]- 8-benzyloxy-5-chloro-quinoline (5.34 mmol) was subjected to the general conditions described above for Staudinger reduction of azides to give 2-(8-benzyloxy-5-chloro-quinolin- 7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethylamine as an amber oil that was used directly in the ensuing step. 2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl- phenyl)-ethylamine (0.701 mmol) and 2-(4-chlorophenoxy)-2-methylpropanoyl chloride (0.771 mmol, 1.1 eq.) were subjected to the general conditions described above (Alternate General Procedure for N-Acylations) to give N-[2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l- (3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-2-(4-chloro-phenoxy)-2-methyl-propionamide as a tan solid that was purified by recrystallization from dichloromethane/ether. N-[2-(8- Benzyloxy-5-chloro-quinolin-7-yl)-l-(3-pyrrolidin-l-ylmethyl-phenyl)-ethyl]-2-(4-chloro- phenoxy)-2-methyl-propionamide (0.237 mmol) was subjected to the general procedure described above for TMSI-mediated O-benzyl deprotection. After stirring 16h at 7O0C, 1,2- dichloroethane (2 mL) was added and the reaction was stirred 5h at 7O0C after which time the reaction was quenched and worked up as described above. Crude product obtained was a brown solid that was purified by preparative scale HPLC to give the trifluoroacetate salt of the title compound as a yellow solid (0.074 mmol, 6% for 5 steps). MS (ESI) m/z 578.1971; HRMS: calcd for C32H33C12N3O3 + H+, 578.19717; found (ESI, [M+H]+ Obs'd), 578.1971.
Example 265; N-(2-(5-Chloro-8-hvdroxyQuinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyllethyll-2-phenoxyacetamide
[0202] N-{2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl}-2-phenoxy-acetamide was prepared from 2-[8-(benzyloxy)-5-chloroquinolin- 7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.404 mmol) and phenoxyacetyl chloride (0.445 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations). Ethyl acetate was used in place of dichloromethane in the workup procedure. Crude product obtained was a white foam that was subjected to the conditions described above for TMSI-mediated O-benzyl deprotection. After stirring 16h at 7O0C, 1,2-dichloroethane (5.6 mL) was added and the reaction was stirred 3h at 7O0C after which time the reaction was quenched and worked up as described above. Crude product obtained was a brown oil that was purified by column chromatography using 10% acetone/dichloromethane followed by concentration and washing the solid with diethyl ether (3 X 5 mL) to give the title compound as a tan solid (0.171 mmol, 42% for 2 steps). MS (ESI) m/z 529.4.
Example 266; 2-(Benzyloxy)-N-{2-(5-chloro-8-hvdroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienvl)phenyll ethyll acetamide
[0203] 2-Benzyloxy-N-{2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl- thiophen-2-yl)-phenyl]-ethyl} -acetamide was prepared from 2-[8-(benzyloxy)-5- chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.411 mmol) and benzyloxyacetyl chloride (0.452 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations). After stirring 15 min at room temperature, additional benzyloxyacetyl chloride (0.206 mmol, 0.5 eq.) and triethylamine (0.206 mmol, 0.5 eq.) was added. Stirring was continued for 2 min at room temperature and the reaction was worked up as described in the general procedure. Ethyl acetate was used in place of dichloromethane in the workup procedure. Crude product obtained was a white foam that was subjected to the conditions described above for TMSI-mediated O-benzyl deprotection. Crude product obtained was a brown solid that was purified by column chromatography using 10% acetone/dichloromethane to give the title compound as a tan solid (0.118 mmol, 29% for 2 steps). MS (ESI) m/z 543.4.
Example 267; N-{2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyllethylI-2-(4-chlorophenoxy)-2-methylpropanamide
[0204] N-{2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl}-2-(4-chloro-phenoxy)-2-methyl-propionamide was prepared from 2-[8- (benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.409 mmol) and 2-(4-chlorophenoxy)-2-methylpropanoyl chloride (0.450 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations). Ethyl acetate was used in place of dichloromethane in the workup procedure. Crude product obtained was a tan solid that was subjected to the conditions described above for TMSI- mediated O-benzyl deprotection. Crude product from the deprotection was a brown solid that was purified by column chromatography using 5% methanol/dichloromethane to give the title compound as a white solid (0.270 mmol, 66% for 2 steps). MS (ESI) m/z 591.4.
Example 268; 2-(4-tert-Butylphenoxy)-N-(2-(5-chloro-8-hvdroxyαuinolin-7-yr)-l-[3-(5- methyl-2-thienyl)phenyllethyllacetamide
[0205] N-{2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-[3-(5-methyl-thiophen-2-yl)- phenyl]-ethyl}-2-(4-tert-butyl-phenoxy)-acetamide was prepared from 2-[8-(benzyloxy)-5- chloroquinolin-7-yl]-l-[3-(5-methyl-2-thienyl)phenyl]ethanamine (0.414 mmol) and 4-tert- butyl-phenoxyacetyl chloride (0.455 mmol, 1.1 eq.) according to the general procedure described above (Alternate General Procedure for N-Acylations). Ethyl acetate was used in place of dichloromethane in the workup procedure. Crude product obtained was a white solid that was subjected to the conditions described above for TMSI-mediated O-benzyl deprotection Crude product obtained was a brown solid that was purified by column chromatography using 5% methanol/dichloromethane to give the title compound as a white solid (0.262 mmol, 64% for 2 steps). MS (ESI) m/z 585.4.
Scheme D; Synthesis of N-[2-r5-Chloro-8-hvdroxyquinolin-7-yl)-l-{5- [(dimethylamino)methyll-2-furyllethyll-2-phenoxyacetamide and
N-[2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-{5-[(dimethylamino)methyll-2-furyllethyll-2- methylpropanamide
2-[8-
Figure imgf000105_0001
(benzyloxy)-5-chloroquinolin- 1-(5-{1-Azido-2-[8-(benzyloxy)- 7-y Q-1 -{5-[(d im ethy lami nojmethyl]- 5-chloroquinolin-7-yl]ethyl}-2-f uryl)- 2-furyl}ethanol N,N-dimethylmethanamine
Figure imgf000105_0002
2-[8-(Benzyloxy)-5-chloroquinolin- N-(2-[8-(Benzyloxy) -5-chloroquinolin- N-[2-(5 -ChIo ro-8 -hydroxy qu in olin-7-y I)- 7-yQ-1-{5-[(dimethylamino)methyl]- 7-y[] -1-{5-[(dimethylamino)methy!]-2- 1-{5-[(dimethylamino)methyl]-2-furyl} 2-f uryljethanamine furyl}ethyl)-2-phenoxyacetamide et hyl]-2-p henoxyaceta mid e
Figure imgf000105_0003
2-[8-(Benzyloxy)-5-chloroquinolin- N -[2-( 8-Be nzy to xy-5- chl oro -qu i no Ii n-7 -y I)- N-[2-(5-Chloro-8-hydroxyquinolin- 7-yl]-1-{5-[(dimethylamino)methyl]- 1 -(5-dimethylaminomethyl-furan-2-yl)- 7-yl)-1-{5-[(dinethylamino)methyl]- 2-furyl}ethanamine ethyl]-isobutyramide 2-f uryl}ethyl]-2-methylpropanamide
Example 269; l-rS-ll-Azido^-fS-rbenzyloxyVS-chloroquinolin-T-yllethyll^-furvD-^N- dimethylmethanamine
[0206] To a stirring solution of 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-{5-
[(dimethylamino)methyl]-2-furyl}ethanol (2.18 mmol) in toluene (13.5 mL) and dimethylformamide (2.7 mL) at O0C was added diphenyl phosphoryl azide (5.46 mmol, 2.5 eq.) followed by dropwise addition of l,8-diazabicyclo[5.4.0]undec-7-ene (5.46 mmol, 2.5 eq.). The reaction mixture was stirred 5 min at O0C then warmed to room temperature and stirred 16h. The mixture was next diluted with saturated aqueous lithium bromide solution (25 mL) and extracted with ethyl acetate (3 X 15 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a dark brown syrup that was purified by column chromatography using 30% acetone/dichloromethane to give the product as a brown syrup (1.65 mmol, 76%). MS (ESI) m/z 462.4; HRMS: calcd for C25H24C1N5O2 + H+, 462.16913; found (ESI, [M+H]+ Obs'd), 462.1693.
Example 270 ; 2- [8-(Benzyloxy)-5-chloroq uinolin-7-yll -l-{5-[(dimethylamino)methyll -2- furyllethanamine
[0207] To a stirring solution of l-(5-{l-azido-2-[8-(benzyloxy)-5-chloroquinolin-7- yl]ethyl}-2-furyl)-N,N-dimethylmethanamine (0.1.451 mmol) in tetrahydrofuran (5 mL) and water (1.5 mL) in a round bottom flask equipped with a reflux condenser was added triphenylphosphine (1.596 mmol, 1.1 eq.) (CAUTION: vigorous gas evolution, do not seal reaction vessel) and the resulting mixture was then warmed to 7O0C and stirred 2h. The reaction mixture was then allowed to cool to room temperature, diluted with ethyl acetate (50 mL) and was washed with IN HCl (3 X 25 mL). The aqueous layers were combined, backextracted with ethyl acetate (25 mL) and then adjusted to pH=12 by addition of 5N NaOH resulting in a precipitate. The aqueous solution was extracted with ethyl acetate (3 X 50 mL) and the organic layers were combined, dried (MgSO4), filtered and concentrated a yellow oil that was used directly in the ensuing step. MS (ESI) m/z 436.4; HRMS: calcd for C25H26C1N3O2 + H+, 436.17863; found (ESI, [M+H]+ Obs'd), 436.1788.
Example 271; N-^-fS-rBenzyloxyVS-chloroquinolin-T-yll-l-IS- [(dimethylamino)methyll-2-furyllethyl)-2-phenoxyacetamide
[0208] To a stirring solution of 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-{5-
[(dimethylamino)methyl]-2-furyl}ethanamine (0.431 mmol) and triethylamine (0.474 mmol, 1.1 eq.) in tetrahydrofuran (4 mL) at O0C was added phenoxyacetyl chloride (0.474 mmol, 1.1 eq.) and the resulting solution was stirred 5 min at O0C then warmed to room temperature and stirred 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution (15 mL) and the resulting aqueous solution was extracted with ethyl acetate (3 X 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a white foam that was purified by column chromatography using 10% methanol/dichloromethane to give the final product as a clear oil (0.113 mmol, 26%). MS (ESI) m/z 570.3; HRMS: calcd for C33H32C1N3O4 + H+, 570.21541; found (ESI, [M+H]+ Obs'd), 570.2155. Example 272; N-[2-(5-Chloro-8-hvdroxyquinolin-7-yl)-l-{5-[(dimethylamino)methyll-2- furyllethyll-2-phenoxyacetamide
[0209] To a stirring solution of N-(2-[8-(benzyloxy)-5-chloroquinolin-7-yl]-l-{5-
[(dimethylamino)methyl]-2-furyl}ethyl)-2-phenoxyacetamide (0.113 mmol) in acetonitrile (3 mL) was added sodium iodide (0.565 mmol, 5.0 eq.) followed by chlorotrimethylsilane (0.565 mmol, 5.0 eq.). After warming to 7O0C, the solution was capped and stirred 1.5h then cooled to room temperature and quenched by the addition of 10% sodium thiosulfate (0.25 mL) and the acetonitrile was removed by rotary evaporation. The resulting solution was diluted with 0.1N NaOH (10 mL) and extracted with dichloromethane (3 X 8 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a yellow solid that was purified by preparative scale HPLC to give the trifluoroacetate salt of the final product as a yellow solid (0.016 mmol, 14%). MS (ESI) m/z 480.2.
Example 273; N-[2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-(5-dimethylaminomethyl- furan-2-yl)-ethyll-isobutyramide
[0210] To a round bottom flask containing 2-[8-(benzyloxy)-5-chloroquinolin-7-yl]- l-{5-[(dimethylamino)methyl]-2-furyl}ethanamine (0.710 mmol) at O0C was added a solution of isobutyryl chloride (0.852 mmol, 1.2 eq.) and triethylamine (0.852 mmol, 1.2 eq.) in tetrahydrofuran (5 mL) that was pre-mixed and stirred 5 min prior to addition. After warming to room temperature, the resulting solution was stirred 2h and quenched with saturated aqueous sodium bicarbonate solution (1 mL) and stirred 5 min. The reaction was diluted with 0. IN NaOH (15 mL) and extracted with ethyl acetate (3 X 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a yellow syrup that was purified by column chromatography to afford the final product as a white solid (0.344 mmol, 47% for 2 steps). HRMS: calcd for C29H32C1N3O3 + H+, 506.22049; found (ESI, [M+H]+ Obs'd), 506.2208.
Example 274; N-[2-(5-Chloro-8-hvdroxyquinolin-7-ylM-(5-[(dimethylamino)methyll-2- furyll ethyll -2-methylpropanamide
[0211] To a stirring solution of N-[2-(8-benzyloxy-5-chloro-quinolin-7-yl)-l-(5- dimethylaminomethyl-furan-2-yl)-ethyl]-isobutyramide (0.266 mmol) in acetonitrile (3 mL) and 1,2-dichloroethane (1 mL) was added sodium iodide (1.33 mmol, 5.0 eq.) followed by chlorotrimethylsilane (1.33 mmol, 5.0 eq.). After warming to 7O0C, the solution was capped and stirred 4h then cooled to room temperature and quenched by the addition of 10% sodium thiosulfate (2 mL). The resulting solution was diluted with pH=7.4 phosphate buffer (15 mL) and extracted with dichloromethane (3 X 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to a brown oil that was purified by preparative scale HPLC to give the trifluoroacetate salt of the final product as a yellow solid (0.111 mmol, 42%). MS (ESI) m/z 416.3.
Examples 275-277
[0212] 2-[amino(phenyl)methyl]quinolin-8-ol, N-[(8-hydroxyquinolin-2- yl)(phenyl)methyl]-2-phenoxyacetamide and 2-
{[(phenoxyacetyl)amino](phenyl)methyl}quinolin-8-yl phenoxyacetate were prepared as outlined in below.
Figure imgf000109_0001
2-[amino(phenyl)methyl]quinolin-8-ol
Figure imgf000109_0002
Et3N, DMAP CH9Cl9, -780C- RT N- [(8 -h ydro xyqu inol in-2 -yl) (phenyl)methyl]-2-phenoxyacetamide
+
Figure imgf000109_0003
2-{[(phenoxyacetyl)amino] (phenyl)methylJquinolin-8-yl phenoxyacetate
The experimentals are presented below:
Figure imgf000110_0001
2-[amino(phenyl)methyl]quinolin-8-ol
[0213] To a solution of 8-hydroxyquinoline-2-carbonitrile (416 mg, 2.45 mmol) in
THF (5 mL) at -780C was added phenyllithium solution (1.8M in nBu2O) (2.72 mL, 4.9 mmol) dropwise. The flask was allowed to warm to room temperature over 2 h. After recooling to to -780C ethanol (7 mL) was added dropwise followed by sodium borohydride (110 mg, 2.9 mmol). Upon completion of the reduction 1 N HCl was added until hydrogen evolution ceased. The mixture was treated with saturated aqueous sodium bicarbonate and was then back extracted with chloroform. Combined organic layers were dried over sodium sulfate, filtered and reduced to dryness. Silica gel flash chromatography (dichloromethane, methanol) furnished 306 mg of an orange solid (50% yield).
2-[amino(phenyl)methyl]quinolin-8-ol MS (ESI) m/z 251.2
[0214] To a solution of 2-[amino(phenyl)methyl]quinolin-8-ol in dichloromethane
(10 mL) was added triethylamine (0.098 ml, 0.7 mmol) and 4-(dimethylamino)pyridine 5 mg. After cooling to -780C phenoxyacetyl chloride (0.085mL, 0.617 mmol) was added dropwise and the resulting solution was stirred for 12 h at room temperature. The reaction was partitioned between ether and water. The organic layer was dried over sodium sulfate, filtered and reduced to dryness. The resulting residue was subjected to silica gel flash chromatography ( hexanes/ethyl acetate 30: 1-2: 1) and two products were eluted. Eluting first was 95 mg of a white solid (40% yield).
Figure imgf000111_0001
N-[(8-hydroxyquinolin-2-yl)(phenyl)methyl]-2-phenoxyacetamide MS (ESI) m/z 385.2
E
Figure imgf000111_0002
2-{ [(phenoxyacetyl)amino] (phenyl)methyl}quinolin-8-yl phenoxyacetate
2- { [(phenoxyacetyl)amino](phenyl)methyl}quinolin-8-yl phenoxyacetate MS (ESI) m/z 519.2
The Agg-l/Agg-2 FRET data for N-[(8-hydroxyquinolin-2-yl)(phenyl)methyl]-2- phenoxyacetamide and 2- {[(phenoxyacetyl)amino](phenyl)methyl}quinolin-8-yl phenoxyacetate is presented in Table 1.
Table 1. N-[(8-hydroxyquinolin-2-yl)
Figure imgf000112_0001
Example 278
Figure imgf000112_0002
[0215] To a mixture of Ia (0.12 mmol) and potassium carbonate (0.13 mmol) in
DMF:acetone (2 mL of 1 : 1 mixture) is added an alkyl iodide (0.13 mmol). The reaction is heated to 50 C and stirred for 18 h. The reaction mixture is concentrated and purification via preparative HPLC affords Ha. The scheme depicts synthesis of a compound of formula (I):
Figure imgf000113_0001
in which X is N, Y is -COR4, R43 is H and p is 0. Analogous reactions can be used to make compounds of formula (I) in which X is N, Y is -COR4, R43 is H and p is 1 ; in which X is -COR4, Y is N, Ri is H and p is 0; and in which X is -COR4, Y is N, Ri is H and p is 1 ; by substitution of the appropriate starting compound having a hydroxy group in place of the compound labeled "Ia" in the scheme.
Example 279
Aggrecanse 2 In vitro Enzyme assay
[0216] A continuous assay was used in which the substrate was a synthetic peptide containing a fluorescent group (o-aminobenzyl, Abz), which was quenched by energy transfer to a 2,4-dinitrophenyl group (Dnp). The buffer used in this assay was 50 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM CaCl2, 0.1 % CHAPS, 5% glycerol. The source of enzyme was purified recombinant human Aggrecanase-2 Agg2-Phe628 (MW = 41,737). This is a truncated form of full-length human aggrecanase-2 that was expressed in CHO cells and purified. The final concentration of Agg2-Phe628 was 0.5 μg/ml. The substrate in the assay was synthesized by AnaSpec, Inc. and was >95% pure based on HPLC analysis. It is a synthetic peptide that is designed after a portion of brevican, one of the naturally occurring substrates of Aggrecanase-2, of the sequence Abz-TESESRGAIY-Dap(Dnp)-KK-NH2 (mass = 1740). The concentration of this substrate stock was spectrophotometrically determined using the extinction coefficient at 354nm of 18,172 M 1Cm"1. The Fmax and Km for this enzyme/substrate reaction were determined to be insensitive to DMSO up to at least 10% (v/v). The final concentration of substrate in the assay was 25 μM.
[0217] Test compounds (in duplicate) were serially diluted from 2 mM to 0.01 μM in
100% DMSO. The total reaction volume was 100 μl. The buffer and enzyme were added first followed by addition of 1OX inhibitor from the dilution plate. Enzyme and buffer alone samples were included in order to obtain the maximal rate of substrate cleavage. The reaction was allowed to stand at 300C for 15 min. Then substrate was added, mixed and the reaction monitored for 40 min at 300C in kinetic mode using λex: 340 nm and λem: 420
(GeminiXS Molecular Devices).
[0218] Compound A, a hydroxamic acid with an Agg2 IC50 of 36 +/- 4 nM, is of formula:
Figure imgf000114_0001
Compound A
[0219] Compound A was run on each plate (in duplicate) as a positive control for the assay at the following concentrations: 200 nM, 20 nM and 10 nM which correspond to 100, 60 and 40 % inhibition of Agg2-Phe628 activity respectively.
Example 280
Aggrecanse 2 Enzyme Fluorescence Polarization assay a) Introduction
[0220] The fluorescence polarization assay is used to determine the dissociation constant of the enzyme nhibitor complex (Ki) and the binding interaction mode (competitive, non-competitive or uncompetitive) of reversible inhibitors. The fluorescence polarization assay monitors the rotational motion of the fluorescent ligand. In the free state the fluorescent ligand has high rotational motion corresponding to a low polarization value and when fully bound to the protein, the fluorescent ligand has a lower rotational motion, corresponding to a higher polarization value. The rotational motion of the fluorescent ligand bound to the enzyme is compared to the rotational motion of the fluorescent ligand in the presence of increasing concentrations of inhibitors in order to assess the potency of small molecules.
b) Materials and Methods
[0221] The source of enzyme was purified recombinant human Aggrecanase-2, Agg2-
Phe628 (41737 Da). This is a truncated form of full-length human aggrecanase-2 that is purified. Aliquots of this enzyme are stored at -800C in 5OmM HEPES-NaOH (pH 7.4), 10OmM NaCl, 5mM CaCl2, 20% glycerol. [0222] A fluorescent ligand was constructed from Compound B:
Figure imgf000115_0001
Compound B
and Oregon Green 488 carboxylic acid, succinimidyl ester (Molecular Probes, Eugene, Oregon). The fluorescent ligand, Compound C, has a mass of 815.8, is >95% pure based upon HPLC analysis and has the structure:
Figure imgf000116_0001
[0223] Stock solutions of the fluorescent ligand are prepared in 100% DMSO and aliquots are stored at -800C. The stock concentration was determined by a NMR ratio method, comparing the area under the control compound peak (TSP; trimethyl silyl proprionate sodium salt) to the area under a well-defined sample peak. [0224] To determine the dissociation constant between Aggrecanase-2 and
Compound C, saturation experiments were performed by adding various concentrations of aggrecanase to a constant concentration of Compound C (2nM), in the assay buffer 5OmM HEPES-NaOH (pH 7.4), 10OmM NaCl, 5mM CaCl2, 0.005% Brij-35. Anisotropy values were calculated and converted to fraction bound values as described in the data analysis section below. The plot of the fraction of bound FP ligand against compound concentration were fit to a quadratic equation, assuming a single-site binding model, where FB = Fraction of bound Fluorescent Ligand, Kd = Fluorescent Ligand Dissociation Constant, E0 = Total Enzyme Concentration and L0 = Total Ligand Concentration to determine the dissociation constant. The equilibrium dissociation constant was determined to be 60 +/- 2.9 nM.
(L0 + Kά + E0 ) - ((L0 + Kά + E0)2 - (4 L0 E0 ))0 5
FR =
2 L o
[0225] The fluorescent polarization assay buffer contains 5OmM HEPES-NaOH (pH
7.4), 10OmM NaCl, 5mM CaCl2, 0.005% Brij-35. Each well of black polystyrene 384-well plate contains a 70 μl reaction consisting of assay buffer, Aggrecanase-2 (final concentration 165 nM; 2.75 times Kd), fluorescent ligand Compound C (final concentration 2 nM), and varied concentrations of inhibitor (prepared by serial dilution in DMSO in 96-well round- bottom polypropylene plates). For each compound a 12-point titration of sample and control (minus enzyme) is performed in duplicate. The reaction is mixed by pipetting up and down and allowed to reach equilibrium over 30 minutes, at room temperature. Final DMSO concentration is 10% - 7.14% from the addition of the compound and 2.86% from the addition of Compound C.
[0226] Polarization values are determined using an Analyst AD fluorometer (LJL
Biosystems Inc., Sunnyvale, CA) with a 485 ± 20nm excitation filter and a 530 ± 25nm emission filter. The instrument is set to use SmartRead detector counting with a sensitivity of 1 for 10 msec, with the attenuator in the out position.
c) Positive Control
[0227] A broad spectrum MMP inhibitor, Compound B, with an established IC50 value of 37 +/- 2 nM and a Ki value of 39 +/- 0.7 nM for rAgg-2 was run in duplicate as a positive control for the assay.
t0 Data Analysis
[0228] The anisotropy values were calculated from the parallel and perpendicular measurements using the equation: Anisotropy = [Iw - GIVH]/[IW + 2GIVH], where Iw = intensity of vertically excited and vertically emitted light, IVH = intensity of vertically excited and horizontally emitted light, and G = G-factor = 1.05. The total intensity values were calculated from the parallel and perpendicular measurements using the equation: Total Intensity = [Iw + 2GIVH], where Iw = intensity of vertically excited and vertically emitted light, IVH = intensity of vertically excited and horizontally emitted light, and G = G-factor = 1.05.
[0229] Anisotropy values were converted to fraction of bound FP ligand using the equation: Fraction bound = (r - rfree) / (r - rfree) + Rebound - r), where r = anisotropy,
Figure imgf000117_0001
= anisotropy of fluorescent ligand in the absence of enzyme, rbound = anisotropy of fluorescent ligand in the presence of a saturating amount of enzyme, R = ratio of intensities of the free and bound fluorescent ligand = 0.92. Plots of compound concentration against fraction bound are fit to the exact solution to the competitive inhibition equation to determine the Ki value, assuming a competitive single binding site, where I0 = Total Inhibitor Concentration, Ki = Inhibitor Dissociation Constant, Kd = Fluorescent Ligand Dissociation Constant, fB = Fraction of bound Fluorescent Ligand, E0= Total Enzyme Concentration and L0 = Total Ligand Concentration.
KΛ dFr b Eo(I - Fb ) Lo(l - Fb)
I0 = + K,
1 - F1 KA dΈr b K,
Example 281
Aggrecanase 2 Cell Based assay
[0230] Bovine carpal joints were obtained from young (1-2-week-old) animals, disinfected with 10% Wescodyne (Steris Corporation, St. Louis, MO) followed by 70% ethanol. Full-depth articular cartilage plugs were harvested using a cork borer and then sliced to generate individual articular cartilage discs about 6 mm wide and 1 mm thick. These cartilage discs (explants) were used for the explant assay.
[0231] Cartilage explants were cultured at 37°C for 5 days in a humidified atmosphere of 5% CO2 in air in cartilage explant culture medium. Explants were washed with media and 1 weighed explant per well were placed in a 96-well culture dish with 0.2 ml of medium and 6-8 replicates per treatment and cultured for 3 days in the presence or absence of recombinant human IL-I (rhIL-1, 5 ng/ml, Sigma, St. Louis, MO) and presence or absence of test compounds. Media were replaced every day. The aggrecan content in the medium was measured each day by Dimethylmethelene Blue (DMMB) assay using chondroitin sulphate C as a standard. Measured aggrecan was expressed per weight of cartilage.
Assay Data
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000126_0002
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Agg-1 IC50 (μM) or % Agg-2 IC50 (μM) or %
Compound Inhibition Inhibition
Figure imgf000131_0001
N-[2-(8-Hydroxyquιnolιn-7-yl)-1 - phenylethyl]-2-phenoxyacetamιde 2.1 +/- 0.3 59 % @ 100 uM
Figure imgf000131_0002
N-[1-(1 ,3-Benzodιoxol-5-yl)-2-(5- chloro-8-hydroxyquιnolιn-7- yl)ethyl]-2-phenoxyacetamιde 67% @ 22μM 9.6 +/- 3.7
Figure imgf000131_0003
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n-
7-yl)-1 -[4-(morpholιn-4- ylmethyl)phenyl]ethyl}bιphenyl-4- carboxamide 59% @ 22μM 50% @ 22μM
Figure imgf000132_0001
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n-
7-yl)-1 -[3-(pyrrolιdιn-1 - ylmethyl)phenyl]ethyl}bιphenyl-4- carboxamide 5.9 +/- 1.3 3.4 +/- 0.4
Figure imgf000132_0002
2-(Benzyloxy)-N-{2-(5-ch loro-8- hydroxyquιnolιn-7-yl)-1 -[3-(5- methyl-2- thιenyl)phenyl]ethyl}acetamιde 48% @ 66.7μM 56% @ 22μM
Figure imgf000132_0003
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n-
7-yl)-1 -[3-(5-methyl-2- thιenyl)phenyl]ethyl}-2-(4- chlorophenoxy)-2- methylpropanamide 47% @ 66.7μM 51 % @ 22μM
Figure imgf000132_0004
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n- 7-yl)-1 -[3-(5-methyl-2- thιenyl)phenyl]ethyl}-2- enoxyacetan Tide 42% (Q g 66.7μM 58% ( g 22μM
Figure imgf000132_0005
2-(4-tert-Butylphenoxy)-N-{2-(5- chloro-8-hydroxyquinolin-7-yl)-1-[3-
(5-methyl-2- thienyl)phenyl]ethyl}acetamide
Figure imgf000133_0001
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n-
7-yl)-1-[3-(pyrrolidin-1- ylmethyl)phenyl]ethyl}-2- phenoxyacetamide 56% @ 200μM 20.0 +/- 3.4
Figure imgf000133_0002
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n-
7-yl)-1-[3-(pyrrolidin-1- ylmethyl)phenyl]ethyl}-2-(4- chlorophenoxy)-2- methylpropanamide 50% @ 66.7μM 49% @ 22μM
Figure imgf000133_0003
N-{2-(5-Ch loro-8-hyd roxyq ui nol i n- y.yl^i.^δ-methyl^- thienyl)phenyl]ethyl}biphenyl-4- carboxamide 54% @ 200μM 50% @ 50μM
Figure imgf000134_0001
N-[2-(5-Ch loro-8-hydroxyq ui nol i n- 7-yl)-1 -{5-[(dιmethylamιno)methyl]- 2-furyl}ethyl]-2-phenoxyacetamιde 16.8 +/- 2.8 68% @ 200μM
Figure imgf000134_0002
N-[2-(5-Ch loro-8-hydroxyq ui nol i n- 7-yl)-1 -{5-[(dιmethylamιno)methyl]- 2-furyl}ethyl]-2-methylpropanamιde 56% @ 200μM 49% @ 200μM
[0232] When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combination and subcombinations of ranges of specific embodiments therein are intended to be included. [0233] The disclosure of each patent, patent application, and publication cited or described in this document are hereby incorporated herein by reference, in their entirety. [0234] Those skilled in the art will appreciate that numerous changes and modifications can be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is, therefore, intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

Claims

CLAIMSWhat is claimed is:
1. A compound of the Formula (I):
Figure imgf000135_0001
or a pharmaceutically acceptable salt thereof, wherein
X is -N- and Y is -COR4, or Y is -N- and X is -COR4; p is 0 or 1;
Ri and R13 are each independently hydrogen, halogen, -OR7, -CN, -Ci-Cβ-alkyl, -C2-C6- alkenyl, -C2-C6-alkynyl, -NO2, -NR5R6, -SO2NR5R6, -COR7, -COOR7, -C5-C7-cycloalkyl or - C5-C7-aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C3-alkyl, provided that when X is -N- then Ri3 is hydrogen and when Y is-N- then Ri is hydrogen;
R2 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, Cg-Cis-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR7, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is optionally substituted with one or more hydroxyl, halogen, oxygen, -Ci-C6-alkyl, - C2-C6-alkenyl, -C2-C6-alkynyl, -Cs-C^cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, -C5-C7- aryl, -Cj-Cio-arylalkyl, -Cj-Cio-arylalkenyl, -Cj-Cio-arylalkynyl, -NO2, -CH2NR5R6, -NR5R6, -NR5SO2R6, -SO2NR5R6, -SO2R7, -COR7, -Ci-Cs-alkyl-COR?, -COOR7 or -CONR5R6, wherein (1) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a - C5-C7-aryl;
R3 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-C7-cycloalkyl, -R8-C5-C7-cycloalkyl, -Cs-Cio-arylalkyl, -C7-Ci2-bicyclic hydrocarbon or -Ri2-C7-Ci2- bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO2NR5R6, -COR7, - COOR7, -CONR5R6, -CORs-B-R9, or -R8-B-R9, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with one to three substituents independently selected from halogen, -Ci-C4-alkyl, -C2-C3-alkynyl, -C5-C7-aryl, -NR5R6, -C≡N, and -COR7;
R4 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -SO2NR5R6, -SO2R7, -COR7, -COOR7 or -CONR5R6, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
R5 and R6 are each independently hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, - COR7, -C5-C7-aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C3-alkyl;
R7 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, or -C5-CiO- arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with one to three substituents independently selected from halogen, -Ci-C3-alkyl, -C5-C7-aryl, and - NR5R6, -OR5;
Rs is -Ci-Cβ-alkyl, -C2-C6-alkenyl, or -C2-C6-alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl;
Rg is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Cio-arylalkyl or -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with one to three substituents independently selected from halogen, -C1-C4-alkyl branched, a -C5-C7-aryl, B-C5-C7-aryl, -NR5R6, and -COR7, and wherein one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom;
R12 is -CH2- or -CH2CH2-; B is a bond, -0-, -NR7- or -S-.
2. The compound according to claim 1 of Formula (I), wherein Ri is chlorine, bromine or fluorine.
3. The compound according to claim 1 of Formula (I), wherein Ri is -CH3.
4. The compound according to claim 1 of Formula (I), wherein Ri is hydrogen.
5. The compound according to claim 1 of Formula (I), wherein Ri is -NO2.
6. The compound according to claim 1 of Formula (I), wherein Ri is -NR5R6.
7. The compound according to claim 6 of Formula (I), wherein Ri is -NH2 or -N(CHs)2.
8. The compound according to claim 1 of Formula (I), wherein Ri is -C5-C7-cycloalkyl or -C5-C7-MyI.
9. The compound according to claim 8 of Formula (I), wherein Ri is
Figure imgf000138_0001
10. The compound according to any one of claims 1-9 of Formula (I), wherein R2 is -C5-C7- aryl.
11. The compound according to claim 10 of Formula (I), wherein R2 is a -Cs-C7-aryl, which is optionally substituted with one to three substituents independently selected from hydroxyl, halogen, -Ci-Cβ-alkyl, -C2-C6-alkynyl, -Cs-C7-aryl, -Cs-Cio-arylalkyl, -Cs-Cio-arylalkenyl, - Cs-Cio-aiylalkynyl, -NO2, -Cs-Cr-cycloalkyl, -d-Cs-alkyl-Cs-Cr-cycloalkyl, -BR9, -COR7, - Ci-C3-alkyl-COR7, -CH2NRsRe, and -NR5R6, and wherein one to three carbon atoms of the aryl or the substituent are each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and the substituent is optionally substituted with one to three halogen atoms or -Ci-C3-alkyl groups that optionally have one to three of the carbon atoms each independently replaced with a nitrogen, sulfur or oxygen atom.
12. The compound according to claim 11 of Formula (I), wherein R2 is
Figure imgf000138_0002
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000140_0002
Figure imgf000141_0001
13. The compound according to claim 11 of Formula (I), wherein R2 is:
Figure imgf000141_0002
Figure imgf000141_0003
Figure imgf000142_0001
Figure imgf000143_0001
14. The compound according to any one of claims 1-9 of Formula (I), wherein R2 is a -C7-Ci2-bicyclic or a -Cg-Cis-tricyclic hydrocarbon.
15. The compound according to claim 14 of Formula (I), wherein R2 is a -C7-Ci2-bicyclic or a C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic, one to three carbon atoms are each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and the hydrocarbon group is optionally substituted with an oxygen, halogen, or one to three -Ci-Cβ-alkyl groups having one to three carbon atoms each independently optionally replaced with an oxygen atom.
16. The compound according to claim 15 of Formula (I), wherein R2 is:
Figure imgf000143_0002
Figure imgf000144_0001
17. The compound according to any one of claims 1-9 of Formula (I), wherein R2 is -C2-C6-alkenyl.
18. The compound according to claim 17 of Formula (I), wherein R2 is:
Figure imgf000145_0001
19. The compound according to any one of claims 1-9 of Formula (I), wherein R2 is -C5-Cio-arylalkyl or -Cs-Cio-arylalkenyl.
20. The compound according to claim 19, wherein R2 is a -Cs-Cio-arylalkyl or -Cs-C1O- arylalkenyl, which is optionally substituted with a -Ci-C6-alkyl, and wherein one to three carbon atoms of the alkyl are each independently optionally replaced with an oxygen atom.
21. The compound according to claim 20 of Formula (I), wherein R2 is:
Figure imgf000145_0002
22. The compound according to any one of claims 1-9 of Formula (I), wherein R2 is a -Cs- C7-aryl.
23. The compound according to claim 22 of Formula (I), wherein R2 is a -Cs-C7-aryl which is optionally substituted with -CH2NRsRe, -NR5R6 or -NRsSO2Re, and wherein one to three of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom.
24. The compound according to claim 23 of Formula (I), wherein R2 is:
Figure imgf000146_0001
25. The compound according to any one of claims 1-24 of Formula (I), wherein R3 is -COR8-B-R9 or -R8-B-R9.
26. The compound according to claim 25 of Formula (I), wherein R3 is -COR8-B-R9 or -R8- B-R9, wherein R8 is a -Ci-C3-alkyl, R9 is a -Cs-C7-aryl or C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein the aryl or bicyclic hydrocarbon is each independently optionally substituted with one to three halogen atoms, -Ci-C4-alkyl groups, -C5-C7-cycloalkyl groups, -Cs-C7-aryl groups, -B-Cs-C7-aryl groups, -NR5R6 groups, or -COR7 groups and one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom, and B is -O-.
27. The compound according to claim 26 of Formula (I), wherein R3 is:
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
28. The compound according to any one of claims 1-24 of Formula (I), wherein R3 is -COR8-B-R9 , -Rs-Cj-Cv-cycloalkyl, or -R8-B-R9.
29. The compound according to claim 28 of Formula (I), wherein R3 is -COR8-B-R9 , -R8-Cs- C7-cycloalkyl or -R8-B-R9, wherein R8 is a -Ci-C3-alkyl, R7 is a -Ci-C3-alkyl or hydrogen, R9 is a -C5-C7-aryl, -Ri2-C5-C7-cycloalkyl, or -Ri2-C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic and R12 is -CH2-, wherein (a) one or more of the carbon atoms are each independently optionally replaced with a nitrogen or oxygen atom, and (b) the cycloalkyl, aryl or bicyclic hydrocarbon group is optionally substituted with one to three halogen, -Ci-C4-alkyl groups, -C2-C3-alkynyl groups, -Cs-C7-aryl groups, -NR5R6, or -COR7; and B is -NR7-.
30. The compound according to claim 29 of Formula (I), wherein R3 is:
Figure imgf000149_0002
Figure imgf000150_0001

Figure imgf000151_0001
31. The compound according to any one of claims 1-24 of Formula (I), wherein R3 is -COR7.
32. The compound according to claim 31 of Formula (I), wherein R3 is -COR7, and R7 is a - Ci-C6-alkyl, -C5-C7-aryl or -C5-C10-arylalkyl.
33. The compound according to claim 32 of Formula (I), wherein R3 is:
Figure imgf000151_0002
34. The compound according to any one of claims 1-24 of Formula (I), wherein R3 is -C5-Cio-arylalkyl with a carbon atom optionally replaced with an oxygen atom.
35. The compound according to claim 34 of Formula (I), wherein R3 is:
Figure imgf000151_0003
36. The compound according to any one of claims 1-24 of Formula (I), wherein R3 is -d-Cβ-alkyl.
37. The compound according to claim 36 of Formula (I), wherein R3 is -Ci-Cβ-alkyl optionally substituted with a halogen.
38. The compound according to claim 37 of Formula (I), wherein R3 is
X>«
39. The compound according to any one of claims 1-38 of Formula (I), wherein R4 is hydrogen.
40. The compound according to any one of claims 1-38 of Formula (I), wherein R4 is methyl.
41. The compound according to any one of claims 1-38 of Formula (I), wherein R4 is - SO2R7.
42. A compound or pharmaceutically acceptable salt thereof wherein the compound is:
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(pyridin-3- yloxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-[3- (dimethylamino)phenoxy]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methoxypheny l)methy 1] acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-[3- (dimethylamino)phenoxy]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-(pyridin-3- yloxy)acetamide
2-(4-acetylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitrophenyl)methyl] acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-(4-chloro-3- methylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-(3,5- dichlorophenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-2-(pyridin-3- yloxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-2-[3- (dimethylamino)phenoxy]acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
2-[4-(acetylamino)phenoxy]-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-(4-tert-butylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(3,5- dichlorophenyl)glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-(4- cyanophenyl)glycinamide
N2-(4-acetylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-[3- (dimethylamino)phenyl]glycinamide Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-(4-tert-butylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-pyridin-3- ylglycinamide
N2-(4-acetylphenyl)-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitropheny l)methy 1] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N2-[4-(acetylamino)phenyl]-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- nitropheny l)methy 1] glycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2-pyridin-3- ylglycinamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2-(4-chloro-3- methylphenyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-fluorophenyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-cyanophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,4-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,5-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(2-chloro-4-hydroxyphenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(2-chloro-6-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(2-chloro-4-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N- { (5 -chloro- 8-hydroxyquinolin-7 -y 1) [2 -(trifluoromethy l)pheny 1] methyl } -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,4-dichlorophenyl)methyl]-2- phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chloro-5-nitrophenyl)methyl]-2- phenoxyacetamide
N-[(2-chlorophenyl)(8-hydroxy-5-methylquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-methylquinolin-7-yl)(3-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-methylquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
N 1 -[(5-chloro-8-hydroxyquinolin-7-yl)(3 -fluorophenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methyl]glycinamide
2-(benzyloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(3- fluorophenyl)methy 1] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2-methyl-N2- phenylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] glycinamide
2-(benzyloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methylphenyl)methyl] acetamide
Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2-methyl-N2- phenylglycinamide N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-N2- methylglycinamide
N2-benzyl-Nl-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]glycinamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]benzamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]benzamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(pyridin-3-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-thienyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,5-dimethoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3,4-dichlorophenyl)methyl]-2- phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-methoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-phenoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- methoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- methylphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(4-nitrophenyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4- phenoxyphenoxy)acetamide
N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-phenoxyacetamide
N-[(2-chlorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(4-chlorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-nitrophenyl)methyl]-2-phenoxyacetamide
N-[(3-fluorophenyl)(8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[[4-(dimethylamino)phenyl](8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-hydroxy-3-methoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-chlorophenoxy)acetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-fluorophenyl)methyl]-2-phenoxyacetamide
N-[(3-chloro-4-fluorophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,6-dichlorophenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(pyridin-3-yloxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methoxyphenyl)methyl]-2-(3- methoxyphenoxy)acetamide
2-(4-tert-butylphenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(4- methoxypheny l)methy 1] acetamide
N-[(2-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl]-2-phenoxyacetamide N-[(8-hydroxy-5-nitroquinolin-7-yl)(2-methylphenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-fluoro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methylphenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-methylphenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-nitrophenyl)methyl]-4-phenylbutanamide
N-[(5-chloro-8-methoxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-methoxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenoxyacetamide
N-[(S)-(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2- phenoxyacetamide
N-[(R)-(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2- phenoxyacetamide
N-[(R)-(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide N-[(S)-(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-methoxyphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-morpholin-4-ylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-hydroxyphenyl)methyl]-2-phenoxyacetamide 2-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}benzoic acid
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-methoxyphenyl)methyl]-2- phenoxyacetamide ethyl(3-{(5-chloro-8-hydroxyquinolin-7- yl)[(phenoxyacetyl)amino]methyl}phenyl)acetate
N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-methoxyphenoxy)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-chlorophenoxy)phenyl]methyl}-2- phenoxyacetamide N-{(5-chloro-8-hydroxyquinolin-7-yl)[3-(4-methylphenoxy)phenyl]methyl}-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-phenoxyphenyl)methyl]-2- phenoxyacetamide
N- [ [3 -(benzy loxy)pheny 1] (5 -chloro-8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-fluorophenyl)methyl]-2-phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(dimethylamino)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(diethylamino)phenyl]methyl}-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(dibutylamino)phenyl]methyl}-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-isopropylphenyl)methyl]-2- phenoxyacetamide
N- [ [4-(ally loxy)pheny 1] (5 -chloro- 8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(4-butoxyphenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-hex-l-yn-l-ylphenyl)methyl]-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(phenylethynyl)phenyl]methyl}-2- phenoxyacetamide
N- [ [4-(benzy loxy)pheny 1] (5 -chloro-8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[biphenyl-4-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-pyridin-4-ylphenyl)methyl]-2- phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(lH-pyrazol-l-yl)phenyl]methyl}-2- phenoxyacetamide
N-[[4-(4-tert-butyl-l,3-thiazol-2-yl)phenyl](5-chloro-8-hydroxyquinolin-7- yl)methyl]-2 -phenoxyacetamide
N-{(5-chloro-8-hydroxyquinolin-7-yl)[4-(l,2,3-thiadiazol-4-yl)phenyl]methyl}-2- phenoxyacetamide N-[(5-chloro-8-hydroxyqumolin-7-yl)(3,4-dimethylphenyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyqumolin-7-yl)(3,4-dimethoxyphenyl)methyl]-2- phenoxyacetamide
N-[[3-(benzyloxy)-4-methoxyphenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(5-methyl-2-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-furyl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(5-phenyl-2-furyl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyqumolin-7-yl)(3-methyl-2-thienyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(lH-indol-7-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(lH-indol-4-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyqumolin-7-yl)(l -methyl- lH-indol-3-yl)methyl]-2- phenoxyacetamide
N- [ 1 , 3 -benzodioxol-4-y 1(5 -chloro-8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-8-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-4-yl)methyl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-5-yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyqumolin-7-yl)(4-methoxy-l-naphthyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(9-phenanthryl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyqumolin-7-yl)(6-methoxy-2-naphthyl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,3-dihydro-l,4-benzodioxin-6-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(quinolin-3-yl)methyl]-2-phenoxyacetamide N-[I -benzofuran-2-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2 -phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(l -methyl- lH-indol-2-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,3-dihydro-l-benzofuran-5-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2,2-dimethyl-3,4-dihydro-2H-chromen-6- yl)methyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-oxo-4H-chromen-3-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(6-methyl-4-oxo-4H-chromen-3-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4H-pyrazolo[l,5-c][l,3]thiazol-2-yl)methyl]-2- phenoxyacetamide
N- [ 1 , 3 -benzodioxol-5 -y 1(5 -chloro-8 -hydroxy quinolin-7 -y l)methy 1] -2 - phenoxyacetamide
N-[(6-chloro-l,3-benzodioxol-5-yl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(l-methyl-lH-l,2,3-benzotriazol-5-yl)methyl]- 2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(5,6-dihydro-8H-imidazo[2,l-c][l,4]oxazin-2- yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-2- yl)methyl]-2 -phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-3-phenylpropanamide benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(pyridin-2-yl)methyl]carbamate benzyl [(5-chloro-8-hydroxyquinolin-7-yl)(2-furyl)methyl]carbamate benzyl [l,3-benzodioxol-5-yl(5-chloro-8-hydroxyquinolin-7-yl)methyl]carbamate
N-[l-(5-chloro-8-hydroxyquinolin-7-yl)prop-2-en-l-yl]-2-phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)but-2-en-l-yl]-2-phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)hex-2-en-l-yl]-2-phenoxyacetamide N-[(5-chloro-8-hydroxyquinolin-7-yl)(cyclohex-l-en-l-yl)methyl]-2- phenoxyacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylprop-2-en-l-yl]-2- phenoxyacetamide
N-[(2Z)-l-(5-chloro-8-hydroxyquinolin-7-yl)-2-methoxy-3-phenylprop-2-en-l-yl]-2- phenoxyacetamide benzyl [ 1 -(5-chloro-8-hydroxyquinolin-7-yl)-2-phenylethyl]carbamate
N-[l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylpropyl]-2-phenoxyacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(4-fluorophenyl)methyl]-2-phenylacetamide
N-[[3-(benzyloxy)-4-methoxyphenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenylacetamide
N-[(2E)-l-(5-chloro-8-hydroxyquinolin-7-yl)-3-phenylprop-2-en-l-yl]-2- phenylacetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(3-methyl-2-thienyl)methyl]-2-phenylacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-chloroacetamide
N-[(4-chloro-l-hydroxy-2-naphthyl)(phenyl)methyl]-2-phenoxyacetamide
N-[(3-aminophenyl)(5-chloro-8-hydroxyquinolin-7-yl)methyl]-2-phenoxyacetamide
5-chloro-7-{ {3-
[(methylsulfonyl)amino]phenyl} [(phenoxyacetyl)amino]methyl}quinolin-8-yl methanesulfonate
N-[[3-(acetylamino)phenyl](5-chloro-8-hydroxyquinolin-7-yl)methyl]-2- phenoxyacetamide
2 -chloro-N-(3 - { (5 -chloro- 8 -hydroxy quinolin-7 - yl)[(phenoxyacetyl)amino]methyl}phenyl)acetamide
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)- N2,N2-dimethylglycinamide
N-(3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)-N2- methylglycinamide (3-{(5-chloro-8-hydroxyquinolin-7-yl)[(phenoxyacetyl)amino]methyl}phenyl)acetic acid
2-(4-bromophenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(3,4,5- trimethoxyphenoxy)acetamide
2-(biphenyl-4-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(3,5- dimethoxyphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- pentylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- propylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- isopropylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(4- cyclopentylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(3- ethylphenoxy)acetamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-2-(3,5- dimethoxyphenoxy)acetamide
2-(biphenyl-4-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-(4-bromophenoxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
2-(l,3-benzodioxol-5-yloxy)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl] acetamide
N-[(5-bromo-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N2-benzyl-N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-(4-phenylpiperidin-l- yl)acetamide N2-(l,3-benzodioxol-5-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7- yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-2- ylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-3- ylmethyl)glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl]-N2-(pyridin-4- ylmethyl)glycinamide
N2-(biphenyl-4-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7- yl)(phenyl)methyl]glycinamide
N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-chlorophenyl)methyl]-N2-(l- naphthylmethyl)glycinamide
N2-(l,3-benzodioxol-5-ylmethyl)-N-[(5-chloro-8-hydroxyquinolin-7-yl)(2- chlorophenyl)methyl]glycinamide
N-[(5-amino-8-hydroxyquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[[5-(dimethylamino)-8-hydroxyquinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide
N-[[8-hydroxy-5-(lH-pyrrol-l-yl)quinolin-7-yl](phenyl)methyl]-2-phenoxyacetamide
N-[(8-hydroxy-5-pyrrolidin-l-ylquinolin-7-yl)(phenyl)methyl]-2-phenoxyacetamide
N-[2-(8-Hydroxyquinolin-7-yl)-l-phenylethyl]-2-phenoxyacetamide
N-[l-(l,3-Benzodioxol-5-yl)-2-(5-chloro-8-hydroxyquinolin-7-yl)ethyl]-2- phenoxyacetamide
2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- y lmethy l)pheny 1] ethanamine
2 - [ 8 -(Benzy loxy)-5 -chloroquinolin-7 -y 1] - 1 - [3 -(5 -methy 1-2 -thieny l)pheny 1] ethanamine
N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[4-(morpholin-4- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-[3-(pyrrolidin-l- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[4-(morpholin-4- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l- ylmethyl)phenyl]ethyl}biphenyl-4-carboxamide N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl]ethyl}biphenyl-4-carboxamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l-ylmethyl)phenyl]ethyl}- 2-phenoxyacetamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(pyrrolidin-l-ylmethyl)phenyl]ethyl}- 2-(4-chlorophenoxy)-2-methylpropanamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2-thienyl)phenyl]ethyl}-2- phenoxyacetamide
2-(Benzyloxy)-N-{2-(5-chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl] ethyl} acetamide
N-{2-(5-Chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2-thienyl)phenyl]ethyl}-2- (4-chlorophenoxy)-2-methylpropanamide
2-(4-tert-Butylphenoxy)-N-{2-(5-chloro-8-hydroxyquinolin-7-yl)-l-[3-(5-methyl-2- thienyl)phenyl] ethyl} acetamide
2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-{5-[(dimethylamino)methyl]-2- furyl} ethanamine
N-(2-[8-(Benzyloxy)-5-chloroquinolin-7-yl]-l-{5-[(dimethylamino)methyl]-2- furyl} ethyl)-2-phenoxyacetamide
N-[2-(5-Chloro-8-hydroxyquinolin-7-yl)- 1 - {5-[(dimethylamino)methyl]-2- furyl} ethyl]-2-phenoxyacetamide
N-[2-(8-Benzyloxy-5-chloro-quinolin-7-yl)-l-(5-dimethylaminomethyl-furan-2-yl)- ethyl] -isobutyramide
N-[2-(5-Chloro-8-hydroxyquinolin-7-yl)- 1 - {5-[(dimethylamino)methyl]-2- furyl} ethyl] -2-methylpropanamide
2-{[(phenoxyacetyl)amino](phenyl)methyl}quinolin-8-yl phenoxyacetate
N-[(8-hydroxyquinolin-2-yl)(phenyl)methyl]-2-phenoxyacetamide or
2-[amino(phenyl)methyl]quinolin-8-ol.
43. A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
44. The method of making a compound according to claim 1 of Formula (I), wherein said method comprises: treating a compound of Formula (II):
Figure imgf000166_0001
with a compound of Formula (III)
Figure imgf000166_0002
(III) and H2NR3 , followed by treatment with R4Z under conditions effective to produce a compound of Formula (I)
Figure imgf000166_0003
wherein Z is chlorine, bromine, or iodine, X is N, Y is COR4, R13 is hydrogen, p=0 and R1, R2, R3, and R4, are as defined in claim 1.
45. The method according to claim 44, wherein R3 is -COR7, and R7 is as defined in claim 1.
46. The method of making a compound according to claim 1 , wherein said method comprises:
(a) treating a compound of Formula (II):
Figure imgf000167_0001
with an aldehyde of Formula (III)
Figure imgf000167_0002
(III) and at least one acetamide of Formula (IV)
Figure imgf000167_0003
(IV) wherein Hal is halogen, under conditions effective to produce a compound of Formula (V)
Figure imgf000167_0004
(b) first treating the compound of Formula (V) with a compound of formula AH under basic conditions, followed by treatment with R4Z to produce a compound of Formula (Ia)
Figure imgf000168_0001
wherein A is -OR7, -NR5R6 or -OR8-B-R9, Z is chlorine, bromine, or iodine, X is N, Y is COR4, Ri3 is hydrogen, p=0; R1, R2, R3, R4 and R8 are as defined in claim 1, and
R5, R6, R7 and R9 are each independently -Cs-C7-aryl or -Cs-Cio-arylalkyl, as defined in claim 1.
47. The method of making a compound according to claim 46, wherein AH is a compound of formula
Figure imgf000168_0002
and the compound produced is of formula
Figure imgf000168_0003
wherein Ri0 is a hydrogen, halogen or -Ci-C3-alkyl, X is N, Y is COR4, Ri3 is hydrogen, p=0, and R1, R2, and R4 are as defined in claim 46.
48. The method of making a compound according to claim 47, wherein the basic conditions comprise a strong base in a polar aprotic solvent at a temperature of about -5° to about 100C.
49. The method of making a compound according to claim 48, wherein the strong base is NaH, KH or t-BuOK.
50. The method of making a compound according to claim 48, wherein the polar aprotic solvent is DMF, DMSO, NMP, MeCN or THF.
51. The method of making a compound according to claim 50, wherein the temperature is about 00C.
52. The method of making a compound according to claim 46, wherein AH is a compound of formula
Figure imgf000169_0001
and the compound produced is of formula
Figure imgf000169_0002
wherein Ri0 is a hydrogen, halogen or -Ci-C3-alkyl,
X is N, Y is COR4, Ri3 is hydrogen, p=0, and R1, R2, and R4 are as defined in claim 46.
53. The method of making a compound according to claim 52, wherein the basic conditions comprise the presence of a weak base in a polar aprotic solvent at a temperature of about 10° to about 300C.
54. The method of making a compound according to claim 53, wherein the weak base is DIEA or K2CO3.
55. The method of making a compound according to claim 53, wherein the polar aprotic solvent is DMF, DMSO, NMP, MeCN or THF.
56. The method of making a compound according to claim 55, wherein the temperature is about 200C.
57. A compound of the Formula (I):
Figure imgf000170_0001
or a pharmaceutically acceptable salt thereof, made by a process comprising treating a compound of Formula (II):
Figure imgf000170_0002
with a compound of Formula (III)
Figure imgf000171_0001
(III) and H2NR3 , followed by treatment with R4Z under conditions effective to produce a compound of Formula (I), wherein
X is -N-, Y is -COR4, Ri3 is hydrogen, p=0;
Ri is hydrogen, halogen, -OR7, -CN, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -NO2, -NR5R6, -SO2NR5R6, -COR7, -COOR7, -C5-C7-cycloalkyl or -C5-C7-aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C3-alkyl;
R2 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Cio-arylalkyl, -C5-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, C9-Ci5-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR7, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is optionally substituted with one or more hydroxyl, halogen, oxygen, -Ci-C6-alkyl, - C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, -C5-C7- aryl, -C5-Ci0-arylalkyl, -C5-Ci0-arylalkenyl, -C5-Ci0-arylalkynyl, -NO2, -CH2NR5R6, -NR5R6, -NR5SO2R6, -SO2NR5R6, -SO2R7, -COR7, -Ci-C3-alkyl-COR7, -COOR7 or -CONR5R6, wherein (1) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a - C5-C7-aryl; Ri is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -Cs-C^cycloalkyl, -Rs-Cs-C^cycloalkyl, -Cs-Cio-arylalkyl, -C7-Ci2-bicyclic hydrocarbon or -R12-C7-C12- bicyclic hydrocarbon wherein at least one cyclic group is aromatic, -SO2NR5R6, -COR7, - COOR7, -CONR5R6, -COR8-B-R9, or -R8-B-R9, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with one to three substituents independently selected from halogen, -Ci-Cralkyl, -C2-C3-alkynyl, -C5-C7-aryl, -NR5R6, -C≡N, and -COR7;
R4 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -SO2NR5R6, -SO2R7, -COR7, -COOR7 or -CONR5R6, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -d-Cs-alkyl;
R5 and R6 are each independently hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, - COR7, -C5-C7-aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C3-alkyl;
R7 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, or -C5-CiO- arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with one to three substituents independently selected from halogen, -Ci-C3-alkyl, -C5-C7-aryl, and - NR5R6, -OR5;
Rs is -Ci-C6-alkyl, -C2-C6-alkenyl, or -C2-C6-alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl;
R9 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Ci0-arylalkyl or -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with one to three substituents independently selected from halogen, -C1-C4-alkyl branched, a -C5-C7-aryl, B-C5-C7-aryl, -NR5R6, and -COR7, and wherein one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom;
R12 is -CH2- or -CH2CH2-;
Z is chlorine, bromine, or iodine; and
B is a bond, -O-, -NR7- or -S-.
58. A compound of the Formula (Ia):
Figure imgf000173_0001
or a pharmaceutically acceptable salt thereof, made by a process comprising:
(a) treating a compound of Formula (II):
Figure imgf000173_0002
with an aldehyde of Formula (III)
Figure imgf000174_0001
(III) and at least one acetamide of Formula (IV)
Figure imgf000174_0002
(IV) wherein Hal is halogen, under conditions effective to produce a compound of Formula (V)
Figure imgf000174_0003
(b) first treating the compound of Formula (V) with a compound of formula AH under basic conditions, followed by treatment with R4Z to produce a compound of Formula (Ia), wherein A is -OR7, -NR5R6 or -OR8-B-R9;
Ri is hydrogen, halogen, -OR7, -CN, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -NO2, -NR5R6, -SO2NR5R6, -COR7, -COOR7, -C5-C7-cycloalkyl or -C5-C7-aryl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted with a halogen or a -Ci-C3-alkyl;
R2 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -C5-Ci0-arylalkyl, -C5-Cio-arylalkenyl, -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, Cg-Cis-tricyclic hydrocarbon wherein at least one cyclic group is aromatic or - COR7, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl, arylalkenyl, bicyclic hydrocarbon or tricyclic hydrocarbon group is optionally substituted with one or more hydroxyl, halogen, oxygen, -Ci-C6-alkyl, - C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-cycloalkyl, -Ci-C3-alkyl-C5-C7-cycloalkyl, -C5-C7- aryl, -C5-Ci0-arylalkyl, -C5-Ci0-arylalkenyl, -C5-Ci0-arylalkynyl, -NO2, -CH2NR5R6, -NR5R6, -NR5SO2R6, -SO2NR5R6, -SO2R7, -COR7, -Ci-C3-alkyl-COR7, -COOR7 or -CONR5R6, wherein (1) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, arylalkenyl or arylalkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (2) the alkyl, alkenyl, alkynyl, cycloalkyl, aryl arylalkyl, arylalkenyl or arylalkynyl group is optionally substituted with a halogen, a -Ci-C3-alkyl or a - C5-C7-aryl;
R4 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -SO2NR5R6, -SO2R7, -COR7, -COOR7 or -CONR5R6, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, or alkynyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-Cs-alkyl;
R5 and R6 are each independently hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, - COR7, -C5-C7-aryl, or -Cs-Cio-arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with a halogen, an oxygen or a -Ci-C3-alkyl;
R7 is hydrogen, -Ci-C6-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, or -C5-CiO- arylalkyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl or arylalkyl group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl or arylalkyl is optionally substituted with one to three substituents independently selected from halogen, -Ci-C3-alkyl, -C5-C7-aryl, and - NR5R6, -OR5; Rs is -Ci-Cβ-alkyl, -C2-C6-alkenyl, or -C2-C6-alkynyl, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl or alkynyl, group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl or alkynyl group is optionally substituted with a halogen or a -Ci-C3-alkyl;
Rg is hydrogen, -Ci-Cβ-alkyl, -C2-C6-alkenyl, -C2-C6-alkynyl, -C5-C7-aryl, -Cs-Cio-arylalkyl or -C7-Ci2-bicyclic hydrocarbon wherein at least one cyclic group is aromatic, wherein (a) one or more of the carbon atoms in the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is each independently optionally replaced with a nitrogen, sulfur or oxygen atom, and (b) the alkyl, alkenyl, alkynyl, aryl, arylalkyl or bicyclic hydrocarbon group is optionally substituted with one to three substituents independently selected from halogen, -C1-C4-alkyl branched, a -C5-C7-aryl, B-C5-C7-aryl, -NR5R6, and -COR7, and wherein one to three carbon atoms are each independently optionally replaced with an oxygen or nitrogen atom;
R12 is -CH2- or -CH2CH2-;
Z is chlorine, bromine, or iodine; and
B is a bond, -O-, -NR7- or -S-.
59. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is an arthritic disorder, osteoarthritis, rheumatoid arthritis, atherosclerosis, tendonitis, invertebral disc degeneration, or osteopenia.
60. The method of claim 59, wherein the disorder is osteoarthritis.
61. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is malignant neoplasm, angiogenesis, or abnormal wound healing.
62. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is asthma or chronic obstructive pulmonary disease.
63. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is age-related macular degeneration, myocardial infarction, a corneal ulceration, or an ocular surface disease.
64. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is a central nervous system disorder, stroke, or multiple sclerosis.
65. A method of treating a disorder in a mammal in need thereof, which comprises administering an effective dose of at least one compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is hepatitis, an aortic aneurysm, restenosis, cirrhosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, or a periodontal disease.
66. The compound of any one of claims 1-41, wherein X is -N-, Y is -COR4, R43 is hydrogen, and p=0.
PCT/US2007/076661 2006-08-23 2007-08-23 8-hydroxyquinoline compounds and methods thereof WO2008024922A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0715872-6A2A BRPI0715872A2 (en) 2006-08-23 2007-08-23 COMPOUND; PHARMACEUTICAL COMPOSITION; Compost preparation method; COMPOUND PREPARED BY THE METHOD; AND METHOD OF TREATMENT OF A DISORDER IN A MAMMALIAN NEEDED
MX2009001929A MX2009001929A (en) 2006-08-23 2007-08-23 8-hydroxyquinoline compounds and methods thereof.
CA002659952A CA2659952A1 (en) 2006-08-23 2007-08-23 8-hydroxyquinoline compounds and methods thereof
EP07814400A EP2056823A2 (en) 2006-08-23 2007-08-23 8-hydroxyquinoline compounds and methods thereof
AU2007286659A AU2007286659A1 (en) 2006-08-23 2007-08-23 8-Hydroxyquinoline Compounds and methods thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83956806P 2006-08-23 2006-08-23
US60/839,568 2006-08-23

Publications (2)

Publication Number Publication Date
WO2008024922A2 true WO2008024922A2 (en) 2008-02-28
WO2008024922A3 WO2008024922A3 (en) 2008-10-09

Family

ID=39107689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/076661 WO2008024922A2 (en) 2006-08-23 2007-08-23 8-hydroxyquinoline compounds and methods thereof

Country Status (8)

Country Link
US (1) US7947712B2 (en)
EP (1) EP2056823A2 (en)
CN (1) CN101505751A (en)
AU (1) AU2007286659A1 (en)
BR (1) BRPI0715872A2 (en)
CA (1) CA2659952A1 (en)
MX (1) MX2009001929A (en)
WO (1) WO2008024922A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014948A1 (en) * 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
EP2300005A1 (en) * 2008-05-28 2011-03-30 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
EP2536709A2 (en) * 2010-02-17 2012-12-26 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
US20150105412A1 (en) 2010-01-06 2015-04-16 Joseph P. Errico Combination therapy with mdm2 and efgr inhibitors
WO2016053855A1 (en) 2014-09-29 2016-04-07 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
EP3388419A1 (en) 2017-04-12 2018-10-17 Leadiant Biosciences SA Gli1 inhibitors and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151784A2 (en) * 2009-06-26 2010-12-29 The General Hospital Corporation Antimicrobial compounds
WO2011085126A2 (en) * 2010-01-06 2011-07-14 Errico Joseph P Methods and compositions of targeted drug development
JP2013526576A (en) * 2010-05-18 2013-06-24 アメリカ合衆国 Human 12-lipoxygenase inhibitor
HUP1500098A2 (en) * 2015-03-09 2016-09-28 Avidin Kft New enantiomers of 8-hydroxyquinoline derivatives and their synthesis
CN111925376B (en) * 2020-07-23 2023-09-08 陕西科技大学 Fluorescent probe for detecting Cu (II) and Hg (II) and preparation method thereof
CN115536644A (en) * 2022-09-27 2022-12-30 广西民族大学 Application of chromone-2-formamide compound in preparation of hypoglycemic drugs and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US6863895B2 (en) * 2001-04-20 2005-03-08 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395695A1 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
JP3772258B2 (en) * 2002-01-25 2006-05-10 信越化学工業株式会社 Method for producing organopolysiloxane
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP5599614B2 (en) * 2006-11-09 2014-10-01 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6863895B2 (en) * 2001-04-20 2005-03-08 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERKSON R.G. INTERNATIONAL JOURNAL OF CANCER vol. 115, no. 5, 2005, pages 701 - 710, XP008104151 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300005A1 (en) * 2008-05-28 2011-03-30 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
EP2300005A4 (en) * 2008-05-28 2011-07-13 Us Of America As Represented By The Secretary Of The Army On Behalf Of U S Army Medical Res And Mate Small molecule inhibitors of botulinum neurotoxins
WO2010014948A1 (en) * 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20150105412A1 (en) 2010-01-06 2015-04-16 Joseph P. Errico Combination therapy with mdm2 and efgr inhibitors
US9273031B2 (en) 2010-01-06 2016-03-01 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
US9023354B2 (en) 2010-01-06 2015-05-05 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
EP2891649A1 (en) * 2010-02-17 2015-07-08 Cornell University Prolylhydroxylase inhibitors and methods of use
EP2536709A4 (en) * 2010-02-17 2013-11-27 Univ Cornell Prolylhydroxylase inhibitors and methods of use
EP2536709A2 (en) * 2010-02-17 2012-12-26 Cornell University Prolylhydroxylase inhibitors and methods of use
US9505741B2 (en) 2010-02-17 2016-11-29 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
WO2016053855A1 (en) 2014-09-29 2016-04-07 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
JP2017534591A (en) * 2014-09-29 2017-11-24 ザ スクリプス リサーチ インスティテュート Sphingosine-1-phosphate receptor modulator for the treatment of cardiopulmonary disorders
EP3209732A4 (en) * 2014-09-29 2018-04-18 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
US11034691B2 (en) 2014-09-29 2021-06-15 The Scripps Research Institute Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders
EP3388419A1 (en) 2017-04-12 2018-10-17 Leadiant Biosciences SA Gli1 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2007286659A1 (en) 2008-02-28
BRPI0715872A2 (en) 2014-08-26
CA2659952A1 (en) 2008-02-28
WO2008024922A3 (en) 2008-10-09
US7947712B2 (en) 2011-05-24
MX2009001929A (en) 2009-03-06
US20080269213A1 (en) 2008-10-30
EP2056823A2 (en) 2009-05-13
CN101505751A (en) 2009-08-12

Similar Documents

Publication Publication Date Title
EP2056823A2 (en) 8-hydroxyquinoline compounds and methods thereof
US8563551B2 (en) Method for preventing or treating a disease related to the glucocorticoid receptor
DE60022906T2 (en) Heterocyclic compounds with sulfonamide groups
JP2793195B2 (en) Benzothiazole derivative
JPH05112531A (en) Hydroxyquinoline derivative
IE68593B1 (en) Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
JPH0219359A (en) Substituted 4-(quinolin-2-yl-methoxy)phenyl acetic acid derivative
BG62402B1 (en) Quinoline derivatives as leucotrine antagonists
JP4571863B2 (en) Quinazolinone derivatives useful as antihyperalgesic agents
JP2009538358A (en) Oxazolyl piperidine modulator of fatty acid amide hydrolase
US9409864B2 (en) Sulfonamide TRPA1 receptor antagonists
ES2403592T3 (en) New benzimidazole derivatives and their use as FXR agonsites
JP5063708B2 (en) Quinolone compounds and pharmaceutical compositions
JP2016128465A (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
US20040132724A1 (en) Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
KR20210082466A (en) Benzoxazoles and related compounds useful as modulators of chaperone-mediated autophagy
CZ20014637A3 (en) Substituted phenoxyacetic acids
CA2405163A1 (en) Soluble beta amyloid precursor protein secretion promoters
JPH0314023B2 (en)
US20080070946A1 (en) Hydroxymethylbenzothiazoles Amides
US9062061B2 (en) Compound having PARP inhibitory activity
EP3760633A1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
US5310744A (en) Quinolylmethoxyphenyl-acetamides
RU2500669C2 (en) Novel pyrrole derivative having as substitutes ureide group, aminocarbonyl group and bicyclic group, optionally substituted
US20120190694A1 (en) Selective sphingosine-1-phosphate receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780030958.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2659952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007814400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009525784

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007286659

Country of ref document: AU

Ref document number: MX/A/2009/001929

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1884/DELNP/2009

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0715872

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0715872

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090220